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The molecular torsion balance concept was applied to a peptide-hybrid balance to accurately 
investigate the effects of amino acid changes on antiparallel β-sheet configuration and stability for 
applications in molecular recognition and computational drug design.  In this study, we report an 
engineered design of that balance for improved interchain alignment by introduction of 
noncovalent steric constraint at the reverse turn. Our design utilizes a restricted N-aryl bond 
rotation to impose a two-state folded model by incorporating an (ortho-tolyl)amide into a locked 
biaryl system.  The turn mimetic nucleates hairpin formation in an antiparallel β-sheet 
configuration upon attachment of peptide sequences, providing a minimal model system to 
investigate biologically interesting epitopes. Bromine installation ortho to peptide chain 
attachment sites imposed an additional degree of conformational control for improved 
thermodynamic stability in the folded conformation.  Our design approach, which relied upon 
Monte Carlo simulations of substituted native chorismate pyruvate lyase (CPL75-93), is described 
along with solution-phase and solid-phase synthetic strategies.  1H and 2D NMR experiments 
revealed improved interchain alignment to promote hydrogen bond formation in the 
conformationally controlled synthetic peptidomimetic torsion balance hybrid compared to a 
control molecule. Line shape analysis of low temperature 1H NMR data approximated rotational 
restriction around the aryl ether bond to be 11 kcal/mol at 193 K in CD2Cl2.  
1H NMR AND 2D 
ROESY analyses reveal an improved shape to mimic the ends of an antiparallel β-sheet. Hydrogen 
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v 
bond formation has been identified between NH amide proton of the upper side chain (proton 
donor) and glycine acetamide of the lower side chain (proton donor) and glycine acetamide of the 
lower side chain (proton acceptor).  Results confirm bromine substituents impose noncovalent 
steric constraints ortho to the peptide side chains to reduce conformational entropy of the upper 
peptide chains.  
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1.0  INTRODUCTION 
Biomolecular recognition processes are orchestrated by a combination of biochemical interactions 
and equilibria. Biomolecular interactions are essential for cellular function and biological 
processes, both physiological and pathological.  Fundamental understanding of the mechanisms of 
such interactions is a goal in both basic and applied research.  For a given event, the molecular 
function, or binding, of each molecular component is determined by its molecular shape, or 
folding.  Hence, intermolecular interactions rely upon intramolecular stabilization, and, are further 
influenced by energetic contributions from solvation.1,2 As such, it is challenging to accurately 
measure the quantitative energetic differences of the component forces of interactions due to the 
thermodynamic substates present in macromolecular systems.1-3  However, such an endeavor is of 
significant interest for advancements in computational drug design and molecular recognition.  
Understanding molecular conformation preferences in solution can greatly assist in 
developing new methods to modulate conformation-dependent properties in drug design. 
Generally, the conformational variability of an enzyme is determined by the flexibility of rotatable 
bonds in the peptide backbone and amino acid side chains.  Moreover, drug-like compounds adopt 
a variety of conformations even in solid states as evident in the Protein Data Bank (PDB)4 and 
Cambridge Structural Database (CSD).5  Molecular dynamics simulations used to accurately 
measure complexities between structure, electrostatic interactions, solvation and energetics are 
limited by the force field applied during calculations.3,6  Comparisons between NMR experiments 
 2 
and molecular dynamics are instrumental to benchmark simulations to further our understanding 
of biomolecular interactions critical to folding, such as hydrogen bonds, salt bridges and 
hydrophobic clusters.7,8  Furthermore, construction of minimal model systems, which isolate 
chemical components critical to interactions in macromolecular systems, provides powerful 
biological templates to test computational models and molecular recognition theories in a 
controlled manner.    
1.1 PEPTIDE-BASED THERAPEUTICS 
Many complex diseases, such as cancer, metabolic and neurodegenerative diseases,7 are a result 
of aberrant protein-protein interactions (PPIs) or enzyme deficiencies, in which conventional 
therapeutics are too non-specific for treatment.8  As a result, the attractive pharmacological profile 
of proteins and peptides, such as high selectivity, efficacy, safety and tolerability, has led to the 
emergence of novel biologic-based therapeutics, or amino-acid based drugs.9-12  Amino acid-based 
therapeutics are defined as proteins, peptides and peptidomimetics.   
Enthusiasm has waivered for peptide-derived therapeutics since the advent of insulin 
therapy in the 1920s.13  Physiological and chemical limitations of native peptides as therapeutics, 
such as short plasma half-life, poor bioavailability, membrane impermeability and stability, were 
first overcome by implementation of small molecules as therapeutics for ligand receptor binding 
and selective modulation.9,10 Though combinatorial libraries, high-throughput screening (HTS) 
technologies,11,13  and structural biology.9-11,15 revolutionized drug discovery, small molecules 
developed from lead compounds present their own set of drawbacks in terms of druggability.10,14   
Modern day synthetic strategies mitigate the inherent limitations of native peptides, allowing for 
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pharmacokinetic modulation15-17 by sequence and peptide backbone modification,18-21 
incorporation of canonical and non-canonical amino acids18b,19,21,22 as well as improved solubility23 
and half-life- by conjugation. 24  Moreover, formulary advancements offer improved stability and 
permeability, with peptide-based candidates of up to 40 amino acids in length entering clinical 
development.25,26   
Advances in molecular engineering have enabled peptide-derived drug discovery and 
development to keep pace with scientific innovation, leading to 60 approved peptide-based 
pharmaceuticals in global markets to-date that are known to disrupt PPIs, inhibit intracellular 
pathways and target receptor tyrosine kinases.9  With 150 and 250 drug candidates in clinical and 
pre-clinical development, respectively, the projected market opportunity of future peptide and 
peptidomimetic pharmaceuticals is expected to exceed $50 billion by 2024 (from under $30 billion 
in 2018).9 
1.2 THE MOLECULAR TORSION BALANCE AS A MINIMAL MODEL SYSTEM 
FOR STUDYING PROTEIN FOLDING 
As the barriers to entry are substantial for the preclinical and clinical development of any drug, the 
combination of theoretical and experimental investigations designed to predict biomolecular 
structure, folding, binding and catalysis, are necessary to lower basic scientific impediments to 
progress.  The molecular torsion balance is used for measuring molecular folding energies to gain 
understanding of preferred physical forces that stabilize the folded state of a biomolecule; such 
forces include Keesom forces,9 Debye forces10 and solvation effects in folded biomolecules.1,2  The 
torsion balance molecular scaffold was designed to have accessible modification to allow 
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evaluation of the many possible variables that influence non-covalent interactions, and, to give 
unambiguous spectroscopic data that would not require time-consuming analysis. 
1.2.1 The Torsion Balance Concept 
The Wilcox torsion balance was developed in 1994 as a molecular tool to measure isolated non-
covalent interactions critical to molecular recognition and protein folding (Figure 1).29  The torsion 
balance molecular design allowed for gently restricted rotation (G‡ = 14 to 24 kcal/mol) of the 
top asymmetrical aryl ring about a Tröger’s base analog.  That barrier is low enough to allow 
conformational equilibration at room temperature but high enough to study the populations of two 
conformations, folded and unfolded, by 1H NMR.  In Figure 1, the folded and unfolded states of 
the first generation torsion balance are illustrated on the left and right, respectively.  We note the 
upper and lower halves are shown in blue and black, respectively.  In the folded state, the phenyl 
subunit of the phenyl ester is orientated perpendicular to the toluenic ring to form a compact 
structure; whereas in the unfolded state, the phenyl subunit of the phenyl ester is oriented away 
from the toluenic ring.  Here, interconversion of the rotatable bond allowed for investigation of 
substituent effects on preferential folding.  Thus allowing for direct comparison of small-molecule 
drug-receptor interactions and residue side-chain interactions.  If there is an attractive force, there 
is a deviation from a 1:1 ratio between the two orientations of the top ring. That deviation is 
detectable by 1H NMR studies.  Furthermore, changes in environmental media, such as solvent, 
temperature, and pH, were carried out to probe those effects on folding and are summarized in 
Chapter 1.2.2 and 1.2.3. 
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Figure 1.  Wilcox molecular torsion balance.  Folded (left) and unfolded (right) conformational 
states of aryl esters in the first generation molecular torsion balance.  Restricted rotation (G‡ = 16 
kcal/mol at 298 K) allows for two distinct sets of NMR signals.   The upper and lower halves of the 
balance are shown in blue and black, respectively.  
 
 
 
Analogs of 2,3-dimethyldibenzodiazocine (Tröger’s base; Figure 2) are known as ideal 
templates for biomimetic systems due to their relative rigidity, unique cleft-shape and potential to 
direct functionalities towards the cleft through substitution at C2 and C8.30,31  The scaffold has 
many applications,32 including but not limited to receptors for benzenoid substrates,30 hydrogen 
bonding hosts in diacids,31,33,34  ligands in asymmetric catalysis,31 drug candidates,35 and new 
materials for optical applications.36  Although the Tröger’s base was originally synthesized by Carl 
Julius Ludwig Tröger in 1887,37 the Tröger’s base structure was not described until 1935.38  
Finally, in 1987, Dr. Craig S. Wilcox established the structure by crystallographic analysis.39 The 
C2-symmetrical molecule owes its chirality to the two configurationally stable amines. The 
structure is concave and V-shaped with an angle of 89-104° between the two aryl rings.30  That 
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angle provides flexibility at the bridge and allows for optimal distance requirements for stabilized 
non-covalent interactions. 
 
Figure 2.  Tröger’s base. 
1.2.2 First Generation Torsion Balance 
The first generation torsion balances were studied in non-polar solvents to evaluate the benzene 
dimer edge-to-face, aryl and alkyl CH-π, cation-π (Figure 3) and fluorination effects on the folding 
ratio. Using 1H NMR data, folding free energies of synthesized derivatives were measured by 
integration and line-shape analysis.40 A brief synopsis of the first generation torsion balance is 
described in Chapter 1.2.2.1. 
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Figure 3.  First generation torsion balances. 
1.2.2.1 Aryl and alkyl CH-π interactions 
Initially, the torsion balance was used to measure the stability of the tilted-T edge-to-face 
interaction and effects of substitution on preferential folding (Table 1).29  Here, deactivation of the 
phenyl ester phenyl subunit by electron withdrawing groups (2d-e) were shown to perturb the 
folding ratio. In considering the alkyl groups (3a-c), the t-butyl-aryl interaction (3c) was 
discovered to be as significant as the edge-to-face interaction. 
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Further interest in the forces contributing to the aryl and alkyl CH-π interactions led to 1H 
NMR studies of substituted phenyl, methyl and isopropyl esters (4-6; Table 2).41 Folding was 
preferred in the isopropyl ester (6) over the phenyl ester (5) at room temperature.  Because there 
was no evidence of substitution effects, the data negated the significance of electrostatic potential 
on preferential folding.  It was apparent that edge-to-face interactions are a result of London 
dispersion forces. 
 
 
 
 
 
 
Table 1. Experimental folding energies for esters 2-3 in CDCl3 at 25 °C.29 First-
generation torsion balances for investigation of benzene dimer tilted-T edge-to-
face interactions. 
 
Ester Y R -ΔGºa,b 
2a H - 0.24 
2b p-CH3 - 0.37 
2c p-OCH3 - 0.24 
2d p-CN - 0.65 
2e p-NO2 - 0.65 
2f p-I - 0.65 
2g m-CH3 - 0.00 
2h m-CN - 0.24 
2i 3,5-dimethyl - -0.37 
3a  CH3 0.00 
3b  cyclohexyl 0.37 
3c  t-butyl  0.82 
a) ±10% error. b) kcal/mol. 
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1.2.2.2 Amide and organic fluorine interactions 
The discovery of a characteristic geometry of an organic fluorine orthogonal to a carbonyl in many 
complexes in the CSD and PDB was described by Diederich and coworkers.42  The exchange of 
hydrogen for fluorine is common in medicinal chemistry due to improvements in absorption, 
distribution, metabolism, excretion and toxicity (ADMET).43,44 Diederich et al.  employed the 
torsion balance to measure the C-F…C(O) dipole interaction, in combination with the double 
mutant cycle approach, to support an investigation of improved efficacy in fluorine-substituted 
synthetic drug candidates (Figure 4).45,46  Solvent effects on the C-F…C(O) dipole interaction 
between triflourophenyl and methyl amide derivatives 7-9 revealed evidence of an attractive 
Table 2. Folding energies for methyl (4), phenyl (5), and isopropyl esters (6) in 
CDCl3 at 25 °C to support an investigation of electrostatic potential of the aromatic 
face ring and the strength of edge-to-preferentially folded.41 
 
 
X     -ΔGºa,b (4)           -ΔGºa,b (5) -ΔGºa,b (6) 
NO2 -0.11 0.21 0.51 
CN -0.06 0.30 0.64 
I 0.06 0.23 0.46 
Br -0.02 0.26 0.54 
OCH3 0.04 0.27 0.44 
OH 0.03 0.23 0.47 
NH2 0.06 0.18 0.34 
a) ±10% error. b) kcal/mol. 
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noncovalent dipole Csp2–F∙∙∙C(O)  and Csp2–F∙∙∙C(O) interactions between organic fluorine and 
amide groups. 
 
 
Figure 4.  Torsion balance derivatives (7-9) used by Diederich et al. to measure preferential folding 
amongst Csp2–F∙∙∙C(O) and Csp3–F∙∙∙C(O) dipole interactions.45,46  (7-9) used by Diederich et al. to 
measure preferential folding amongst Csp2–F∙∙∙C(O) and Csp3–F∙∙∙C(O) dipole interactions.45,46  Note 
the indole and napthyl incorporation in torsion balances 8 and 9, respectively. 
 
1.2.3 Second Generation Torsion Balance 
A second generation torsion balance (Figure 5) was designed to measure nonconvalent interactions 
in water.47  Until this point, the design of the torsion balance scaffold incorporated a rotatable 
asymmetrical alkyl or aryl 3-methyl benzoate atop a Tröger’s base derivative.  For these 
experiments to be successful, it was necessary to improve solubility and prevent solvation from 
disrupting the folding ratio.  To improve solubility, isophthalates were decorated with hydrophilic 
groups along the torsion balance rotational axis and revealed the desired result without imposing 
energetic differences in folding preference.  To prevent solvation from disrupting the folding ratio, 
the symmetry of the upper half of the balance was improved.  Asymmetry in the methyl benzoate 
creates a difference in dipole moments.  To avoid any consequential deviations in isomeric ratio 
from polarity changes, the methyl group was replaced with a methyl ester.47   
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Figure 5. Second generation torsion balance scaffold. 
1.2.3.1  Alkyl CH-π interactions 
In comparing the difference between the folding energies of the torsion balance in D2O and 
nonpolar solvents, Bhayana showed the hydrophobic assistance to folding was significant.  
Specifically, the greater the size of the alkyl substituent, the greater the folding ratio.47   
 
 Table 3. Folding energies for torsion balances 12a-f at 25 °C to examine 
hydrophobic effects in D2O.47  Torsion balances 10-12 were also used in this study. 
 
Ester Y             -ΔGfold [CDCl3]a,b -ΔGfold [D2O]a,b 
12a (CH3)2HC 0.50 0.72 
12b (CH3)3C 0.65 0.92 
12c cyclohexyl 0.36 0.67 
12d 1-adamantyl 0.55 0.68 
12e 1-adamantyl 0.00 0.90 
12f CH3 - 0.00 
a) ±10% error. b) kcal/mol. 
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1.2.3.2  Halogen bonding  
The second generation torsion balance was used to evaluate the halogenated bond effect48 on the 
XH-π interaction (13-16; Table 4).49 Preferential folding was observed for derivatives forming an 
intramolecular hydrogen bond over the halogen bond.  Carbamate and hydroxyalkyl substituents 
had similar acceptor ability, which was improved in tertiary carbamates 16a and 16b.  Contrary to 
expected halogen bond strength, folding ratios were higher for bromides and chlorides derivatives 
than iodides.  
 
 
 
 
Table 4.  Folding energies for esters 13-16 at 5 °C to determine effects of 
halogenated bond on XH-π.49 
 
           Ester   R X -ΔGfold[CDCl3]a,b 
13a BocNH Br 0.18 
13b BocNH Cl 0.2 
13c BocNH OH 0.37 
14a HOCH2 Br 0.21 
14b HOCH2 Cl 0.18 
14c HOCH2 OH 0.48 
15a Me2NOCCH2 Br 0.25 
15b Me2NOCCH2 Cl 0.26 
15c Me2NOCCH2 OH 0.71 
15d Me2NOCCH2 I 0.13 
16a BocNMe Br 0.36 
16b BocNMe Cl 0.37 
        a) ±15% error. b) kcal/mol. 
N
N
R
O
O O
O
NO2
X
13-16
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1.2.3.3 Salt bridge stability 
Salt bridges are important for protein stability, recognition and regulation.  Buried salt bridges are 
known to stabilize the protein-folded state.50  Yet, an accurate description of surface, or partially 
or fully solvent exposed, salt bridges in the protein-folded state is still elusive.  Experimental data  
from an investigation of salt bridge stability in torsion balance derivatives revealed no change in 
stabilization between buried and solvent exposed salt bridges in ammonium-carboxylate 17 and 
guanidinium-carboxylate 18 (-ΔGfold = 0.3 to 0.5 kcal/mol; Figure 6).
49  In addition, temperature 
changes from 5-25 °C and pD changes from 3.1 to 10.0 offered negligible effects on preferential 
folding.  Results of these temperature studies disputed Thomas and Elcock’s theory that salt 
bridges are stabilized at higher temperatures.51  
 
(a) 
                                                       
(b) 
 
 
 
 
 
Figure 6.  (a) Ammonium-carboxylate torsion balance 17 and guanidinium-carboxylate 18 used to 
measure salt bridge stability. (b) Minimized structure modeled using force field MMFF94s.49 
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The use of molecular dynamics studies to accurately measure complexities between salt 
bridge structure, solvation and energetics is limited by the force field applied during 
calculations.50d  This computational impediment was confirmed by the same torsion balance salt 
bridge stability study (Figure 6b).  Experimental data revealed small differences in stabilizing 
energy between salt bridges in ammonium-carboxylate 17 and guanidinium-carboxylate 18, 
whereas dynamic modeling using force field MMFF94s indicated larger differences, or stronger 
interactions, in 18 compared to 17.49  Results of this torsion balance study demonstrate the 
importance of NMR experiments to assess the energetic contributions of salt bridge formation and 
to validate the accuracy of simulations calculated by predictive models.  
1.2.3.4  Neighboring group effects in hydrophobic surface association 
The second generation balance was used to investigate polar neighboring group effects on 
hydrophobically-assisted folding (Table 5).52  Specifically, the water structure at the molecular 
surface was examined to determine effects of polarity in hydrophobic surface association.   Based 
on Lum-Chandler-Weeks (LCW) theory, 53 Ling hypothesized an effect would arise from polarity 
differences on structure and orderliness of water at the hydrophobic surface. If the polar group 
influenced the excess free energy of water at the nearby hydrophobic surface, changes in folding 
energies would indicate the contribution of desolvation in preferential folding. 
Though torsion balances bearing a bicyclo[2.2.2]octyl subunit were preferably folded to 
those bearing trans-cyclohexyl units, the neighboring group effect on contact surfaces in torsion 
balances 19-26 was negligible.  Results showed branching functionalities increased folding 
compared to linear functionality in MeOD; however, the difference in folding energy between 
branched and linear derivatives was diminished in D2O.
52   Data from NMR experiments in D2O 
reveal higher folding energies compared to MeOD. Therefore, london dispersion forces appear to 
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be enhanced more in water for poorly bound surfaces than for tightly bound surfaces.  In addition, 
evaluation of alkyl chain length effects, revealed excess surface free energy (γ) of the interacting 
surfaces is not significantly changed as the surface is extended in torsion balances 19-26. This is 
interesting because LCW theory predicts γ is different among hydrophobic spheres of changing 
size.53 
 
Table 5.  Folding energies for esters 19-26 at 5 °C to measure nearest neighbor 
group effects in hydrophobic surfaces.52   
 
Ester             R1               R2 -ΔGfold [CDCl3]a,b   -ΔGfold [MeOD]b,c 
19a Bco-H NO2 1.9  
19b Bco-H NH2 1.3  
19c Bco-H NHCO(CH2)3CO2H  2.3 
20a Cy-Me NO2 1.2  
20b Cy-Me NH2 1.1  
20c Cy-Me NHCO(CH2)3CO2H  1.7 
21a Bco-CO2Et NO2 2.2  
21b Bco-CO2Et NH2 2.2  
21c Bco-CO2Et NHCO(CH2)3CO2H  3.0 
22a Cy-CO2Et NO2 1.4  
22b Cy-CO2Et NH2 1.5  
22c Cy-CO2Et NHCO(CH2)3CO2H  1.9 
23a Bco-CO2Bn NO2 2.4  
23b Bco-CO2Bn NH2 1.6  
23c Bco-CO2H NHCO(CH2)3CO2H  3.3 
24a Cy-CO2Bn NO2 1.4  
24b Cy-CO2Bn NH2 0.3  
24c Cy-CO2H NHCO(CH2)3CO2H  2.3 
25a Bco-CH2OBn NO2 0.9  
25b Bco-CH2OBn NH2 1.6  
25c Bco-CH2OH NHCO(CH2)3CO2H  2.3 
26a Cy-CH2OBn NO2 0.7  
26b Cy-CH2OBn NH2 0.7  
26c Cy-CH2OH NHCO(CH2)3CO2H  1.4 
a) Error = ±0.2 kJ/mol. b) kJ/mol. c)  Error = ±0.2-0.5 kJ/mol. 
N
N
O
O O
O
R2
R1
19-26
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1.2.4 Third Generation Torsion Balance: A Novel Peptide Hybrid Torsion Balance 
The design of compounds capable of interfering with PPIs requires understanding of sources of 
affinity and specificity in each interface.  Most interfaces are composed of two relatively large 
protein surfaces with the correct shape and electrostatic complementarity for binding. 
Computational techniques, directly correlating protein-protein binding energy with buried 
hydrophobic surface area, failed to accurately measure the energetic contributions of individual 
residues in binding.55b Despite the large size of binding interfaces, single residues contribute a 
large fraction of binding free energy in a domain, known as hotspots.55  Such hot spot residues 
often cluster near the center of the interface and are surrounded by energetically less important 
residues. Still, energetically important interactions can be grouped into independent clusters, 
having additive contributions.54  We applied the torsion balance concept to experimentally probe 
the energetic contributions of amino acid residues in protein binding.  
A novel peptide torsion balance hybrid was designed to support an investigation of pairwise 
amino acid interactions in antiparallel orientation of a β-sheet and the effects of changes in amino 
acids on a short β-strand. Though moderately high risk compared to the previous work by the 
Wilcox group, the third generation balance potentially offers a robust experimental tool relevant 
to testing current computational methods and theories of biological recognition and in identifying 
guiding principles for biological drug design. Stated otherwise, can the molecular torsion balance 
concept be applied to evaluate competitive binding between biologically relevant domains larger 
and richer in detail than amino acid side-chain interactions and small-molecule drug-receptor 
interactions?  In this study, we describe the design (Chapter 2), synthesis (Chapters 2.3, 4.1, 5, 6) 
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and NMR analysis (Chapters 3, 4, 6) toward a hybrid synthetic-natural peptide that incorporates a 
conformationally controlled torsion balance.   
 
 
 
 
 
Figure 7.  Wilcox β-turn mimetic torsion balance.  Folded (left) and unfolded (right).  Each R group 
represents a different amino acid side chain.  Restricted rotation around the N-aryl bond (G‡ = 21 
kcal/mol) allows for two distinct sets of NMR signals. 
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2.0  DESIGN AND SYNTHESIS OF A CONFORMATIONALLY CONTROLLED        
ß-TURN MIMETIC TORSION BALANCE  
The results in this chapter have been published in: 
Lypson, A.B. Wilcox, C.S. "Synthesis and NMR Analysis of a Conformationally Controlled 
β‑ Turn Mimetic Torsion Balance." Journal of Organic Chemistry, 2017, 82, 898-909. 
 
 
Computational techniques are instrumental to designing amino acid-based therapeutics.55-59  
However, docking of a highly flexible peptide into a protein remains a major challenge.55 The 
degrees of freedom arising from rotatable bonds in the peptide backbone and residue side chains 
can generate an infinite number of configurations for a single amino acid sequence.1,2  Traditional 
protocols developed for docking small molecules, such as AutoDock, Vina56 and MOE-Dock,57 
have been used to dock peptides to protein receptors.57a-e,59 Though, such methods are challenged 
by the growing quantity and complexity of experimental data. Comparisons between simulation 
and experimental data remain necessary to access the accuracy of computational methods to 
predict protein folding.    
Many strategies exist for designing proteins and amino-acid based targets.61 Traditional 
methods for protein design, such as template-based design, rely upon a three-dimensional structure 
of a predefined template to adapt into a sequence.58 This strategy eliminates the ambiguity of 
predicting the fold of an unknown sequence.  For example, if the template is reliable and the 
framework is stabilized by the connected amino acid side chains, the fold is unaltered. Hirschman 
introduced this concept for cyclic somatostatin derivatives.59  Alternatively, de novo design60 alters 
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amino acid arrangement to produce a novel protein sequence and structure. More recently rational-
based designed has been applied to peptidomimetics and is categorized as target-based design and 
ligand-based design methods.61 The latter can be further classified into subcategories, including 
sequence-based design.  Such subcategories were recently described in Drug Design, Development 
and Theory.62   
2.1 PEPTIDOMIMETICS 
Paramount to the function of any active biomolecule is its three-dimensional folded structure.  
Mimicking that structure, and thereby function, of biological peptides using non‑peptidic scaffolds 
has become an established method to modulate specific PPIs and to improve the pharmacokinetic 
drawbacks of peptides.  Strategies for modulating PPIs include the development of non-canonical 
amino acid containing -peptides as well as unnatural polyamide-based and non-polyamide-based 
secondary structure mimics. 18-23, 59,62   
Gellman, Horne, and others have used sequence-based design to develop peptide-like 
structures.18,63  Such models are based on a combination of natural and synthetic amino acids to 
induce peptide interactions of a protein folded state.  As defined by Gellman, secondary structures 
with non-canonical amino acid monomers, or foldamers, are “any polymer with a strong tendency 
to adopt a specific compact conformation.”64  In the biological environment, peptidomimetic 
structures can accurately provide the desired shape and function of the secondary structural 
elements (-helices, -strands, and reverse turns) to mimic the parent in its native environment, 
or, to bind off-target.  The traditional peptidomimetic approach is based upon the design of 
synthetic molecules to mimic unique secondary structural motifs for incorporation into 
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biologically relevant sequences.  In example, we highlight design requirements for synthetic 
templates to mirror intramolecular and intermolecular interactions ubiquitous in hydrogen-bonded 
antiparallel β-sheet domains.65   
Formation of pairwise interchain interactions requires perpendicular orientation of amino 
acid side chains between two β-strands. The adopted geometry enforces both intramolecular (local 
and non-local) and intermolecular interactions between residues. Specifically, the intramolecular 
interactions are critical to protein shape, while intermolecular stacking of these structures executes 
function. We note β-sheets are well-known to be implicated in pathogenesis of cancer as well as 
Alzheimer’s and Parkinson’s disease, and are therefore of significant interest in 
peptidomimetics.8,66  However, development of accurate -sheet mimics has been slow compared 
to progress made in development of -helix mimics.21  Nevertheless, efforts to accurately design 
structures modeling antiparallel β-sheets have been successful and are discussed in Chapter 2.1.1. 
2.1.1 Conformationally Controlled Hybrid Synthetic Natural Peptides as -Sheet 
Mimetics 
Of the secondary protein structures, reverse-turns (-, -, -, - and -turns) are well-known to 
govern peptide and protein folding and therefore are accessible for protein modification.66   
Because turns typically reside at the surface, or solvent-exposed location, within a globular protein, 
turns are well-suited for mimetic design.  The most common of the turns is the β-turn.  The β-turn 
is formed by four adjacent residues, where i + 1 and i + 3 are less than 7 Å apart, ideal for nucleating 
the formation of β-sheets.  These structural motifs are defined by the backbone torsion angles  
and   of residues i + 1 and i + 2.  Folded β-hairpin structural stability is determined by the β-turn 
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conformation as well as intermolecular forces between the β-turn-linked β-strands, such as 
hydrogen bonds, salt bridges, and hydrophobic clusters.  Moreover, forces of interactions affecting 
the number of thermodynamic substates of a folded conformation are confounded by solvation, 
sequence, chain length and environmental effects.2,3  Thus, the β-turn structural motif provides an 
excellent model for probing thermodynamics of ligand binding and molecular recognition in 
biological systems. 
In order to accurately study determinants of hairpin formation and to probe the importance 
of bioactive epitopes, designed sequences must be contained in the context of a compact folded 
structure.3  Yet, rational design, based on X-ray crystallography and theoretical calculations, of a 
truncated peptide is limited by the elusive affinity and intrinsic flexibility of peptides.  The 
enthalpy change of secondary interactions may be unable to compensate for the entropy loss during 
folding.  Energetic contributions from conformational entropy of the unfolded state can be reduced 
by restricting the freely rotatable peptide bonds necessary for folding.  Modification of synthetic 
templates to increase molecular rigidity is common in template-based design to enforce residue 
alignment.21,59   Introduction of rotational restraint, such as using a semi rigid linker or template, 
to connect natural or unnatural bioactive man can provide the compact conformation needed for 
investigating bioactive and thermodynamic properties.  
Approaches have been developed to transfer hairpin sequences from folded proteins onto 
semirigid hairpin-stabilizing templates to afford macrocyclic, conformationally restrained protein 
epitope mimetics (PEM).69  Conformational restriction, induced by covalent and non-covalent 
constraints, provides higher binding potency and target selectivity than its native parent.68  In 2004, 
the Verdine group introduced the idea of a locked structure design to stabilize -helices in targeting  
B-cell lymphoma 2 (BCL-2).8  The combination of constrain-based design strategies provides 
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cooperatively stabilized hairpin conformations via backbone cyclization, template-imposed 
conformational bias and  hairpin loop size and sequence effects.   
Exhaustive efforts have been put forth by the chemical community to develop β-turn 
mimics for nucleating β-sheets with conformational constraint as a key design requirement.18,69-73  
Cyclic and acyclic structures as well as metal chelates have been exploited to nucleate the hairpin 
motif and to measure folding by 1D and 2D NMR studies.  We show a small representative 
collection of these structures (Figure 8) to convey the diverse approaches to such scaffolds.  Kelly 
and coworkers incorporated dibenzofuran propionic acid at the i +1 and i + 2 residues of the turn 
in both peptide and protein substructures to facilitate hairpin formation in CDCl3.
69  Upon 
improving solubility of that template, results of NMR studies showed similar free energies of 
solvation for the mimetic and wild-type sequences in D2O.
23  Gellman also used NMR studies in 
water to compare thermodynamic differences in folding parameters of trans-5-amino-3,4-
dimethylpent-3-enoate conformations.  Nowick et al. applied a peptide/oligourea/azapeptide 
hybrid to adopt a β-turn by forming two intramolecular hydrogen bonds in chloroform. Later, 
Nowick showed hairpin formation by replacing a β-turn peptide sequence with an artificial amino 
acid, “Orn(i-PrCO- Hao)”.65   
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Figure 8. Examples of cyclic and acyclic β-turn mimcs.65 
 
Of interest to our mimetic design is the biaryl amino acid unit, which has been incorporated 
into many turn mimetics.18b,66-69 Biaryls occur in peptide natural products, such as the glycopeptide 
antibiotic vancomycin and the peptide-based antibiotic WS-43708A.9 The rigid structure makes 
for an attractive template to control the conformation of the folded substate.74  Kemp’s pioneer 
study used a disubstituted diphenylacetylene as a β-turn mimic to nucleate hydrogen-bonded β-
sheet formation (27a-c; Figure 8).67    Since, the oligophenyl scaffold has been pursued for both 
helical21 and sheet-like64,68,72-73 templates.  The rigid structures of sequential aromatic rings linked 
by a single bond are not in the same molecular plane and are therefore asymmetrical.   
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Kelly and colleagues72 used the template-based design concept to develop a biphenyl-
amino acid unit to nucleate β-sheets via a hydrogen-bonded hydrophobic cluster conformation 
(Figure 9).  Hydrophobic clusters are important intermediates in folding and are known to reduce 
the local entropy penalty for folding by preorganizing the unfolded state.53,72  Destabilization of 
the hairpin conformation occurred when phenyl amides replaced the phenyl ethyl unit.  The amide 
subunit restricted flexibility of the peptide chains compared to the ethyl subunit, preventing 
hydrophobic cluster formation between the phenyl and -hydrophobic amino acid.  
 
Figure 9.   Kelly’s biphenyl-amino acid unit to nucleate β-sheets via a hydrogen-bonded 
hydrophobic cluster conformation.72 
 
Brandmeier,73b Suich73a and Robinson68 studied biphenyl-amino acid scaffolds in o,o’-
biphenyl, o,m’-biphenyl and m,m’-biphenyl  scaffolds as macrocylic turn mimics.  Robinson 
showed the rate of atropisomer interconversion around the biaryl link could not be slowed down 
in o,o′-biphenyl templates of macrocyclic peptidomimetics of PG-1 compared to o,m’-biphenyl 
and m,m’-biphenyl scaffolds (Figure 10).68  Conformational analysis relied upon 2D NMR data to 
investigate folding because 1H NMR data of o,o’-biphenyl tetrapeptide derivatives revealed only 
the trans amide conformation.  A comparison of  and  angles of several amino acid-substituted 
macrocyclic o,o’-biphenyl tetrapeptides indicated many residues were prohibited by the 
Ramachandran plot for β-turns due to imposed cyclic strain. That result was not observed for o,m’-
biphenyl and m,m’-biphenyl derivatives.  
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Figure 10. Robinson’s cyclic biphenyl amino acid templates as cationic macrocyclic 
peptidomimetics of PG-1. o,o’-Biphenyl tetrapeptide (left) was destabilized compared to the o,m’-
biphenyl and m,m’-biphenyl hexapeptides.68c 
 
 
We exploit the use of restricted rotation in a biaryl amino acid unit to develop the β-turn 
mimetic torsion balance for investigating the forces of interactions and effects of the molecular 
environment on folding for competing pairwise amino acids, as well as, peptide sequences in the 
antiparallel β-sheet motif.    
2.2 DESIGN STRATEGY OF A CONFORMATIONALLY CONTROLLED ß-TURN 
MIMETIC TORSION BALANCE 
Our design of the β-turn mimetic torsion balance allows for the direct comparison of two different 
competing amino acid interactions and further lends itself to comparing two different competing 
peptide sequences in a compact hairpin structure (Figure 11).  We emphasize that rather than 
imitate a β-turn, our goal was to ensure the turn scaffold enforced the hydrogen-bonded antiparallel 
β-sheet motif.  Stated otherwise, the design demand required that our scaffold (1) match the ends 
of an antiparallel β-sheet and (2) establish the distances and orientations required for interchain 
peptidomimetic hydrogen bond formation. The illustration in Figure 11 represents our design. 
Like the first and second generation torsion balances,29,41our approach provides two 
configurations, imposed by restricted rotation about a single rotatable bond, for observation of 
folded and unfolded states by 1D and 2D NMR.  The upper and lower β-strands of a native β-
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hairpin sequence (shown in magenta) are covalently connected by the torsion balance.  Sequence 
modulation introduces a mutation into the native peptide sequence (shown in green).  The design 
allows covalent attachment of the mutant sequence along the torsion balance rotatable axis, 
opposite the upper native sequence.  Incorporating the rotational axis into the β-turn allows the 
preferential pairwise interactions between the upper and lower strands as well as the corresponding 
energetic differences to be identified by NMR and line shape analysis.40 An example of two 
possible folded configurations used to probe substitution of -amino acid hydrophobic residues 
(Ala vs Leu) on preferential folding is shown (Figure 11B).  The upper chains maintain a similar 
level of hydrophobicity and therefore, do not alter the charge.  We discuss a detailed account of 
our approach to design the turn template and third generation balance, here.     
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(a)
 
 
 
(b) 
 
Figure 11.  (a) Representation of design requirements for the (b) Wilcox β-turn mimetic torsion 
balance. 
 
2.2.1 Peptide Structure and Sequence Survey of Antiparallel ß-Sheets 
Several well-defined β-sheet substructures of enzymes in the PDB, including examples from 
bovine pancreatic trypsin inhibitor, lysozyme,74 barnase, and chorismate pyruvate lyase (CPL),75a 
were studied to test our concept and take inventory of the interactions that provide conformational 
stability, such as salt bridge and hydrophobic interactions. Lysozyme has six surface salt bridges 
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that contribute toward the stability of the protein.  Mutational analysis of lysozyme revealed little 
contribution from salt bridges upon solvation, while desolvation provided a large contribution, 
emulating a buried salt bridge.  Moreover, CPL-vanillate (VNL) inhibition was of interest to probe 
both enzymatic stability and conformation necessary for its unusual internal ligand binding 
technique, shown in Figure 12.  Because the CPL-VNL complex was most important for modeling 
the torsion balance, a detailed structural analysis is provided. 
 
         (a)                                                       (b)                                      (c)  
 
Figure 12. Chorismate pyruvate lyase-vanillate internal ligand-binding pocket.  (a) Flaps 1 (residues 
21-40) and 2 (residues 97-119) are colored in grey and orange, respectively.  The ligand, VNL, is 
shown buried in the internal ligand-binding site behind flaps 1 and 2.  (b) and (c) Internal binding 
cavity and nearby pockets with key flap and binding site residues.  Residues are colored to match 
the CPL structure in (a). Hydrogen bonding interactions are displayed as yellow dashed lines.  The 
opening and closing of flaps is dependent upon 3 residues of flap 1 (D32, S33, and T35) hydrogen 
bonding to flap 2 (L114 and R116). Complexation forms at sidechains of R76 (2 H-bonds) and E155, as 
well as backbone amides of M34 and L114.  PDB: 1XLR. 75a 
 
2.2.1.1 Structural analysis of chorismate pyruvate lyase 
 
CPL catalyzes the cleavage of the pyruvate group from chorismate to provide 4-hydroxybenzoate 
(4HB), the key intermediate for ubiquinone biosynthesis.75b  CPL has two interior flaps (shown in 
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orange and grey in Figure 12) comprised of hydrophobic residues, located adjacent to the central 
-sheet of the enzyme. Mutation and modeling studies of the binding and release mechanism 
indicate three hydrogen bonds that are pivotal for keeping the flaps together; flap 1 residues (D32, 
S33, and T35) hydrogen bond to flap 2 (L114 and R116; Figure 12B).
75b-d  Enzyme activation and 
inhibition occur upon flap opening and subsequent 4HB and VNL binding to the densely packed 
hydrophobic pocket, respectively.  We show ligand binding requires hydrogen bond formation 
between VNL and sidechains, R76 and E155, as well as backbone amides, M34 and K114. Of most 
interest to us were the hydrophobic and hydrophilic residues neighboring the binding cavity 
(Figure 13). 
Interchain hydrophobic clusters from main chain hydrogen bonded residues within the 
central β-sheet provide stability to the binding pocket.  Specifically, amide backbone of I78 and L80 
form hydrogen bonds to L88 and A90, respectively.  These pairwise interactions orient the residue 
sidechains directly toward vanillate, indicating the ideal radius for van der Waals interactions 
between each structure.  This compact hydrophobic cluster appears to shape, or tile, the cavity 
surface (Figure 13E). Formation of tightly packed hydrophobic clusters in the core of a protein is 
a common practice for optimizing van der Waals interaction via substitution with non-polar 
residues to enhance the protein stability.  Further stabilization to this region of the folded -sheet 
is provided by interchain salt bridge formation between R91 and E77 (Figure 13B).  Altogether, the 
structural knowledge available for the enzyme receptor-ligand binding provided a feasible 
structure for our torsion balance model to probe interactions of protein hotspots buried beneath the 
surface.  
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Figure 13.  Structural analysis of CPL-vanillate binding site.  (a) CPL is complexed with VNL 
(yellow) in coordination site (grey surface).  Flaps 1 and 2 are colored in grey and orange, 
respectively, and the -structure of interest is colored in magenta.  The inset shows the five hydrogen 
bonding interactions (yellow dashed lines) between VNL with labeled residues of CPL, and two 
interactions to L114 main chain amide of flap 1.  (b, c) View of the -sheet of interest with 
hydrophobic residues (I78, L80, L88, and A90) and hydrophilic residues (R91 and E77) in magenta.   
Interaction between R91 and E77 offer additional stabilization to the folded - sheet.  (d) Binding 
cavity and surrounding hydrophobic residues with -sheet removed for clarity.  (e) Formation of 
hydrophobic cluster between alkyl side chain residues in folded CPL75-93. neighboring residues 
appears to shape, or tile, the cavity surface as shown by above (top) and side (bottom) views. PDB: 
1XLR. 75a 
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2.2.2 ß-Turn Mimetic Template Design 
Monte Carlo simulations were applied to model the dibenzodiazocine scaffold with the β-sheet 
template structure CPL75-93.  It was determined that the dibenzodiazocine architecture did not have 
the correct shape to match the ends of the hydrogen-bonded antiparallel β-sheet.  
  In order to construct a β-turn mimetic that would structurally complement the hydrogen-
bonded antiparallel β-sheet motif, we turned to a biaryl (ortho-tolyl)amide-amino acid core 
template.  The use of biphenyl alkylamino acid subunits to nucleate β-sheets has been described 
by Kelly,72 Robinson,68 and Hamilton, 21 amongst others73 (discussed in Chapter 2.1).  However, 
NMR data revealed orthogonal arrangement of the biphenyl gave poor alignment of amino acid 
side chains for some examples (Chapter 2.1).68  We exploit this knowledge by imposing a 
rotational barrier in a biaryl-amino acid derivative to give two competing conformational states.  
Our biaryl (ortho-tolyl)amide-amino acid core design imposes restricted rotation around 
an N-aryl bond  (G‡ = 15 to 20 kcal/mol).  An ortho substituent is well-known to constrain 
rotation about the N–aryl bond.  This was reported by Mislow76a for acyclic and cyclic (ortho-
tolyl)amides (Figure 14) and by the Curran group76b for o-haloanilide atropisomers in asymmetric 
radical cyclizations (G‡ = 28-31 kcal/mol).  The design also incorporated an o,o,o′-trisubstituted 
biphenyl unit as an additional site of restricted single bond rotation.  Although ortho-substituents 
are mostly responsible for the biaryl bond restriction, the attachment of additional meta-
substituents is known to introduce further rotational restriction due to a “buttressing effect” (Figure 
14).  Computer simulations were carried out, based upon Kawano’s work on methyl-2,2',6-
trimethoxy-[1,1'-biphenyl]-3-carboxylate, to predict the biaryl rotational barrier to be 
approximately 27 kcal/mol at 343 K.77c    
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Figure 14.  N-aryl and aryl-aryl restricted rotation.  (a) Mislow’s acyclic and cyclic (ortho-tolyl) 
amide.76a  (b) Kawano’s o,o,m,o’-biphenyl.77c The meta substituent offers increased rotational 
restriction due to a “buttressing effect.” 
2.2.2.1 Substitution of CPL75-93 with biaryl (ortho-tolyl)amide-amino acid subunit 
The shape of the biaryl(ortho-tolyl)amide-amino acid was tested using mutational analysis in 
CPL75-93 to answer whether the torsion balance template had the correct orientation to match an 
antiparallel β-sheet. Modeling showed replacement of amino acids CPL81-87 with the biaryl (ortho-
tolyl)amide-amino acid template gave the correct native CPL80-75  and CPL88-93 β-strands on the top 
and bottom halves of the scaffold, respectively.  We remind the reader that our goal was not to 
model the turn, but rather to enforce the desired conformation for interchain hydrogen bonding in 
the antiparallel β-sheet motif.  Figure 15 shows this model and the relationship to the primary 
CPL75-93 β-hairpin sequence.  The biaryl (ortho-tolyl)amide-amino acid scaffold replaces CPL87-81 
and links residues L80 and L88, reinforcing the antiparallel β-sheet orientation. We anticipated our 
strategy could accommodate considerable amino acid sequence variation, permitting the use of our 
method to reproduce structures of other β-sheets.  This can be achieved by attaching the appropriate 
amino acid side chains on the top and bottom halves of the balance and replacing the turn sequence 
with our turn scaffold.  
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Figure 15.  Chemical structure of a native and mutant CPL75-93  β-hairpin for modeling the Wilcox 
β-turn mimetic torsion balance. The biaryl (ortho-tolyl)amide-amino acid template links truncated 
CPL hairpin strands at L80 and L88.  The strands are colored to match the cartoon of design 
requirements in Figure 11A as well as the CPL structural analysis (Figure 12; Figure 13). 
 
 
 
Computational models revealed that our peptide-torsion balance hybrid template, derived 
from CPL75-93, can directly reproduce the primary (Figure 15) and secondary (Figure 16) structures 
of a hydrogen-bonded antiparallel β-sheet motif.  Figure 16 shows the native and truncated three-
dimensional hairpin structures of CPL77-93 in I and II, respectively.  Though most turn mimetics 
are designed to replace  i + 1 and i + 2 residues, modeling revealed that replacement of CPL81-87 
provided the optimal geometry for our template to mimick the antiparallel β-sheet motif.  It was 
not our goal to mimic the sequence of CPL81-87, but rather to connect the strands at the correct 
angles and distances for interchain alignment to promote hydrogen bonding.  
Modeling revealed backbone modification with the torsion balance template gave dihedral 
angles within normal limits to connect two antiparallel β-strands, as indicated by the Ramachadran 
plot78 (Figure 16).  Initially, the emulation shown in III indicated the backbone of L80 did not 
match the orientation of our template to mimic CPL80-75 in a CPL93-75 hairpin.   Small changes in 
alignment of the lower C-N main chain of amide carbonyls, ranging from  = 109 in III to  = 
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129 in IV, improved alignment and did not cause the native peptide sequences to adopt an 
unnatural conformation. The clustered points within the plot represent the average backbone 
torsion angles for modeled conformers between values  = 109 and  = 129.  These are 
representative of conformers modeled between III and IV, and, correspond to the allowed regions 
of the Ramachadran plot -sheet conformation.  Modeling predicted the global minimum for the 
template structure as 86.5 kcal/mol (Figure 17).   
 The two conformational states of the torsion balance are observed upon introduction of 
the mutant CPL88-93  sequence to the upper aromatic ring.   The nonnative sequence is covalently 
linked to compete against the native top strand for pairwise amino acid hydrogen bond formation 
with the lower strand (Figure 11; Figure 13).  The -carbonyl ethers connecting the upper phenyl 
substructure to peptides adopts a low energy perpendicular conformation where the aliphatic C-O 
bond in the phenyl methoxy ether fragment is oriented perpendicular to the plane of the aromatic 
ring.  Molecular dynamics studies incorporating our scaffold indicated that conformational 
preference makes it feasible for one of the upper peptide side chains to hydrogen bond with the 
lower peptide side chain, leading to a compact hydrogen-bonded structure.  We considered the 
possibility of upper chains hydrogen bonding but did not find evidence of this (discussed in 
Chapter 5).  The test strategy would allow us to test if the torsion balance design was feasible to 
measure amino acid interactions in a hydrogen-bonded antiparallel β-sheet configuration.  An 
example of the folded and unfolded torsion balance, shown in Figure 11B, compares the effects of 
leucine insertion on reverse turn stabilization.   
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Figure 16. (a) Native CPL75-93 (I); truncated CPL77-93 gives CPL75-80 and CPL88-93 (II); overlay of 
biaryl (ortho-tolyl)amide-amino acid template to link CPL75-80 and CPL88-93 (III; IV). (b) Averaged 
backbone torsion angles benchmarked within the Ramachadran plot. The torsion is defined as Ci-1-
C-1-C-1’-C-i-1’ from NHC(O) to C(O)NH.  Rotation of the truncated strands from  = 109 to  = 
129 (from III and IV) enforces desired strand/strand alignment in allowed region for -sheets. 
Minimized structure of the biaryl(ortho-tolyl)amide amino acid template for -turn mimetic torsion 
balance scaffold from the side and bottom views. 
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Figure 17.  Minimized structures of the -turn mimetic torsion balance from the top (left) and 
bottom (right) views of (a) the core scaffold and  (b) tetrapeptide CPL derivative. (c) Formation of 
hydrophobic cluster between alkyl side chain residues in folded CPL75-93 reproduced from Figure 
13 for comparison to the hexapeptide mimetic.  PDB: 1XLR. 75a 
 
A secondary objective was to develop a reliable strategy to prepare a library of hairpin 
structures.  Our design allowed for this desired utility.  To address the unknown solubility of our 
model, a methyl ester was incorporated on the upper ring.  Ester hydrolysis could provide increased 
hydrophilicity to improve solubility in aqueous media for NMR experiments.  Aware of the 
problematic self-assembly of sheet mimics to form intermolecular hydrogen-bonded cross 
structures, we planned to acetylate the terminal amine to form an N-acetyl amide, and, amidate the 
terminal carboxylate to form an N-methyl amide to avoid intermolecular association.  These 
 
(
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(
c) 
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termini modifications have been shown in interleukin-8 (IL-8) to adopt the trans amide 
conformation required for -sheet formation and to prevent dimerization.79   
Structural assignment of the torsion balance derivatives is required to validate our design 
and accurately determine the effects of amino acid changes on β-turn configuration and stability.80  
Initial synthetic work and NMR experiments were described by Liberatore.81 1H NMR and EXSY 
experiments were described by Dr. Melissa Liberatore were used to calculate the torsion balance 
rotational barriers, which we discuss in Chapter 3.81  NMR data indicate the unfolded and folded 
states of the torsion balance are related as atropisomers in the biaryl template.  Although the 
modeled scaffold has the overall shape necessary to match with the ends of an anti-parallel β-sheet, 
further investigation of the torsion balance structure was necessary to probe hydrogen bond 
formation.  
 In the current study, we aimed to conformationally control the balance through 
incorporation of bromines ortho to the side chains, with the goal of investigating alignment of the 
o-methylene ether side chains on the top half of the balance to promote interchain hydrogen 
bonding.  Modeling suggests that 90˚ (relative to the plane of the aromatic ring) is the best angle 
to provide alignment (Figure 18).  To achieve this conformation, we introduced bromine atoms 
ortho to the aryl ethers to enforce intramolecular interchain hydrogen bonding. This strategy would 
allow us to minimize the conformational entropy at the site of nucleation by imposing a 
noncovalent steric constrain between the bromine and ether methylenes.  This technique was 
recently reported by Chatterjee et al. to induce a pseudoallylic strain between atoms of i+1 and i+2 
residues in the reverse turn. Computational models indicated the radius of bromine was the correct 
size to provide a steric effect on the ether side chains and impose the desired conformational bias 
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in our template. 1D and 2D NMR experiments were carried out to investigate preferential folding 
and stability of the β-turn sequence.   
 
Figure 18.  Conformationally controlled β-turn mimetic torsion balance core targets and control 
analogs. (a) 90˚ (relative to the plane of the aromatic ring) is the best angle to provide alignment for 
interchain hydrogen bonding in an antiparallel β-sheet motif. (b) Thermodynamic β-turn mimetic 
torsion balance core target 37 and control 38. Ac-Gly-N(H)Me-N(Me)2 Target 41 and control 42. 
(c) Kinetic β-turn mimetic torsion balance core target 39 and control 40. Ac-Gly-(N(H)Me)2 Target 
43 and control 44. 
 
2.2.2.2 ß-Turn Mimetic Template  
 
Core scaffolds of the thermodynamic (37) and kinetic (39) conformationally controlled β-turn 
mimetic torsion balances are shown in Figure 18.  These structures differ from controls 38 and 40 
by the presence of bromines on the top ring of 37 and 39.  We determined the control structures 
would be best to evaluate conformational effects from the bromines alone.  We hypothesized 41 
and 43 would form a stronger hydrogen bond than 42 and 44.  This study describes the synthesis 
toward targets 41 and 42.  
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2.3 SYNTHESIS OF A CONFORMATIONALLY CONTROLLED ß-TURN 
MIMETIC TORSION BALANCE CORE  
In this project, two alternate routes to core targets were examined. Our first experiments were 
directed toward the thermodynamic, or asymmetric, torsion balance, which has orthogonally 
protected side chains at positions a, b, and c.  The pathway was based on installment of two 
different upper side chains before the aryl coupling to give an asymmetrical balance (Scheme 1).  
In contrast, the second set of experiments discussed features addition of the upper side chains after 
the aryl coupling to form the kinetic, or symmetrical, biaryl core. 
 
 
 
 
Figure 19.  Orthogonal protection sites of conformationally controlled asymmetrical (37) and 
symmetrical (39)  β-turn mimetic torsion balance core scaffolds. 
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2.3.1 Asymmetrical Synthesis 
2.3.1.1  Method I 
Following Liberatore’s synthesis of the asymmetrical desbromo balance, we individually prepared  
the asymmetrical top and bottom halves of the balance for Suzuki coupling (Scheme 1.)81  Fischer 
esterification of commercially available 4-bromo-3,5-dihydroxybenzoic acid 45 afforded the 
methyl benzoate 46 in 99% yield.  Alkylation of 47 with commercially available t-butyl 
bromoacetate gave 47 in 35% yield.82  Asymmetrical product was separated from its symmetrical 
ether via flash chromatography and subjected to the alkylation protocol using commercially 
available benzyl bromoacetate to form asymmetrical coupling fragment 48 in 80% yield.82  The 
bottom half of the balance 50 was provided in 70% yield by subjecting commercially available 2-
bromo-6-nitrotoluene 49 to Miyaura boration conditions89 with bis(pinacolato)diboron ((Bpin)2) 
as the boron nucleophile.  Suzuki Miyaura cross-coupling reactionx of 48 and 50 provided biaryl 
51, which could then be brominated to afford the dibromo derivative 52.   
 
Scheme 1.   Synthesis toward asymmetrical β-turn mimetic torsion balance 37. 
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We anticipated the coupling step should be done before bromination because of the 
coupling fragments exhibiting a total of three ortho-substituents and a meta-substituent; 
dibromination of 48 would not only increase the difficulty of the coupling reaction due to the 
presence of two additional meta-substituents but also decrease the yield because of competing 
cross-couplings reactions. Treatment of fragments 47 and 48 with 
tris(dibenzylideneacetone)dipalladium(0) (Pd2(dba)3) in toluene, accompanied by Buchwald’s 
phosphine ligand88 afforded the Suzuki-Miyaura cross-coupled product 48 with a yield of 34%. 
Methods attempted to achieve dibromination ortho to the side chains to produce 51 from 52 were 
unsuccessful.   
2.3.1.2 Method II 
A modified synthetic route was developed (Scheme 2).  The pathway featured the addition of the 
upper side chains after the aryl coupling and after bromination.  Bromination on the phenol 
substrate before side chain attachment was readily achieved because of the enhanced activation 
and diminished steric hindrance of the phenol substrate in comparison with 51.  The alkylation 
step led to a symmetrical ether. Although this synthesis does not include the attachment of 
orthogonally protected side chains, our central question regarding the effect of dibromination on 
conformation could be answered using the symmetrical balance (Figure 19; Scheme 3) as 
discussed in Chapter 4.  
 
 
 
 
 
 42 
 
Scheme 2.   Synthesis of the torsion balance biaryl 57. 
 
 
Scheme 3.  Three conformers of torsion balance 44 and control 43 (enantiomers not shown). 
 
The synthesis of coupling fragment 53 was readily achieved with dimethylsulfate (DMS) 
to methylate commercially available 4-bromo-3,5-dihydroxybenzoic acid 45 in quantitative yield 
following recrystallization.86  Cross-coupling of bromide 53 with boronic ester 50 using the same 
conditions for the Suzuki-Miyaura reaction as before afforded 51 with an exceptional yield of 74%.  
The increase in percent yield compared to formation of 52 (a yield of 34% in Scheme 2) is most 
likely due to the less sterically hindered nature of 51.  We employed a two-step reaction sequence 
of non-selective demethylation and subsequent Fischer re-esterification to afford dihydroxy-biaryl 
ester 55 in 78% overall yield.  Biaryl 56 was subjected to 6 equivalents of BBr3 in dichloromethane 
(DCM) followed by immediate esterification of the acid.   Biaryl 54 was considered to be an 
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improved substrate for dibromination due to the more strongly electron-donating hydroxyl groups 
that replaced the inductively less activating -benzyloxycarbonyl ether groups and due to 
diminished steric hindrance compared to substrate 48.  Treatment of 54 with 2.5 equivalents of Br2 
in carbon tetrachloride (CCl4) afforded dibromination product 56 in 76% yield.
40  The symmetrical 
intermediate 57 was isolated in 80% yield after side chain attachment.   
2.3.2 Symmetrical Synthesis  
The bottom half of the balance was functionalized using the following protocol (Scheme 4). 
Reduction of biaryl 14 by Zn/HCl gave an 80% yield of 19.50  Treatment of 19 with 20, followed 
by reduction with NaBH4 afforded the methylated biaryl 60 in 53% yield.  Commercially available 
9-fluorenylmethyloxycarbonyl-glycine (Fmoc-Gly) was converted to its corresponding acid 
chloride 62 with thionyl chloride, which was immediately coupled with biaryl 60.  Amide 63 was 
isolated in 67% yield.  The final step to synthesize torsion balance core 39 involved treatment of 
63 with piperidine in DMF to deprotect the amino acid, followed by immediate acylation with 
acetic anhydride (Ac2O) and pyridine (76% yield). 
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Scheme 4.  Successful completion of the symmetrical glycine core 39.39 
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3.0  EVALUATION AND VALIDATION OF THE WILCOX ß-TURN MIMETIC 
TORSION BALANCE DESIGN 
The results in Section 3.1 have been published in: 
Liberatore, M. A. Synthesis and NMR Studies of a β-Turn Mimetic Molecular Torsion Balance. 
Ph.D. Dissertation, University of Pittsburgh, Pittsburgh, PA, 2012.81 
 
 
In order to establish the peptide-hybrid molecular torsion balance scaffold as a viable β-turn mimic 
for the anti-parallel β-sheet motif, it was essential to first validate the novel design as a molecular 
torsion balance. Generally, a molecular torsion balance connects two functional groups (the top 
and bottom halves) by a gently restricted bond rotatable at room temperature (G‡ = 14 kcal/mol) 
for detection of intramolecular folding preferences between the top and bottom halves by 1H NMR. 
Liberatore evaluated rotational restriction of the desbromo torsion balance scaffold to meet the 
general criteria, which provides a foundation for our study of the dibromo torsion balance.  
3.1 CONFORMATIONAL ANALYSIS OF CORE STRUCTURE  
Model systems were used to gain insight into the folding preferences of advanced torsion balance 
derivatives (Figure 20).  Carbamates 64 and 65 and amides 66 and 67 were analyzed by dynamic 
line shape analyses and EXSY experiments to determine torsion balance rotational barriers about 
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the aryl amide and N-aryl bonds, respectively.19 Biaryl amine 68 was studied by HPLC kinetic 
equilibrium methods to determine the torsion balance aryl-aryl barrier to rotation.17   
 
 
 
Figure 20.  Systems studied to determine folding preferences of the β-turn mimetic torsion balance 
scaffold.81  (a) Models for quantifying aryl amide, N-aryl and aryl-aryl bond rotational barriers. (b) 
Example β-turn mimetic torsion balance derivative and possible rotations around N-aryl and aryl 
amide bonds. The R groups are different and each represents an amino acid. 
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Liberatore’s results quantify restricted rotation around the aryl amide N-C(O), N-aryl and 
aryl-aryl bonds.81  Results of conformational analyses of 64-7 are reported in Table 6.  The R 
groups studied were determined to have no effect on bond rotation, and therefore data reported for 
carbamates 64-65 and amides 66-67 are the same for each pair of model systems.  The methyl 
substituent ortho to the carbamate led to a larger aryl amide N-C(O) rotational barrier (G‡ = 17 
kcal∙mol-1 at 298 K in CDCl3) for syn/anti rotamers of 64-65 compared to Smith’s 2-methyl-2-
propanylmethyl(phenyl)carbamates.102   
Smith reported a rotational barrier of 12.5 kcal∙mol-1 around the aryl amide N-C(O) axis in 
a series of para-substituted t-butyl N-methyl-N-aryl carbamates that unlike 64 and 65, lack a 
substituent ortho to the carbamate.  The aryl amide N-C(O) rotational barrier in 66 and 67 was 
approximated to be the same as that in 64 and 65.  The higher barrier to rotation about the N-aryl 
bond in 66 and 67 (G‡ = 21 kcal∙mol-1 at 343 K in toluene-d8) compared to that of the aryl amide 
N-C(O) bond, suggested that the N-aryl bond was responsible for the major conformer while the 
aryl N-C(O) bond rotation was responsible for the minor conformer in 1H NMR spectra at 298 K.  
This ratio of conformers was 93:7 in 66 and 67.  The aryl-aryl barrier to rotation in 68 (G‡ = 36 
kcal∙mol-1at 418 K in hexanes with a t1/2 = 2.2 days at 418 K or t1/2 = 2.8 x 106 years at 298 K) is 
so high that it is essentially a locked system at room temperature.  We expect the rotational barriers 
in these systems to provide a good estimate of those in advanced desbromo and dibromo torsion 
balance targets (Figure 20).   
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Table 6. N-Aryl and aryl amide N-C(O) rotational barriers in 64-67.81,108 
 
 
 
Compound       Bond     G‡a,b  T t1/2 (298 K)
c t1/2 (312 K)
c 
    (kcal/mol) (K) (s)     (s) 
64 N-C(O) (i) 17 298 0.2 0.04 
65 N-C(O) (i) 17 298 0.2 0.04 
66d N-C (ii) 21 343 140 30 
67d N-C (ii) 21 343 140 30 
a Calculated from line shape analysis of the 1H NMR spectra acquired on a 500 MHz NMR. b 
0.5 kcal/mol.   c Calculated usingG‡, assuming S‡ = 0.  d For G‡ of N-C(O) (i), see G‡ of 
N-C(O) (i) in 64 and 65.  
3.2 INVESTIGATION OF CONFORMATIONAL CONSTRAIN IN THE DIBROMO 
TORSION BALANCE  
In the desbromo torsion balance scaffold, there was no substituent ortho to the aryl ether bonds to 
restrict rotation about the aryl C-O axis.  We anticipated the incorporation of bromines ortho to 
the ether side chains would raise the aryl C-O rotational barrier.  Biaryl benzyloxycarbonyl diether 
58 was studied to realize the effects of bromines on the aryl C-O rotational axis.   
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3.2.1 Evaluation of Biaryl Benzyloxycarbonyl Diether 58 and Aryl Ether Bond Rotation 
At 298 K, no evidence of restricted rotation was observed for biaryl benzyloxycarbonyl diether 58 
by 1H NMR analysis in CDCl3 and CD2Cl2.  This led us to examine 58 by 
1H NMR experiments 
in CD2Cl2 over a temperature range from 178 to 273 K to look for evidence of restricted rotation 
around the aryl C-O bond (Figure 21). If aryl C-O rotation was restricted in biaryl 58, we would 
expect to see diastereotopic -methylene protons, “A” and “B”, by 1H NMR.  
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(a)  
 
(b)          
      
Figure 21.   Conformational analysis of biaryl benzyloxycarbonyl diether 58. (a) Conformations I, 
II, and III.  The methylene protons syn and anti to the aryl methyl are shown in gold and blue, 
respectively.  (b) Effect of temperature on the 1H NMR spectra in CD2Cl2  (400 MHz) from 178 K 
to 298 K.   
 
Results of low temperature 1H NMR studies of 58 revealed evidence of conformational 
restriction about the aryl C-O axis.   The AB quartet of diastereotopic -methylene protons, “A” 
and “B”, broadens as temperature decreases and begins to separate into two AB quartets at 183 K. 
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Our hypothesis is one AB quartet is due to -methylene protons that are syn to the amine, and the 
other is due to -methylene protons that are anti to the amine.  These syn and anti conformations 
are highlighted in Figure 21 in gold and blue, respectively.  We expect very similar chemical shifts 
between protons highlighted in blue in 58-I and 58-II, and between protons highlighted in gold in 
58-II and 58-III.   The methyl ester’s methyl proton signal “F” also broadens with decreasing 
temperature and splits into two signals at 183 K, overlapping with the AB quartet of the methylene 
protons.  Additionally, the 1H NMR spectra show the broadening of aromatic protons “C”, “D” 
and “E”.  The doublet of the aromatic proton “C”, ortho to the top aryl group, splits into two 
doublets at 183 K.  This behavior of proton “C” provides further evidence to support our 
hypothesis.  Altogether these observations are consistent with restricted bond rotation around the 
aryl C-O bonds.   
 
 
 
Figure 22.  Simulated and experimental 1H NMR data of biaryl benzyloxycarbonyl diether 58 in 
CD2Cl2 (400 MHz) at 183 K. 
 
Dynamic NMR simulations of these data at 183 K were created using iNMR and agreed 
well with our above hypothesis (Figure 22).  The simulation used a simplified model in that we 
assumed all syn methylene chemical shifts would be the same, and all anti methylene chemical 
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shifts would be the same, as mentioned above; however, it is expected there will be small 
differences amongst proton chemical shifts in those sets. We propose that the slightly different 
chemical shifts of each rotamer contribute to the broader appearance of methylene protons 
observed in the experimental spectrum compared to simulated data; yet, signal overlap of the two 
methyl ester’s methyl proton shifts may also contribute to this effect.  Because we did not know 
the exact chemical shifts of the AB quartet signals in the experimental 1H NMR spectrum due to 
signal overlap of the methyl ester and methylene protons, the value of the shifts and coupling 
constant used for the simulation of syn/anti protons of “A” were estimated. 
 
Table 7. Parameters employed for 1H NMR simulation of 58 (G‡ = 9.9 ± 0.5  
kcal∙mol-1).101 
1H A B C D E F 
N 1 1 1 1 1 3 
Multiplicity d d d dd d s 
1 (PPM) 3.96b 4.02 6.48 7.00 6.70 3.94 
2 (PPM) 3.94b 4.06 6.45 6.99 6.71 3.95 
J (Hz) 14.4b 14.4 8.0 8.0, 8.0 8.0 - 
a G‡ was determined from k = 5.0 s-1 using the Eyring equation.     b Estimated values. 
 
 
The simulation best fit experimental data at an exchange rate of 5.0 s-1. NMR line shape 
analysis provided the rotational barrier of biaryl benzyloxycarbonyl diether 58 of 9.9 ± 0.5 
kcal∙mol-1 at 183 K in CD2Cl2 (Table 7).  In a similar case, Yoshimura reported a barrier to rotation 
for silyl ketene acetal 70 to be 11.5 kcal∙mol-1 at 231 K (Figure 23).101  However, his molecule 
contains a methyl group at the branched α-carbon to the aryl C-O bond as well as  methylmethoxy 
and isopropyl groups ortho to the ether. The lower rotational barrier in 58 compared to 70 is most 
likely due to our structure being less bulky at the α-carbon. 
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11.5 kcal•mol-1 at 231 K in CD2Cl2 
Figure 23. Aryl ether rotational barrier of Yoshimura’s silyl ketene acetal 70.101 
3.2.2 Synthesis and Analysis of Biaryl Isopropyl Diether 71 
We further examined the rotational restriction about the aryl C-O bonds by investigating effects of 
alkyl group size on hindered C-O rotation.  We prepared biaryl isopropyl diether 71 for variable 
temperate 1H NMR data collection to reevaluate the rotational barrier using line shape analysis.  In 
the isopropyl case, we would be able to observe the behavior of the diastereotopic methyl doublets.  
This would eliminate 1H NMR signal overlap with the ester and ether side chains.   
3.2.2.1  Synthesis of biaryl isopropyl diether 71 
Biaryl isopropyl diether 71 was prepared over a straightforward two-step sequence (Scheme 5). 
Alkylation of 56 with iodopropane and K2CO3 in acetone gave 72 in 54% yield.  Intermediate 72 
was subjected to nitro group reduction using Zn/HCl from 0 C to 298 K for 13 hours to produce 
71 in 83% yield.  
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Scheme 5.Synthesis of biaryl isopropyl diether 71.  
 
 
 
3.2.2.2  Analysis of biaryl isopropyl diether 71 
We subjected 71 to variable temperature 1H NMR experiments from 183 K to 298 K in CD2Cl2 to 
examine the restricted rotational barrier about the aryl C-O bond (Figure 24).  The 1H NMR 
spectrum of isopropyl diether biaryl 71 at 298 K revealed only one set of peaks.  If the rate was 
lower than 0.017 s-1 and if -methyl protons, “A” and “B”, have different chemical shifts, we 
would expect aryl C-O rotation to be sufficiently restricted in 71 and to permit observation of 
diastereotopic -methyl protons, “A” and “B”, in the 1H NMR spectrum.   
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(a) 
 
(b) 
 
Figure 24. Conformational analysis of biaryl isopropyl diether 71.  (a) Conformations I, II, and III. 
The methyls syn and anti to the aryl methyl are shown in gold and blue, respectively.  (b) Effect of 
temperature on the 1H NMR spectra in CD2Cl2 (400 MHz) from 193 K to 298 K.  The block on the 
right shows the aryl methyl protons and diastereotopic methyl protons of the isopropyls (A/B) at a 
decreased intensity, relative to that of the downfield aromatic and methine proton signals.  
 
The 1H NMR spectra of 71 provided evidence of conformational dynamics without the 
signal overlap that complicated the spectrum of 58 (Figure 24).  The methyl doublets of the 
diastereotopic isopropyl protons, “A” and “B”, broaden as temperature decreases but never resolve 
into four peaks.  The aromatic protons “C”, “D” and “E” behave similarly to those of 58, in that 
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signals broaden with decreasing temperature.  Because we were unable to recover meaningful data 
at temperatures lower than 193 K, the splitting of aromatic proton “C” and methine proton “F” 
into two separate signals was not observed; however, the aryl methyl protons on the lower ring 
broaden as temperature decreases and split into two signals at 193 K.  We hypothesize this is due 
to the syn and anti conformations of the diastereotopic methyl protons, highlighted in gold and 
blue, respectively, in Figure 24.  This observation is consistent with restricted bond rotation around 
the aryl C-O bonds.  
The rotational barrier of biaryl isopropyl diether 58 was determined to be 10.7 ± 0.5 
kcal∙mol-1 at 193 K in CD2Cl2 by dynamic line shape analysis (k = 3.2 s-1; Figure 25).  This barrier 
for 71 is higher than that of 58.  Their difference (G‡ = 0.5 kcal∙mol-1 at 193 K) is most likely 
due to the increased steric hindrance at the -carbon.  The bulkiness of the isopropyl methyls (“A” 
and “B”) create additional steric crowding over the -benzyloxycarbonyls of 71.   In this 
simulation, as in the simulation of 58, expected small differences in chemical shifts of methyl 
protons are not incorporated. This may be the reason for the simulated peaks being slightly more 
narrow than the experimental result.  
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Figure 25.  Experimental (top) and simulated (bottom) 1H NMR spectra of biaryl isopropyl   diether 
71 in CD2Cl2 (400 MHz) at 193 K using iNMR.   
 
These results quantify restricted rotation about the aryl ether bond in the dibromo -turn 
mimetic torsion balance (Table 8).  The aryl C-O barrier to rotation calculated for C-O bonds in 
biaryl  isopropyl diether 71 and Yoshimura’s silyl ketene acetal 70 (10.7 ± 0.5 kcal∙mol-1 at 193 K 
in CD2Cl2 and 11.5 kcal∙mol-1 at 231 K in toluene-d8, respectively) are in close agreement; however  
the slightly greater barrier observed for 70 is most likely due to steric crowding from the additional 
bulk at the - and -carbons and aryl C2 and C6 positions.   
 
 
 
 
Methyls  
A/B 
Methine 
F 
 58 
Table 8.  Aryl C-O rotational barriers in 58, 70101 and 71. 
 
 
 
Compound ka G‡b,c T t1/2  (193 K)
d t1/2  (213 K)
d 
 (s-1) (kcal/mol) (K) (s) (s) 
58 10.3 10 193 0.067 0.0056 
70 3.2 11 193 0.22 0.017 
71  11.5 231 - - 
 a  Exchange rates that best matched the simulation to the experimental data.  b Calculated from line shape 
analysis of the 1H NMR spectra acquired on a 400 MHz NMR.  c 0.5 kcal/mol. d Calculated using given 
G‡ assumingS‡ = 0.  
3.3 CONFORMATIONAL ANALYSIS OF THE DIBROMO ß-TURN MIMETIC 
TORSION BALANCE CORE  
Because we hypothesized bromine incorporation ortho to the aryl ether bonds would provide steric 
control of upper side chain conformation to improve the structure of our peptide-torsion balance 
for -turn mimicry and interchain hydrogen bonding in an antiparallel -sheet configuration, the 
effects of bromine incorporation on the core conformation were assessed for evidence of 
improvement.     
When both side chains of the dibromo -turn mimetic torsion balance core are the same 
and have only achiral elements, rotation around the N–aryl bonds leads only to enantiomers;  
rotation around the aryl amide N-C(O) bond leads to diastereomers.  Of these diastereomers, only 
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the E isomer has the potential to form an interchain hydrogen bond. Thus, a conformational study 
was carried out on the core structure (Gly target 13) to preliminarily evaluate the propensity of the 
dibromo torsion balance to mimic a -turn and participate in interchain hydrogen bonding.  Gly 
target 39 was subjected to 1H NMR and ROESY experiments in CDCl3 and CD2Cl2 at 298 K 
(Figures 26- 27).   
 
 
Figure  26.  1H NMR spectra of Gly target 39 in CDCl3 (bottom) and CD2Cl2 (top) at 298 K on a 
700 MHz NMR. The chemical shift in CDCl3 is slightly more downfield (δ = 3.25 ppm) than in 
CD2Cl2 (δ = 3.21 ppm).  
 
Because rotation around the N-aryl bond leads only to enantiomers in 39, we expected a 
simple NMR spectrum with only the two conformers that arise from rotation around the aryl amide 
N-C(O) bond.  Two aryl N-methyl group singlets are observed in 1H NMR spectra of 39 at 298 K 
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in both CDCl3 and CD2Cl2 (Figure 26).  ROESY and EXSY data support our hypothesis that 
restricted rotation around the aryl amide N-C(O) bond is responsible for the two conformers 
observed (Figure 27).  The E:Z ratio of 39 was found to be 94:6. This ratio confirms an isomeric 
preference in the dibromo core that is necessary to achieve intramolecular hydrogen bond 
formation within our peptide-torsion balance scaffold.   This work is significant because it will 
inform our later studies in folding preferences and hydrogen bond selectivity of advanced dibromo 
-turn mimetic derivatives.  
 
 
Figure 27.  Two conformers of Gly target 39 by rotation around the aryl amide N-C(O) bond.  
ROESY and EXSY data are highlighted for glycine methylene and N-methyl protons in CDCl3 at 
298 K. 
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4.0  SYNTHESIS AND NMR STUDIES OF MONOMETHYLAMIDE TARGET 43 
AND CONTROL 44  
 
The results in this chapter have been published in: 
Lypson, A.B. Wilcox, C.S. "Synthesis and NMR Analysis of a Conformationally Controlled 
β‑ Turn Mimetic Torsion Balance." Journal of Organic Chemistry, 2017, 82, 898-909. 
 
 
 
We extended our study of the torsion balance to further evaluate the effects of the bromines on 
folding when the ether side chains possess both a proton donor and acceptor.  Therefore, we 
changed the side chain esters to amides to enhance hydrogen bond formation.  Our goal was to 
detect any selectivity in the pattern for hydrogen bond formation, such as the glycine acetamide 
proton or the amide proton showing any preference to act as the hydrogen bond donor. The priority 
targets (dibromo target 43 and desbromo control 44) share the same symmetrical structure, variable 
only at the ortho-substituent of the ether side chains.  This would test the preference of an amino 
acid chain to hydrogen bond when the side chain is conformationally restricted. 
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4.1 RETROSYNTHETIC ANALYSIS OF MONOMETHYLAMIDE TARGET 43 AND 
CONTROL 44 
We envisioned the synthesis of 43 to proceed by amide coupling of acid precursor 45, after 
debenzylation of 39.  Control amide 44 could be formed by deprotection and amidation reactions 
of 73.  Biaryl 73 would be formed by Fmoc-deprotection and acylation of biaryl amine 74.   
 
Scheme 6.   Retrosynthetic pathway to target 43 and control 44. 
 
4.2 SYNTHESIS OF MONOMETHYLAMIDE TARGET 43 AND CONTROL 44 
 
The synthesis of target 44 is shown in Scheme 7.  Debenzylation of amide 39 by H2/PtO2 reduction 
generated diacid 45 in an excellent yield of 95% without any debromination product observed.103  
Amide coupling of diacid 32 by hydroxybenzotriazole (HOBt) with methylamine hydrochloride, 
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1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDCI), and 
diisopropylethylamine (DIEA) afforded the priority target 44 63% yield.  
 
 
Scheme 7.  Synthesis of symmetrical torsion balance derivative 43. 
 
 
Synthesis of control 44 is shown in Scheme 8.  Starting material 74 was supplied by 
Liberatore.81  Amide 73 was afforded in 70% yield by Fmoc deprotection by piperidine in DMF 
and subsequent acylation by treatment with acetic anhydride and pyridine.  The t-butyl ester was 
cleaved with TFA and the same conditions as employed for previous amide couplings afforded the 
control amide 44 in 24% yield. 
 
Scheme 8.  Synthetic steps to control 44. 
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4.3 NMR ASSIGNMENTS AND COMPARISON OF MONOMETHYLAMIDE 
TARGET 43 AND CONTROL 44  
Core target 44 was designed to conformationally control the ether side chains in order to improve 
the configuration of the β-sheet mimetic torsion balance by increasing amino acid hydrogen 
bonding. Evaluation of control amide 43 can provide insight into the degree of control the bromines 
contribute to the torsion balance structure and allow us to discover the preferred identity of the 
hydrogen bond donor/acceptor between the glycine amino acid and amide functionality.  
Conformers of 44 and 43 are shown in Scheme 9.  Only one enantiomer each for these three chiral 
molecules is shown.  Conformers A and B are conformational isomers of one another which 
present two alternative patterns of hydrogen bonding: In A, the top side chain is the hydrogen bond 
acceptor and the glycine acetamide acts as the hydrogen bond donor.   In B, the top side chain is 
the hydrogen bond donor and the glycine acetamide acts an acceptor.  Conformer C arises from 
rotation around the aryl amide N-C(O) amide bond.  Note that conformers A and B will 
interconvert rapidly, so it will not be possible to observe these conformers as separate signals in 
an NMR spectrum.  NMR analysis of the dibenzyl derivative A reveals, as expected, that A and/or 
B are the major conformers and C is a minor component in solution.   
Scheme 9.  Three conformers of gly target 43 and control 44 (enantiomers not shown). 
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In the assignment of NMR resonances observed in 44 and 43, 2D NMR spectroscopy was 
utilized to identify the 1H and 13C peaks of each conformer.  These include COSY, NOESY, 
ROESY, HMQC, and HMBC NMR experiments.  The ROESY data was most useful in assigning 
the acetyl methyl and aryl methyl as well as the amide protons.  Figure 28 and Table 9 include all 
of the 1H and  13C assignments for spectra in CD2Cl2.   
 
 
 
 
Figure 28.    Representation of balances 44 and 43 with atom numbering (hydrogen or carbon) for 
spectroscopic assignment. 
 
 
 
 
 
 
Figure 29.  ROESY and EXSY (700 MHz, CD2Cl2) assignments data for 43. 
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Table 9. Target 43 and control 44 1H (700 MHz, CD2Cl2) assignments and 13C (600 MHz, CD2Cl2) 
assignments. 
 Target 43   Control 44  
  No. 1H, ppm (major/minor) 13C, ppm  1H, ppm (major/minor) 13C, ppm 
1 -- 167.4  -- 168.0 
2 4.00 (s, 3H) 41.8  3.93 (s, 3H) 42.0 
3 -- 131.0  -- 131.1 
4 -- 111.1  7.38 (s, 1H) 108.2 
5 -- 111.4  7.39 (s, 1H) 108.7 
6 -- 153.2  -- 155.5 
7 -- 153.5  -- 155.9 
8 -- 140.0  -- 136.1 
9 4.18-4.00 (two AB q, 2H) 72.2  4.54, 4.34 (two ABq, 2H) 69.0 
10 -- 165.9  -- 166.2 
11 6.80, 6.03 (two broad s, 1H) --  6.08, 6.23 (two broad s, 1H) -- 
12 2.59, 2.47 (two d, 3H) 25.8  2.71, 2.64 (two s, 3H) 25.8 
13 -- 132.0  -- 132.5 
14 7.30, 7.17 (two d, 1H) 128.2  7.27, 7.17 (d, 1H) 127.7 
15 -- 135.8  -- 135.9 
16 7.43, 7.39 (two t, 1H) 129.3  7.44, 7.43 (t, 1H) 128.2 
17 -- 142.0  -- 141.7 
18 7.30, 7.26 (two d, 1H) 128.2  7.29, 7.22 (d, 1H) 123.7 
19 2.02, 1.98 (two s, 3H) 15.2  1.95, 1.88 (two s, 3H) 14.7 
20 3.36, 3.21 (two s, 3H) 36.5  3.37, 3.24 (two s, 3H) 36.5 
21 -- 165.9  -- 166.2 
22 4.30, 4.27 (qd, ABq, 2H) 41.8  4.25, 4.23 (qd, ABq, 2H) 42.0 
23 6.46, 6.36 (two broad s, 1H) --  6.38 (broad s, 1H) -- 
24 -- 168.7  -- 168.7 
25 2.00, 1.88 (two s, 3H) 23.2  2.10, 1.96 (two s, 3H) 23.1 
26 4.10, 4.00  (two ABq, 2H) 72.0  4.46, 4.42 (two ABq, 2H) 68.5 
27 -- 165.9  -- 166.2 
28 6.26, 6.19 (two broad s, 1H) --  5.72, 5.89 (two broad s, 1H) -- 
29 2.65 (d, 3H) 25.8  2.63 (d, 3H) 25.8 
 
The assignments of each 1H signal (Table 9) to its major and minor conformer were aided 
by the ROESY data (Figures 29-31).  The spectrum for control 44 is purposely displayed on the 
left.  Reading the images from left to right will showcase the differences in the spectral data, 
observed when the bromines are present. 
The three amide protons can be observed in Figure 30.  The major and minor conformers 
of 44 and 43 are identifiable among the broad singlets appearing between 5.4  and 6.5 .  The 
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spectra of the control exhibits apparent overlap of NH signals.  Only five NH signals are observed, 
rather than the six possible for three amide NH protons and two observable conformers.  Dynamic 
exchange and ROESY data for the three amide protons and their corresponding neighbors are 
depicted in Figure 30. 
  The most downfield amide proton signal “ii” of control 44 belongs to that of glycine.   We 
have highlighted the ROESY cross peak for this proton and the glycine -protons in Figure 30.  
Major and minor conformers appear to overlap for this proton (as shown by the dashed blue arrow).  
On the other hand, the data for dibromo balance 43 clearly show that it is the middle NH signal 
that corresponds to the major glycine conformer, while the most downfield major NH peak belongs 
to the methylamide proton “i”.  The minor conformer NH signal for “iii” appears most upfield.  
We interpret the large difference in chemical shift found for proton “ii” as being due to a hydrogen 
bond that is present in 43 but not in 44.  Since the gly NH barely moves, we believe its environment 
has not changed.  This also supports our conclusion that the top side chain is the hydrogen bond 
donor and the glycine acetamide is the hydrogen bond acceptor.  
 
ROESY/EXSY                            1H NMR of amide protons for 43 (top) and 44 (bottom)  
  
 
 
Figure 30.  Summary of ROESY/EXSY data (left) and 1H NMR spectra (right) of 43 and 44 in 
CD2Cl2 at 298 K for amide proton 1H NMR assignment of the major (B) and minor (C) conformers. 
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ROESY data were also helpful in assigning the acetyl and aryl methyl protons (Figure 31).  
These two signals are very close in chemical shift.  The data provide important clues.  In 43, it is 
the more upfield methyl signal that shows a strong ROESY effect due to the ether methylenes on 
the upper side chains (I).  At the same time, in 43, the more upfield methyl signal shows a ROESY 
effect due to the glycine methylenes (II).  This establishes that the upfield methyl is the aryl methyl 
and the downfield methyl is the acetyl methyl.  The opposite is observed in the dibromo case.  
Figure 31 also shows a ROESY effect due to the aryl N-methyl (III) that further supports our 
conclusion for 1H assignment of the methyl protons. 
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     ROESY                     Control (44) data                                           Dibromo (43) data 
 
 
 
 
 
 
 
Figure 31. Selected ROESY data of control 44 (left) versus dibromo gly target 43 (right) in CD2Cl2 
at 298 K for 1H assignment of (a) aryl methyl protons and of (b) upper side chain methylene protons. 
 
 
 
Several other prominent observations were used to evaluate conformational change 
between the target balance and the control.  As expected, 2D-ROESY data for dibromo biaryl 43 
show a significant off diagonal peak between the methylene protons on the upper side chains and 
the aromatic proton 14 ortho to the top aryl group (IV; Figure 31).  In contrast, the side chain 
methylenes in 44 have a much stronger cross peak with the upper ring protons 4 and 5 compared 
to  proton 14 (V). The side chains of 44 appear to be coplanar or close to coplanar with the upper 
aromatic ring (Figures 32-33).  CPK models show an interchain H-bond is possible in 43. 
(a) 
 
 
 
 
 
(b) 
43: X = Br 
44: X = H 
43: X = Br 
44: X = H 
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(a) 
  
 
(b) 
 
(c) 
 
 
Figure 32.  CPK models of 43 and 44. (a) Control 44 from front and back view; (b) control 44 from 
top and bottom view; (c) Gly target 43 from front, side and back view. 
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(a)               (b) 
                      
Figure 33.  Models of Gly target 43 and control 44.  (a) Gly control 44 model. Side chains do not 
show the necessary confirmation to achieve interchain hydrogen bonding between the upper and 
lower side chains. (b)  Example hydrogen-bonded confirmation of Gly target 43. The amide proton 
of the upper half is the hydrogen bond donor to the glycine acetamide hydrogen bond acceptor of 
the lower half. 
4.4 ANALYSIS OF MONOMETHYLAMIDE TARGET 43 
4.4.1 Folding Preference of Monomethylamide Target 43 
1H NMR and ROESY experiments were performed to evaluate solvation and concentration effects 
on torsion balance folding.  NMR data collected at concentrations of 1 and 10 mM in CDCl3, C7D8, 
and CD2Cl2, did not have an impact on the chemical shift or folding ratio.  There were some 
solvation effects noted.  Figure 34 shows a comparison of an expanded region of the 1H NMR data 
of 43 in three solvents.  The chemical shifts in CDCl3 and CD2Cl2 were similar but different in 
C7D8.  This was expected since hydrogen bonding is known to be promoted in C7D8.
106  Deuterated 
chloroform and dichloromethane are known to compete for hydrogen bonding sites in comparison 
with toluene-d8 because it is acidic in comparison to its relatively low polarity.  Therefore, the 
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degree of hydrogen bonding between the upper amide chain and lower glycine chain appear to be 
influenced by solvation.  However, the 1H NMR data was assigned in CD2Cl2 since its solvent peak 
did not interfere with any proton signals of the torsion balance.  This is unlike CDCl3 and C7D8, 
which obscured the aromatic, aryl methyl, and acetyl methyl regions (Figure 34; aromatic region 
not shown).  
 
 
 
Figure 34.  1H NMR spectra of 43 (700 MHz) in CDCl3 (bottom), CD2Cl2 (middle) and C7D8 (top) 
at 298 K.   
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4.4.2 Evaluation of Hydrogen Bond Formation in Monomethylamide Target 43 
Our next goal was to measure the effect of the dibromo balance core on the expected hydrogen 
bond formation by 1H NMR experiments from 213 to 273 K.  Gellman et al. has reported on low 
temperature NMR studies to indicate hydrogen bond formation.76  Due to the presence of 
neighboring atoms competing in intramolecular hydrogen bonds, our findings from low 
temperature 1H NMR studies were inconclusive. 
1H NMR studies were performed on 43 in C7D8 over a temperature range of 298 K to 338 
K.  Interesting behavior was observed for the N-methyl protons (Figure 35). 1H peaks for the major 
(“B-iv”) and minor (“C-iv”) N-methyl protons of the methylamide are distinguishable at 298 K 
(2.54 δ and 2.58 δ, respectively). The signals broaden and coalesce into one broad singlet at 323 
K.  Note only one distinct doublet signal for protons 12 at 338 K. This observed behavior suggests 
fast rotation occurring around the N-methyl bonds above 333 K.  This observation is in agreement 
with intramolecular hydrogen bond weakening or breaking in toluene-d8 amide methyl protons.111 
is suggestive that   is in  identifies supports ROESY data used to determine hydrogen bonding  the 
amide participating in hydrogen bonding, and thus supports our conclusion of hydrogen bond 
formation in the major conformer.   
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Figure 35.  The effect of temperature on the 1H NMR of N-methyl protons in 43 in C7D8 from 298 
K to 338 K.   
4.5 SUMMARY OF STUDIES OF MONOMETHYL TARGET 43 AND CONTROL 44  
In conclusion, a new conformationally controlled torsion balance can be applied toward 
quantitative comparison of side chain interactions in the antiparallel β-sheet motif.   The design 
has previously shown a restricted N-aryl bond rotation to impose a two-state folding manifold to 
mimic the potential folding dynamics of a β-turn.  However, the dibromo design features an 
additional degree of conformational control by the incorporation of the bromo substituents ortho 
to the upper side chains.   
C-iv 
iv 
B-iv 
 
 
 
 
 
 
 
 
 
 
iv 
iv 
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Through 1H and 2D ROESY NMR analyses of 43 and 44, we have determined the dibromo 
scaffold has improved the balance’s shape to mimic the ends of an anti-parallel β-sheet.  The side 
chains participating in hydrogen bond formation have the correct configuration and appear to 
display the required distance in interchain hydrogen-bonded amino acids.  Furthermore, we have 
identified the NH amide proton of the top side chain to be the hydrogen bond donor and the glycine 
acetamide as the hydrogen bond acceptor.   
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5.0  ADVANCED ß-TURN MIMETIC TARGETS 76-78 
5.1 DESIGN AND RETROSYNTHETIC ANALYSIS OF ADVANCED ß-TURN 
MIMETIC TARGETS 76-78 
5.1.1 Polypeptide Derivatives 
We next focused on developing more advanced analogs of the symmetrical scaffold of the dibromo 
β-turn mimetic torsion balance (Figure 36).  Derivatives 75 and 76 were chosen to continue our 
investigation into the conformational control present in the dibromo scaffold.  Specifically, we 
planned to search for evidence to study the formation of two interchain hydrogen bonds.  Verifying 
the presence of two hydrogen bonds by 1D and 2D NMR could further validate a structural match 
between the antiparallel -sheet motif and our -turn mimetic torsion balance scaffold.  Alanine 
was selected as the amino acid in 75 to simplify interpretation of NMR data and provide a good 
basis for comparison in studying bulkier side chains like isoleucine in 76.  Further extension of the 
peptide chains would allow us to develop polypeptide targets, such as torsion balance 77. The 
amino acid sequence in 78 was based upon the hydrophobic sequence of the -sheet neighboring 
the CPL-VNL binding pocket, as described in Chapter 1.  Conformational analysis of 77 would be 
paramount to validating the torsion balance configuration to mirror the interactions in the bioactive 
antiparallel -sheet motif. 
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Figure 36.  Advanced polypeptides of the symmetrical dibromo -turn mimetic torsion balance for 
detection of two (75-76) and five (77) interchain hydrogen bonds. 
 
 
 
Synthesis of target 75 would require iterative peptide bond formation for extension of the 
lower side chain with protected amino acids.  Many solution-phase synthetic strategies for the 
installation of amide bonds have been demonstrated to be useful to synthesize peptide chains;105 
however in our case, enhanced access to iterative peptide bond formations from solid-phase 
peptide synthesis (SPPS) was of interest, particularly for developing advanced targets, such as 77.  
Since its advent in 1963,104a SPPS has been well-improved due to microwave-assisted Fmoc-
SPPS.104b,106-7  The value of SPPS has been proven in the synthesis of many natural and modified 
peptide sequences.68  Advantages, such as high product yields by use of excess soluble reagents 
and simple purification from soluble reagents and byproducts, would allow access to a diverse 
library of the β-turn mimetic torsion balance.108  Our interest in applying SPPS methods led to a 
collaboration with Horne and colleagues.  Based on discussions with Dr. Horne about his work on 
backbone alteration of the B1 domain of Streptococcal protein G (GB1),109  we identified hairpin 
torsion balance 78 and closed hairpin control 79  as additional targets (Figure 37).   
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Figure 37. GB1 -turn sequence modification for torsion balance derivatives 78 and 79.  (a) 
Sequence and structural map for GB1.  (b) Structural analysis of GB1. PDB: 2QMT.115a  (c) Model 
-hairpin system derived from GB1.  (d) The peptide backbone structure of model -turn for 
substitution by torsion balance scaffold, as shown in part (e).  The disulfide linkages between 
cysteine residues for 79 (not shown) provide cyclic control hairpins. 
 
 
GB1 is only 56 residues in length and contains four β-strands to form two β-sheets 
connected by an -helix (Figure 37A; B).  GB1 can be prepared by SPPS or by protein expression 
in bacteria and sixteen residue fragments of the C- and N-termina are known to form β-hairpins in 
aqueous solution, like those in Figure 37B.117 In addition to being well-describe by NMR and X-
ray,115 GB1 has been shown that GB1 is amenable to backbone modification and side chain 
substitution.  Introducing our β-turn mimetic torsion balance into GB1 anti-parallel β-sheet mimics 
(Figure 37C; D) would allow the effects of backbone modification on the formation of interchain 
hydrogen-bonded interactions in the antiparallel β-sheet motif to be studied.  The long-term goal 
for this project would be to establish methodology for insertion of our β-turn mimetic torsion 
balance into a protein that has a tertiary folded structure.  Furthermore, in using the GB1 domain, 
we can study modification effects on folding and function.   Because the crystal for GB1 is known, 
crystals of GB1 mutants can be studied to compare mutation effects on peptide folding.  In 
(a) 
 
 
 
(b) 
 
 
 
 
 
 
(d) 
(e) 
 
(c) 
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addition, competitive binding assays with immunoglobin G (IgG)116 using the selected GB1 
segment are available to compare to our mutant GB1 to probe mutation effects on protein function.   
Factors considered in planning the synthesis of advanced derivatives 75-79 included 
selection of solid support, choice of protection of side chains and amino acids as well as 
appropriate conditions for attachment and cleavage reactions.  SPPS required the immobilization 
of the torsion balance substrate onto a solid support.  Consequently, a resin attachment site was an 
additional design consideration for our torsion balance scaffold.  Our molecular design of the 
precursor for SPPS was based on the torsion balance core that included a functional group suitable 
to attach to resin by SPPS.  As in our synthetic strategy introduced in Chapter 2, chain extension 
demanded orthogonal protection of the top and bottom strands.   
 
Scheme 10. (a) The symmetrical dibromo -turn mimetic torsion balance scaffold. (b) 
Retrosynthetic analysis of the torsion balance core Gly target 39. 
 
 
 
The carboxyl group at the C3 position of the upper ring was exploited for resin attachment 
because the side chains would be free for amidation to produce symmetrical product.  We reasoned 
that if the torsion balance methyl ester could be obtained as a free carboxylic acid, the latter could 
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be activated for nucleophilic resin attachment and desired targets 75-79 formed by SPPS. 
Hydrolysis could be incorporated into our established solution-phase synthesis of the torsion 
balance core, described in Chapter 1 and reproduced in Scheme 10.  
Polystyrene PHB Wang resins (80) were selected for resin attachment (Table 10).  
Specifically, the electrophilicity of bromo Wang resin 80b was thought to be well-suited for 
nucleophilic resin attachment by the torsion balance carboxylic acid.  The Wang resin is the most 
prevalent solid support used for carboxylic acid resin attachment in SPPS and employs moderate 
cleavage conditions with TFA.117,119  Perhaps most noteworthy is that Wang resin-bound material 
is known to survive a variety of transformations, such as Suzuki coupling following carbodiimide 
coupling to generate vinyl and iodobenzoic acids.121  Given the loading efficiency and versatility 
of the Wang resin, we planned to explore its utility for the solid-state synthetic route.    
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Table 10. Resins considered for SPPS. 
Resin Name Structure 
PEG/PS Wang resin 
 
 
PEG/PS Bromo Wang resin 
 
 
NOVAPeg Rink amide resin 
 
Rink amide AM resin 
 
 
 
For SPPS to be successful, it was necessary that conditions for orthogonal deprotection of 
the side chains and amino acid coupling not lead to premature substrate-resin cleavage.  Protecting 
groups were selected based on these criteria.  The allyl ester, commonly used in SPPS to protect 
carboxy groups,121 was selected for upper side chain protection. We reasoned that employment of 
the allyl ester protecting group would allow us to selectively deprotect the esters of the upper side 
chains under nonhydrolytic conditions and therefore would  prevent undesired side reactions at the 
attachment/cleavage site and on the lower chain resin.  
 For lower side chain protection,  Fmoc, the most common amino acid protecting group 
for SPPS, was selected.116-7 Using base labile -amino Fmoc deprotection would prevent 
undesirable side reactions with the resin or the upper side chain.  Thus, carboxylic acid 83 was 
determined to be the starting material for SPPS (Scheme 11). 
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Scheme 11.  Target SPPS precursor 83. 
 
 
Our synthesis relies on solid- and solution-phase routes (Scheme 12).  These solid-phase 
syntheses require orthogonal deprotection and amidation to the upper and lower side chains 
following resin loading of substrate 83.  Targets 75 and 76 would be synthesized from 84 and 85, 
respectively, by benzyl deprotection and amidation with N-methyl amine followed by resin 
cleavage with TFA. Extension of the lower chain to form Gly-Ala dipeptide 84 would include 
Fmoc deprotection of glycine in amide 86 and subsequent coupling with commercially available 
acetyl-L-alanine 88.  Gly-Leu dipeptide 85 would be synthesized using this same strategy, but with 
Gly biaryl 87 and acetyl-L-leucine 89.  A three-step sequence would construct amides 86 and 87: 
resin loading of carboxylic acid biaryl 83 to Wang resin (80), deprotection of allyl esters and by 
segment condensation with benzyl protected amino acid (90 or 91).   
 The synthesis of 83 employed solution-phase methods. The retrosynthetic analysis 
suggested that 83 would arise from amine 92 by coupling Fmoc-protected L-glycine acid chloride 
to N-methyl amine 92 to install the lower glycine side chain.  Carpino’s conditions would be used 
to generate the requisite acid chloride for coupling.  N-Methyl bond construction on the lower ring 
of 92 would be achieved by nitro group reduction of 93 and methylation of the resulting amine.  
We anticipated 93 would be synthesized through simultaneous hydrolysis of methyl and benzyl 
esters in 55 followed by esterification of the side chain acids.   
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Scheme 12.  Retrosynthetic analysis of 75-77 using solid- and solution-phase methods. 
 
 
 The synthetic strategy for 75 and 76 was envisioned to be a feasible route to form hairpin 
derivatives 77-79, as shown for 77 in Scheme 12.  Extension of the upper side chains in 83 would 
be accomplished by symmetrical segment condensation using synthesized peptide segment 94 after 
allyl deprotection and before a series of iterative Fmoc deprotections and amino acid couplings to 
form resin-bound hairpin 96.   Cleavage of 96 from resin and amidation of upper side chain would 
provide 77.   
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5.1.2 Zwitterion Derivatives 
We were also interested in studying salt bridge formation and its effects on conformation in the 
dibromo torsion balance scaffold.  Specifically, we wanted to examine salt bridge formation 
between an amino acid ammonium on the torsion balance lower half and amino acid carboxylate 
on the torsion balance upper half.  Liberatore used EXSY analysis to determine effects of salt 
bridge stabiltiy on rates for a balance with a single alanine.81  The barriers were determined to be 
19.7 kcal∙mol-1 at 343 K in CD3CN and 22.6 kcal∙mol-1 at 373 K in deuterated buffer (pD 6.9), 
respectively. The higher rate in water shows that rotation in water is slower, most likely due to the 
capacity of water to form ion dipoles with electrostatic charges in the balance.  Because of the 
improved alignment of our dibromo core scaffold, it would be of interest to study that same effect 
in the dibrominated balance.   
Zwitterions 97 and 98 would test salt bridge effects on rates of rotation around the N-aryl 
bond (Figure 38).  NMR analysis of glycine zwitterion 97 would provide data pertaining to salt 
bridge effects on the torsion balance core structure, while analysis of glycine-alanine zwitterion 
98 would allow us to search for evidence of salt bridge effects after side chain extension.  Control 
amides 99 and 100 were chosen because they eliminate any charge effect by replacing the amine 
with an N-acetyl amide group.  Comparison of NMR data for 97 and 99 would help to reveal 
evidence of salt bridge effects on conformation of the torsion balance core, while comparison of 
98 and 100 would provide insight into salt bridge effects on the formation of two interchain 
hydrogen bonds. After this assessment, we planned to further our study via preparation and 
analysis of a Gly-Leu zwitterion derivative.  
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Figure 38.  Zwitterions 97-98 and control amides 99-100 of the symmetrical dibromo -turn 
mimetic to determine salt bridge effects on rates of N-aryl bond rotation. 
 
Our proposed syntheses of zwitterions 97 and 98 and amides 59 and 60 were based on 
solution phase methods only. The desired zwitterions would be prepared by benzyl and Fmoc 
deprotections of Gly and Gly-Ala derivatives 38 and 101, respectively (Scheme 13).  In our 
proposed synthesis, control amides 99 and 100 would be prepared from amide acetylation, after 
benzyl and Fmoc deprotection of 38 and 101, respectively.  Protected Gly-Ala derivative 101 
would be synthesized from 38 by deprotection and amidation reactions to the upper and lower side 
chains and acetylation of the lower chain amine.   
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Scheme 13.  Retrosynthetic analysis of zwitterions 97-98 and control amides 59-60. 
 
5.2 UPPER SIDE CHAIN PROTECTION STRATEGIES  
We were seeking conditions that would not require separate protection of the aromatic carboxylic 
acid to achieve protection of the hydroxycarbonyl ethers.  Liberatore was unable to achieve 
selectivity in the desbromo analogue; however, the electronic effect of the bromines on the upper 
aromatic ring in the dibromo scaffold would alter the reactivity of the aromatic acid.  We used 
model systems to test reaction conditions of two proposed methods.  
5.2.1 Allyl Protection of Hydroxycarbonyl Ethers 
To use the carboxylic acid of the upper half of the balance as the resin attachment site (Scheme 
14), we needed to protect the side chains.  We chose to use allyl groups.  Our plan was to hydrolyze 
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the methyl and benzyl esters in 55 and then attach the allyl groups to the carboxylic acids on the 
upper side chains by N,N’-dicyclohexylcarbodiimide (DCC) coupling with allyl alcohol.   
 
Scheme 14.  Reaction conditions for upper side chain protection. 
 
 
An important question to be answered was whether the allyl esterification method would 
be selective for the aliphatic carboxylic acids compared to the aromatic carboxylic acid. We 
reasoned that aliphatic carboxylic acids could be more reactive because they are less sterically 
hindered.  To test this, we carried out reactions in Scheme 15.  Test substrate 105 was made 
available by hydrolysis and subsequent bromination of 63.  Subjecting 105 to esterification 
conditions with DCC and allyl alcohol gave a mixture of products that arose from esterification of 
side chain and aromatic carboxylic acids.  This observed lack of selectivity led us to consider 
alternate synthetic methods.   
 
Scheme 15.  Test reaction conditions for upper side chain protection. 
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5.2.2 Incorporation of Allyloxycarbonyl Ethers 
Our new strategy was to introduce protected side chains, allyloxycarbonyl ethers, instead of adding 
protection to already attached hydroxycarbonyl ethers. We intended to find conditions that would 
not require a separate protecting group for the acid.  Liberatore reported a lack of selectivity in the 
desbromo benzoic acid.  We wondered if the bromines in our scaffold would alter this result.  
Model system 66 was studied to determine if a separate protecting group was needed for the 
carboxylic acid in order to allow for selective alkylation of the phenols enroute to our SPPS 
substrate, Fmoc-Gly target 83.  We investigated the relative reactivity of the hydroxyl groups and 
benzoic acid by silylation and by alkylation (Table 11).  Reaction progress was monitored by TLC.  
If the acid was more reactive than the phenols by alkylation, our synthesis would require a separate 
protecting group for the acid, such as the silyl (if selective for the acid) or benzyl group.  In that 
case, deprotection conditions would need to prevent side reactions with the upper and lower side 
chains.   
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Table 11.  Phenol reactivity test and results of alkylation to form 111. 
  
Entry Classification   Conditionsa Productb Yield 
1 silylation TBSCl (1 equiv), TEA (1 equiv), DCM, rt, 13 h  111 52% 
2 silylation TBSCl (2 equiv), TEA (3 equiv), DCM, rt, 13 h  108 47% 
3c silylation TBSCl (1 equiv), TEA (2 equiv), DCM, rt, 13h  112 54% 
4 alkylation 110 (2 equiv), TEA (3 equiv), DCM, rt, 13 h  111 43% 
5 alkylation 110 (2 equiv), K2CO3 (3.3 equiv), 18-c-6, acetone, 
reflux, 20 h 
112 64% 
6 alkylation 110= (2 equiv), TEA (2 equiv), DCM, rt, 13 h  111 48% 
7 alkylation 110 (2 equiv), K2CO3 (2.2 equiv), 18-c-6, acetone, 
reflux, 20 h 
112 74% 
a 0.13 mmol scale;  b Major product observed. c Monoether 108 was used as starting material. 
 
Model substrate 107 was prepared by treating commercially available 4-bromo-3,5-
dihydroxybenzoic acid 45 with bromine.  Dibromo 107 gave monosilyl ether upon treatment with 
1 equivalent of TEA and 1 equivalent of TBSCl at room temperature.  When monosilyl ether 108 
was subjected to 2 equivalents of TEA and 1 equivalent of TBSCl, diether 109 was furnished in 
54% yield.  We attempted to alkylate 107 by similar chemical means without protecting the acid 
(Table 11).  First, allyl bromoacetate (110) was formed by heating allyl alcohol and bromo acetic 
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acid in cyclohexane with catalytic p-toluenesulfonic acid (pTsOH) under Dean-Stark 
conditions.[ref]  Alkylation of dihydroxybenzoic acid 107 with 110 using 2 equivalents of TEA at 
room temperature afforded diether 111 in 43% yield.  When the alkylation was carried out in 
refluxing acetone with K2CO3, 112 was identified as the major product.  The chemoselectivity 
using K2CO3 method was poor compared to the selectivity observed in the TEA-mediated reaction.  
This may be due to the higher temperature needed for the reaction to proceed with K2CO3. The 
observed results suggested that a separate protecting group for the carboxylic acid would not be 
required before subjecting the biaryl complex to the TEA-mediated alkylation.   
Hydrolysis of biaryl methyl ester 56 provided dihydroxy acid 113, which was subjected to 
the aforementioned TEA etherification conditions with allyl bromoacetate 110 to accomplish the 
intended alkylation of the phenol groups (Scheme 16).  In Chapter 5, we discuss methods to 
improve the yield of the hydrolysis step.  The target biaryl carboxylic acid 103 was afforded in 
48% yield.   
 
Scheme 16.   Synthesis of carboxylic acid 103 for upper side chain protection. 
 
5.3 UPPER SIDE CHAIN EXTENSION STRATEGY 
With acid 103 in hand, we focused on testing upper side chain extension on-resin.  Our objective 
was to measure the efficiency of resin coupling to aromatic acid and of amino acid coupling to the 
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aliphatic acids.  We intended to use the PEG/PS (TentaGel) bromo Wang resin, which would 
require the conversion of commercially available Wang resin 80a to its bromo derivative (80b). 
To assess methods for resin loading, we subjected benzoic acid 109 to standard loading conditions 
using commercially available benzyl alcohol and benzyl bromide, which were reasoned to be fair 
models to test resin reactivity.  Like in the resin-loading step, substrate would be in excess to drive 
the reaction to completion.   
 
Scheme 17.  Test reaction conditions for resin loading. 
 
 
Coupling with benzyl alcohol using DCC and DMAP failed. When 108 and benzyl bromide 
were treated with DIEA and KI, the favored benzyl ester product 114 was detected by ESI-MS.  
This supported our hypothesis that the bromo Wang resin 80 would be more reactive with our 
substrate.  Therefore, we investigated the resin loading efficiency on substrates 103 and 111. 
 
5.3.1 Initial Evaluation of SPPS Strategy 
Commercially available Wang resin 80a was converted to the bromo derivative (80b) using 3 
equivalents of triphenyl phosphine dibromide (PPh3Br2) at room temperature (Scheme 18).
120  
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Benzoic acid 111 was loaded onto resin 80a by treatment with DIEA and KI.  The resin-bound 
material was capped using acetic anhydride (Ac2O) and DIEA. Treatment of product with 3.2 
equivalents of tetrakis(triphenylphosphine)palladium(0) (Pd(PPh3)4) followed by employment of 
commercially available 7-azabenzotriazol-1-yloxy)trispyrrolidinophosphonium 
hexafluorophosphate (PyAOP) and HOBt to activate the solid-supported acid in situ for amino acid 
coupling failed to provide diamide 75.  MALDI-TOF MS analysis of small scale TFA cleavage 
product revealed mono-deprotected allyl product and no tyrosine peptide 75.  Because our SPPS 
strategy for the upper side chain extension used C-terminal protected residues we could not employ 
simple tests, such as the Kaiser test, to measure amino acid coupling to our solid-supported 
substrate.  A second attempt to deprotect remaining monoallyl product using 3.2 equivalents of 
Pd(PPh3)4 also failed.  Faced with the result of unsuccessful allyl deprotection and amino acid 
coupling, we reexamined our SPPS protocol.   
 
Scheme 18. Initial attempt of upper side chain extension using SPPS. 
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5.3.2 Evaluation of Upper Side Chain Deprotection 
We needed more efficient analytical methods to monitor reaction progress.  ESI-MS and reverse-
phase HPLC methods were reasoned to be better techniques than MALDI-TOF MS to check the 
success of allyl group cleavage in our test substrate, therefore we explored reaction conditions off-
resin.  Results would indicate if the conditions were only producing monoallyl product or the 
desired symmetrical aliphatic acid on-resin, but also if the Pd(PPh3)4 was causing formation of 
bromine cleavage side product.  If monoallyl product was isolated in addition to the desired triacid 
product, we would be able to determine the retention time of each by reverse-phase HPLC analysis. 
With retention times known, we could have had a simpler analytical method than the 
aforementioned MALDI-TOF MS. 
5.3.3 Evaluation of Allyl Deprotection Conditions Off-Resin 
In separate reaction vessels, 111 was subjected to 3.2 equivalents of Pd(PPh3)4 with 48 equivalents 
of PhSiH3 in DCM and to 0.5 equivalent of Pd(PPh3)4 with 7.5 equivalents of PhSiH3 in DCM.  
Analysis of the crude mixture by ESI-MS did not reveal monoallyl product alongside desired 
triacid; however, monodebromination product was observed.  Reducing the amount of Pd(PPh3)4 
used from 3.2 to 0.5 equivalents of Pd(PPh3)4 did not entirely eliminate but did significantly reduce 
the amount of debromination.  Before developing HPLC methods for this system, we reexamined 
our SPPS protocol. 
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Table 12.  Results of allyl deprotection to form 102. 
 
 
 
 
 
Entry Substrate Conditionsa Product   X ESI MALDI 
1 116 
Pd(PPh3)4 (3.2 equiv), PhSiH3 (48 equiv), 
DCM, rt, 30 min 
 102e    Br - + 
    2 116 
Pd(PPh3)4 (3.2 equiv), PhSiH3 (48 equiv), 
DCM, rt, 30 min 
102e Br        - + 
3 102 
Pd(PPh3)4 (3.2 equiv), PhSiH3 (48 equiv), 
DCM, rt, 30 min 
  102b H + n/d 
4 102 
Pd(PPh3)4 (0.5 equiv), PhSiH3 (7.5 equiv), 
DCM, rt, 30 min 
  102a    Br + n/d 
5 116 
Pd(PPh3)4 (0.5 equiv), PhSiH3 (7.5 equiv), 
DCM, rt, 30 min 
  -    
a Scale = 0.03 mmol, 0.09 g.  Scale reported is based on scale of loading step. 
 
5.3.4 Evaluation of Allyl Deprotection Conditions On-Resin 
For our SPPS attempt using model substrate 111 (Scheme 19), reaction progress of the allyl 
deprotection step was monitored prior to the amino acid coupling step.  If conditions used for resin 
coupling and allyl deprotection were successful, we would expect to observe triacid product 102 
from exposing 116 to TFA.  On the other hand, if starting material 111 was observed, then only 
conditions used for resin coupling would be demonstrated to be successful.  
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Scheme 19.  SPPS test conditions for upper side chain extension. 
 
 
Our attempt to detect the desired allyl deprotection product by MALDI-TOF MS analysis 
failed.  Monoallyl product and starting material 65 were also undetected.  Unsure if product 
formation was unsuccessful or if our analytical method was unsuccessful at detecting formed 
product, we proceeded to the amidation step. 
5.3.5 Evaluation of Amino Acid Coupling 
The solid-state material was activated and subjected to microwave (MW) irradiation with L-
alanine benzyl ester.  After TFA-mediated cleavage, the crude product was subjected to analysis 
by MALDI-TOF MS and ESI-MS (Entry 3 in Table 13).    
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Table 13. Results of solid-state amino acid coupling to upper side chains to form 102.a 
 
 
 
 
 
 
 
 
  Entry AA  Product R1 R2 ESI  MALDI-TOF 
1 L-Tyr-Ot-Bu 102a OAllyl OH - + 
2 L-Tyr-Ot-Bu 102a OAllyl OH        -     + 
3 L-Ala-OBn 121a-b Ala-OBn Ala-OBn/ 
OAllyl 
+ - 
a Scale = 0.03 mmol, 0.09 g.  Scale reported is based on scale of loading step. 
 
ESI-MS and MALDI-TOF MS data revealed products 121a and 121b.  These findings 
validated the following conclusions: (i) resin loading conditions were successful; (ii) deallylation 
conditions produced deprotected and monodeprotected product; (iii) Pd(PPh3)4 was causing 
undesired monodebromination (either as a side product to the deallylation reaction or as a result 
of residual Pd(PPh3)4 remaining on resin after washing the deallylation product); (iv) 
PyAOP/HOBt acid activation and microwave-assisted coupling conditions were successful for 
upper side chain extension.  Despite the accessibility of MALDI-TOF MS for product detection, 
it proved to be a poor analytical method to identify allyl deprotection product. In a control study, 
triacid 103, synthesized by SPS, was undetected by MALDI-TOF;  probably because the m/z ion 
was too small for effective detection upon ionization with MALDI-TOF MS, which is primarily 
used for peptide sequencing (≤ 500 ppm).117   
MALDI-TOF MS was used for initial mass detection and compound identification because 
it requires less time for sample preparation and produces less ions than ESI-MS.  Additionally, we 
reasoned that the method would offer less contamination than LCMS to allow for mass 
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determination with sufficient accuracy (≤ 500 ppm).  Upon detection, the samples were then 
analyzed by ESI-MS for mass detection with higher accuracy (≤ 50 ppm). The matrix and 
deposition technique are both known to influence the quality of MALDI-TOF MS data.  In our 
case, the most common organic matrix for peptide mass detection, α-cyano-4-hydroxycinnamic 
acid (α-CHCA), was used to prepare samples via the dried droplet deposition method.  Yet, 
challenges such as sample inhomogeneity or analyte delocalization experienced in MALDI-TOF 
MS may have also contributed to variability in our results.  
5.3.6 Evaluation of Resin Loading Efficiency 
Certain that conditions for resin loading worked, we turned to biaryl substrate 103 to evaluate 
loading efficiency using improved analytical methods.   
 
Scheme 20.  Resin loading conditions for biaryl aromatic acid 103 with bromo Wang resin. 
 
 
The elution time of substrate 103 was determined by HPLC-DAD analysis to compare to 
the result of SPPS resin-cleaved products.  Because the biaryl torsion balance substrate is UV 
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active at a wavelength higher than that of peptide bonds, we planned to exploit this intrinsic 
property of our structure in order to quantify the yield of the resin loading step.  With the extinction 
coefficient of 103 known, UV/Vis absorbance data of resin-cleaved product would provide the 
information necessary to calculate product concentration.  The extinction coefficient was found to 
be 6100 L · mol-1 cm-1 at 298 nm (Figure 39).  In the end, we chose not to monitor progress by UV 
spectroscopy due to formation of other UV active products detected at 298 nm, as later discussed 
in Chapter 5.   
 
 
Figure 39. Beer-Lambert plot of 103 in ACN at  = 298 nm. 
 
The bromo Wang resin (80b) was generated from its hydroxy precursor 80a with PPh3Br2.  
Carboxylic acid 103 was subjected to standard resin-coupling conditions and treated with Ac2O 
and DIEA.  MALDI-TOF and ESI-MS and HPLC data of TFA-mediated cleavage product showed 
no expected product.  Furthermore, the mass balance of the resulting filtrate from solvent used to 
wash the solid-support material after the resin loading step was indicative of poor resin loading.  
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Table 14.  Results of resin loading to form 111. 
 
Entry Substrate  Product ESI  MALDI 
1 103 103 + + 
2 103 103 + + 
3 111 111 n/d n/d 
n/d = not detected.  a Scale = 0.03 mmol, 0.09 g.  Resin loading was carried out at rt for 16 h.  
 
5.4 SUMMARY AND CONCLUSION OF PROGRESS TOWARD ADVANCED 
DERIVATIVES 77-79 
Advanced torsion balance derivatives were designed to detect multiple interchain hydrogen bonds 
to further assess the dibromo scaffold for mimicry of the antiparallel β-sheet.  Our method for 
solution-phase protection of the upper side chains of the torsion balance was successful (Section 
5.2); however, difficulties arose from solid-phase deprotection and resin loading.  
Standard solid-state methods for deallylation using benzoic acid 111 resulted in incomplete 
deprotection and undesired monodebromination product.  Despite optimization of reaction 
conditions off-resin to achieve deprotection and minimize formation of monodebromination 
product, MALDI-TOF MS was unsuccessful to detect evidence of the desired result when 
optimized conditions were applied on-resin.  Because the of the lower m/z ion value of allyl-
deprotected derivatives of benzoic acid 65, ESI-MS was determined to be an improved method to 
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monitor reaction progress.  Additionally, amino acid coupling to the upper side chain did provide 
an ion detectable by MALDI-TOF MS.   
The unsuccessful SPPS result observed when using biaryl carboxylate 103 was attributed 
to poor resin loading.  We had good prior results of model resin-coupling reactions with benzoates 
107 and 111, but the lack of product formation when employing biaryl carboxylate 103 suggests 
poor loading of the aromatic acid.  Sterically these are very similar substrates; however, there could 
be an electronic effect or solubility effect from the methyl-nitrobenzene ring in 103 that is not 
present in 107 or 111.  We directed our attention to redesigning our SPPS approach for improved 
resin loading.  
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6.0  ADVANCED ß-TURN MIMETIC TARGETS 122-125 
Verification of the presence of interchain hydrogen bonds by 1D and 2D NMR was necessary to 
further validate a structural match between our -turn mimetic torsion balance scaffold and the 
antiparallel -sheet motif.  If our scaffold was proven to match, we envisioned its potential broad 
range application in backbone modification of known tertiary folded peptides.  SPPS methods 
would be integral at that juncture.  Thus, rather than turning to SPS, next steps to generate advanced 
derivatives were still directed toward SPPS methods.  To develop our approach, we focused on the 
challenges from our initial attempt.  
6.1 DESIGN AND RETROSYNTHETIC ANALYSIS OF ADVANCED ß-TURN 
MIMETIC TARGETS 122-126 
6.1.1 Polypeptide Derivatives 
To continue our investigation into the conformational control present in the dibromo scaffold and 
to study the formation of two interchain hydrogen bonds, derivatives 122-123 were identified using 
the same rationale for derivates 75-76 (Figure 40).  Like 77, the extension of the peptide chains in 
124 would allow us to develop polypeptide targets for conformational analysis to validate the 
torsion balance scaffold as a -turn mimetic to match the interchain bonding patterns within an 
antiparallel -sheet motif.  Incorporation of the β-turn mimetic torsion balance into GB1 mimetic 
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sequence (hairpin 125 and control 126) would allow us to determine the effects of backbone 
modification within the antiparallel β-sheet in GB1.   
 
 
Figure 40.  Advanced polypeptides of the symmetrical dibromo -turn mimetics for detection of 
two (121-122) and five (124-126) interchain hydrogen bonds. 
 
In the original strategy, results of SPPS experiments revealed poor reactivity of the biaryl 
carboxylate toward the bromo Wang resin.  To improve the outcome of the attachment step, we 
needed to improve the reactivity of the torsion balance substrate.  Our approach was to activate 
the acid using aminium coupling reagent 2-(6-Chloro-1H-benzotriazol-1-yl)-N,N,N’,N’-
tetramethylaminium hexafluoro-phosphate (HCTU) and replace the resin with NovaPEG Rink 
amide resin 81.  Because the 2-(4-(amino(2,4-dimethoxyphenyl)methyl)phenoxy)acetamide linker 
of the Rink amide resin is not sterically hindered, nor is it inductively deactivated, the 
nucleophilicity of the linker’s amine would be sufficient to anchor the HCTU-activated biaryl acid 
via amidation to achieve resin loading.  Secondary to this change, the biaryl carboxylate (103) was 
modified to afford a less sterically hindered attachment site for activation and amide coupling. 
Extension of the attachment functionality led to a new solid-phase precursor target (127; Scheme 
21).  It was reasoned that moving the carboxylate further from the aromatic ring would remove 
 103 
steric hindrance from the neighboring ortho bromine atoms.  The orientation of ether side chains 
on the top half of the balance needed to achieve interchain hydrogen bonding with the bottom side 
chain would not be disturbed by this change.  Extension of the biaryl carboxylic acid resin 
attachment site demanded orthogonal protection in addition to that of the upper and lower side 
chains.  The t-butyl group was selected for its mild deprotection conditions that would prevent side 
reactions with upper and lower side chains.   
 
 
Scheme 21. Target SPPS acid precursors 83 and 127. (a) Initial SPPS strategy using biaryl acid 83 
and bromo Wang resin (80b).  (b) Alternate SPPS strategy using biaryl carbonyloxy acetic acid 127 
and Rink amide resin 81. 
 
 
 
Before exploring alternate options for upper side chain protection, such as propargyl or 
3,5-dimethoxy benzyl, to eliminate debromination, we planned to continue to use the allyl group. 
If resin loading were improved in our new approach, we reasoned that the deallylation conditions 
on-resin could provide the desired allyl group deprotection and minimize formation of 
debromination side product.  Additionally, the allyl group would not be susceptible to side 
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reactions with the TFA-mediated t-butyl deprotection of the resin attachment site.  This 
modification led us to identify Gly-Ala and Gly-Leu analogs 122 and 123 as our new torsion 
balance targets (Scheme 22).  
 
Scheme 22.  Retrosynthetic analysis of 122-123 using solid- and solution-phase methods.  
 
 
Our retrosynthetic analysis is based on three important objectives, chain extension along 
the upper and lower halves of the balance and the resin attachment site.  The major disconnections 
in Gly-Ala and Gly-Leu torsion balances 122 and 123 are across the amide bonds in the upper and 
lower side chains.  Targets 122 and 123  would be prepared via attachment of upper and lower side 
chains using SPPS methods. The amide bond construction for the lower glycine side chain in 127 
would be formed by amidation of 128 with Fmoc-protected L-glycine acid chloride, generated 
under Carpino’s conditions.  Deprotection of the t-butyl ester would provide carboxylic acid 127 
for resin attachment.  The N-methyl bond of biaryl methyl amine 128 would be prepared by nitro 
group reduction of 129, followed by methylation of the primary amine.  We anticipated 129 would 
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be synthesized by etherification of phenol groups in 130 with allyl bromoacetate to install the C-
O bonds of the upper side chains.   Extension of the resin attachment site in intermediate 130 was 
straightforward by esterification of acid 113. 
6.2 SYNTHESIS OF BIARYL ACID 140 
6.2.1 Synthetic Strategies for Extension of Resin Attachment Site 
We examined two approaches to synthesize 129 from dihydroxybiaryl acid 113 enroute to 140 
(Scheme 23).  One approach to 129 was to introduce allyloxycarbonyl side chains (using our 
known protocol to synthesize 103) followed by esterification of the aromatic acid.  Because the 
aromatic acid 103 showed poor reactivity toward the bromo Wang resin in the resin loading step 
(Chapter 4.3), we hypothesized the esterification of 103 with t-butylbromoacetate would also be 
challenging. A second approach to 129 was pursued. Esterification of the aromatic acid in 113 
prior to etherification could improve the carboxylic acid reactivity.  In this way, acid 113 would 
be more electronically activated than 103 and increase the yield of product 130 enroute to 129.   
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Scheme 23.  Synthetic strategies to t-butyloxycarbonyl ester 129 enroute to biaryl acid 140. 
 
6.2.1.1 Incorporation of t-butyloxycarbonyl ester in biaryl acid 103 
 
Prior experiments for upper side chain protection revealed etherification of 113 was possible 
without separate protection of the hydroxyl groups (Scheme 24).  Yet, we were unsure if 
esterification of 103 was feasible.  Because the observed preference in model substrate 111 at 
refluxing temperatures was ester formation (Table 15), we subjected 103 to refluxing alkylation 
conditions to reveal product in 31% yield.  Increasing the reaction time from 4 to 8 hours resulted 
in a mixture of products.  Exposure to DIEA at room temperature failed to produce 129.  Subjecting 
103 to esterification conditions with DCC and allyl alcohol gave 129 in 26% yield. An alternate 
synthesis to 129 was examined to improve yield.  
 
6.2.1.2  Incorporation of t-butyloxycarbonyl ester in 113 
 
The second synthetic route to 129 was to form 130 from esterification of acid 113 followed by 
incorporation of allyloxycarbonyl ether side chains.  An important question to be answered was 
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whether the conditions would be selective for the acid in the presence of exposed hydroxyl groups.  
Conditions used to test the feasibility of esterification 113 are reported in Table 15. 
 
Table 15. Reactivity of biaryl carboxylic acid 113 and results of alkylation to form 130. 
 
Entry Conditionsa Productb Yield 
1 TEA (1 equiv), DCM, rt, 13 h 132 44% 
2 K2CO3 (1.1 equiv), 18-c-6, acetone, reflux, 4 h 131 41% 
3 2,6-dimethylpyridine (1 equiv), DCM, rt, 14 h 130c 12% 
4 KHCO3 (1.1 equiv), 18-c-6, acetone, reflux, 3 h 130c 36% 
5 KHCO3 (1.1 equiv), 18-c-6, acetone, reflux, 6 h 130 80% 
6 KHCO3 (1.1 equiv), 18-c-6, acetone, reflux, 7 h 130 81% 
7d KHCO3 (1.1 equiv), 18-c-6, acetone, reflux, 6 h 130 78% 
a 0.1 mmol scale.  b Major product observed.  c Starting material recovered. d 0.35 mmol scale. 
 
 
Esterification product 130 was found to be the major product in all entries with the 
exception of 1 and 2.  As expected, subjecting 113 to TEA at room temperature produced the ether 
product 132.   The desired reaction product was achieved by subjecting carboxylic acid 113 to one 
equivalent of t-butyl bromoacetate in the presence of potassium bicarbonate, furnishing 129 in 
78% yield.  Small amounts of side products, arising from alkylation of the phenol groups, were 
observed.    
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6.2.1.3 Incorporation of allyloxycarbonyl ethers in 130 
Etherification of hydroxyl groups in 130 with allyl bromoacetate in the presence of K2CO3 gave 
biaryl 129 in 74% yield (Scheme 24).  Subjecting 130 to TEA in the presence of allyl bromoacetate 
at room temperature also afforded 129 but in slightly lower yield.  Deprotection of 129 with TFA 
afforded test substrate 140, the component to be coupled to the resin, in quantitative yield. 
 
Scheme 24.  Synthesis of symmetrical ether 129 and acid 140. 
 
6.3 SYNTHESIS OF 141  
6.3.1 Solid-Phase Synthesis 
For the following SPPS (0.01 mmol; Scheme 25), we monitored reaction progress via small scale 
cleavage products; product identity was established by MALDI-TOF MS before purification and 
by ESI-MS after purification.  HPLC data for 140 was collected to serve as a baseline indication 
for identification of cleaved products. Substrate 140 was activated by HCTU to couple 140 to Rink 
amide resin 81.  HCTU was selected over more common reagents, such as BOP, PyBOP, and 
HBTU, to transform acid 140 to an activated ester because it’s lower pKa offers increased 
reactivity in comparison to many HOBt counterparts. Next, the resin-bound substrate was capped 
using acetic anhydride in the presence of DIEA. The solid phase was exposed to two deallylation 
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reactions.  This two-step approach was necessary to avoid the debromination side reaction. The 
product was subjected to microwave-assisted amino acid coupling using HCTU to couple L-
alanine benzyl ester to the upper side chain.  MALDI-TOF MS analysis of small-scale cleavages 
showed product 142 and 143.   Failure to detect ions 142 and 143 by ESI-MS upon 
chromatographic separation was most likely due to high dilution caused by the separation process.  
We did an extraction to increase the concentration for detection of 141 by ESI-MS.  Analysis of 
TFA-mediated cleavage product showed evidence of 141 by MALDI-TOF MS and ESI-MS.  Due 
to small scale cleavages diminishing the crude yield of 141, we do not report a yield for this 
sequence.   
Scheme 25.  Preparation of symmetrical Ala derivative 141. 
 
To determine reproducibility of our solid-phase protocol for upper side chain extension 
and resolve the NMR data of 141, the sequence was repeated using the conditions detailed above 
(Scheme 25) without monitoring reaction progress.  The result was a complex reaction mixture in 
which desired product 141 was detected in low concentration by ESI-MS.  Efforts to isolate pure 
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product for NMR analysis were unsuccessful.  Unsure if the low yield of 141 observed in the crude 
product was a result of incomplete resin loading or a result of substrate degradation from side 
reactions on-resin, our attention turned to evaluating the resin loading step.    
6.3.2 Resin Loading 
The HCTU-activated acid of 140 was loaded onto resin 81 with microwave-assistance, and the 
resin-bound product was subjected to capping with acetic anhydride and DIEA to form 142 
(Scheme 26).   Resin-bound product was freed by resin cleavage with TFA in the presence of 
triisopropyl silane (TIS) and H2O.  Product 142 was confirmed by ESI-MS data.  NMR revealed 
acetamide and a complex mixture of products.  Failure to efficiently load substrate 140 to resin 
would result in resin-bound amide 153-i aside  142-i following the capping step.  We also observed 
a mixture of UV active products by HPLC.  The UV active side product formation was probably 
due to linker cleavage or substrate side reaction on-resin. It is well-known that acid cleavage causes 
side reactions at the amide bond used to anchor the linker to the solid support.109  A simple HPLC 
experiment was executed comparing the elution times of our impurity and dimethoxybenzene.  The 
elution times were the same.  We searched for evidence of cleaved linker side product 153 to 
establish that the observed outcome was a result of linker cleavage and not a result of a substrate 
side reaction.  This was necessary because we planned to use photometric methods to determine 
resin loading efficiency.   
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Scheme 26.  Solid-phase synthesis of amide 142. 
 
 
6.3.3 Resin Cleavage  
In our attempt to identify formation of side product, we carried out a control study on resin 81.  By 
subjecting resin 81 to the capping and cleavage protocol, a baseline purity level for the crude 
cleavage product was established (Scheme 27).  NMR and ESI-MS analysis from the control study 
led us to identify resin-linker cleaved product 153.  Comparison of HPLC and NMR data of the 
resin loading test (Scheme 26) and control experiment (Scheme 27) confirmed the identical UV 
active impurity as side product 153.  Thus, the observed outcomes from the resin-loading test 
(Scheme 25) were a result of linker cleavage and not a result of a substrate side reaction.  
Acetamide was used as a standard to estimate purity of the crude product by 1H NMR and resolve 
an approximate 12% yield of 142.  At this point it was evident a more efficient method was needed 
to load our substrate.  We investigated if removing scavengers from the cleavage step would 
eliminate side product formation.  When 81 was subjected to TFA cleavage without H2O or TIS, 
only acetamide product was detected.  The lack of formation of linker cleaved product 153, led us 
to examine the application of scavengers in our SPPS protocol.   
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Scheme 27.  Control test for formation of resin-linker cleavage product 153. 
 
 
6.3.4 Optimization of Resin Loading and Cleavage Steps 
Optimization of the resin substitution and cleavage conditions was our next priority. We needed 
to improve resin loading efficiency and the purity of liberated crude product for accurate 
quantification and characterization of SPPS intermediates.  Since our biaryl substrate was ideal for 
photometric resin loading measurement, it was necessary to prevent formation of UV-active linker 
product to accurately quantify substitution.  The elimination of additional purification steps was 
also necessary for waste minimization practices.   
 
 
Figure 41.  Cleavage sites in resin-bound substrate 142-i. 
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Our approach to improve resin coupling was to activate acid 140 with PyAOP in the 
presence of HOBt instead of HCTU (Figure 42).  PyAOP was expected to improve loading 
efficiency because the pyridine nitrogen provides anchimeric assistance during coupling.106  The 
cleavage protocol was examined to determine if H2O and TIS were necessary during liberation of 
our substrate from resin.  These scavengers as well as ethane dithiol (EDT) are commonly used in 
SPPS to minimize undesired peptide modifications that may occur from reactions with TFA-
liberated reactive species.113  Because the elimination of scavengers decreased the production of 
undesired linker product 153 in our control study (Scheme 27), we examined the effects of those 
on substrate-resin cleavage. NMR and HPLC-DAD analysis were used to determine purity of 
product with dimethoxybenzene standardized samples.   
 
 
Figure 42. Resin coupling reagents for activation of acid 140. 
 
We applied the new activation protocol on acid 140 followed by resin substitution using 
MW irradiation.   The product was treated with capping conditions and subsequent cleavage by 
TFA alone.  Amide 142 was observed in an estimated 14% yield without detection of acetamide 
or 153.  The absence of acetamide was unlikely a result of quantitative loading in the coupling 
step, but rather due to reattachment to the linker in the cleavage step.   The solid-supported material 
was subjected to two additional cleavage reactions using the TFA/TIS/H2O cocktail. HPLC and 
NMR analysis revealed additional amide 142, but with a 30% decrease in purity. The combined 
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results of repetitive cleavages gave amide 142 in approximately 27% yield, a significant 
improvement from the estimated 12% yield of the HCTU-mediated loading conditions.   
Efforts were made to improve purity of reaction product.  We hypothesized that the 
presence of H2O was causing amide bond hydrolysis at the linker-resin attachment point and that 
removal of H2O would decrease production of undesired linker-cleaved product 153.  Treatment 
of our solid-supported substrate with two repetitive TFA/TIS (95/5 v/v) cleavage cocktails 
revealed product 142 in 31% yield and in 90% purity.  These results support our hypothesis that 
H2O was causing hydrolysis of the linker at the resin attachment site.  In summary, these data 
indicate increased resin loading efficiency and crude product purity.  PyAOP and HOBt are 
improved coupling reagents compared to HCTU. Elimination of H2O from the cleavage step, 
significantly minimizes undesired linker cleavage product. Despite our improvements, we chose 
not to utilize photometric measurement to determine resin loading efficiency as planned (Chapter 
4.3.5).  NMR and HPLC-DAD analysis were used for our study due to UV active side product 
formation.   
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Figure 43. Analytical HPLC-DAD chromatograms (280 nm) and NMR data (700 MHz, CD3CN) at 
room temperature of Rink amide resin cleavage experiments.  Product 153 was observed at A220 and 
A298.  (a) Baseline purity of Rink amide cleavage control experiment (TFA/TIS/H2O (95/2.5/2.5 
v/v/v). HPLC and NMR results of treatment of 142-i with (b) TFA, (c) TFA/TIS (95:5 v/v), and (d) 
TFA/H2O/TIS after 2 hours. 
6.3.5 Optimized Synthesis of 141 
Activated acid 140 was anchored onto resin 81, and resin-bound product was capped using Ac2O 
and DIEA (Scheme 28). Formed product was treated with two consecutive aliquots of 0.5 
equivalents of Pd(PPh3)4.  Finally, the microwave-assisted coupling of alanine benzyl ester to the 
aliphatic carboxylic acids in 143-i was carried out and followed by resin cleavage with TFA/TIS 
only.  In this way, target 141 was prepared in six steps and 29% overall yield with an approximate 
153 
153 
153 
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95% purity by HPLC (Figure 44).  In an attempt to further optimize our new cleavage conditions, 
reaction time of the cleavage step was reduced from 3 hours to 1.5 hours.  Cleaved linker 153 still 
remained a minor contaminant. 2D NMR experiments of 141, including ROESY and HMBC, were 
performed at 1 and 10 mM in CD3CN at 298 K on a 700 MHz NMR.  We searched for evidence 
of upper side chain interaction.   Since our preliminary data confirm that the side chains are 
perpendicular to the plane of the aromatic ring, it is of interest to determine the cavity size between 
upper peptide strands of n residues syn to one another (discussed in Chapter 3.2.).  Extending the 
length of the upper side chains in derivatives of 141 would provide important data for solvation 
effects and upper strand interchain aggregation.  
 
Scheme 28.  Synthesis of alanine target 141. 
  
 
Figure 44.  HPLC chromatogram of crude alanine product 141 (A280) from SPPS protocol in Scheme 
28. 
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6.4 SYNTHESIS OF SPPS PRECURSOR BIARYL ACID 127  
With an acceptable route to 141 in hand, we directed our attention to functionalizing the bottom 
half of the balance to generate SPPS precursor 127 for resin attachment.  The synthesis of 127 
proceeded by functionalizing the top half of the balance before the lower half of the balance.   
Scheme 29.  SPPS precursor 127. 
 
 
During our attempt to prepare a library of peptides from solid-phase syntheses, low yields 
were obtained when scaling up the hydrolysis of 54 beyond 1 mmol.  The LiOH-promoted 
hydrolysis of the methyl ester was complicated by inconsistent yields of 113 and complex mixtures 
of products.  At this point we sought a more efficient synthesis of 113. 
6.4.1 Synthesis of Acid 113 
Our inefficient synthesis of 113 relied upon the one-pot synthesis of 54 by cleavage of dimethyl 
ethers and methyl ester by BBr3, followed by immediate Fischer esterification prior to 
dibromination ortho to the phenols and methyl ester; however, dibromination of carboxylic acid 
100 would lead directly to 113 and avoid the additional esterification before dibromination and 
methyl ester cleavage step after debromination (Scheme 30).  Biaryl 54 was subjected to treatment 
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with BBr3 to give 100 but attempts to dibrominate 100 were unsuccessful.  We failed to detect 113, 
the dibrominated product.  Efforts were taken to optimize reaction conditions, such as changing 
solvent, but no positive result was obtained. Experiments employing additional equivalents of Br2 
were not pursued because prior experience showed the lower ring was susceptible to bromination 
under forcing conditions.  We expect our results are due to the carboxylic acid being less 
inductively deactivated than the methyl ester derivative.  The three-step sequence shown in 
Scheme 30 was revisited using different conditions for the crucial step.  
 
Scheme 30.  Attempted synthetic strategies of acid 154. 
 
6.4.1.1 Optimization of biaryl methyl ester cleavage 
We examined conditions for the less efficient strategy of methyl ester cleavage of 56.  Despite 
sufficient yields of initial saponification experiments, large scale saponification of 56 using 
traditional basic hydrolytic methods was complicated by inconsistent yields of 113 and complex 
mixtures of products.  These conditions were initially pursued because of Liberatore’s success with 
similar substrates as well as the inexpensive cost of reagents.  In light of work by Nicolau and 
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coworkers on mild hydrolysis of methyl esters using trimethyltin hydroxide (Me3SnOH),
122 we 
tested such conditions with our substrate. Model reactions with trimethyltin hydroxide on 
commercially available 5-methyl-2-methylbenzoate in DCE afforded the acid derivative in 90% 
yield; however, application of the conditions to biaryl methyl ester 56 failed to produce hydrolyzed 
product 113, even with forcing conditions.  The low-yielding and failed reactions may have been 
due to inefficient aqueous workup or base-promoted decomposition of material.  The use of BBr3 
provided carboxylic acid 113 in 76% yield without incident.  The successful route was not 
considered sooner because of expense.  From this point forward, we used the pathway shown in 
Scheme 31.  With 113 in hand, we converted the acid to 129 via alkylations with t-butyl and allyl 
bromoacetate, respectively.   
Scheme 31.  Improved synthesis of acid 113 enroute to 129. 
 
6.4.2 Incorporation of Lower Peptide Chain 
Less acidic methods for nitro reduction were necessary to prevent cleavage of the t-butyl group 
under acidic conditions. In a model reaction, t-butyl 3,5-bis(allyloxy)-4-bromobenzoate was 
subjected to SnCl2 in DCM and MeOH at 0 C and warmed to room temperature to stir for 13 
hours.  There was no evidence of t-butyl ester cleavage.  Following this success, we found treating 
89 with SnCl2 at 0 C gave 155 in 91% yield.121  N-Methylation using our modified Katritzky route 
afforded derivative 128 (Scheme 32).  This was followed by coupling Fmoc-glycine chloride 62 
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to furnish biaryl 127. Treatment of 155 with 20, followed by reduction with NaBH4 afforded the 
methylated biaryl 128 in 62% yield. Commercially available 9-fluorenylmethyloxycarbonyl-
glycine (Fmoc-gly) was converted to its corresponding acid chloride 62 with thionyl chloride, 
which was immediately coupled with biaryl 128.  Biaryl amide 156 was isolated in 67% yield.  
The final step to synthesize torsion balance core 127 involved treatment of 156 with TFA in DCM 
to deprotect the acid (99% yield).  Finally, cleavage of the t-butyl ester with TFA could provide 
product 86 over 14 steps for upper and lower chain extension on-resin. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 121 
Scheme 32.  Synthesis toward advanced derivatives 81-85. 
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6.5 SUMMARY OF PROGRESS TOWARD ADVANCED DERIVATIVES 122-126 
 
Progress toward the synthesis of advanced derivatives of the -turn mimetic torsion balance using 
solid-phase synthetic methods has been achieved.  We have overcome many setbacks from the 
resin loading step, which is well-known to be the most demanding transformation in SPPS.  In 
conclusion: (i) derivative 140 is an improved substrate to achieve resin loading in comparison to 
103;  (ii) the Rink amide resin is superior to the bromo Wang resin to anchor the torsion balance 
substrate; and (iii) PyAOP activation improves loading efficiency compared to HCTU. 
Additionally, we have established the solid-phase synthetic route is feasible for upper side chain 
extension.  The core structure was successfully coupled to protected amino acid esters on-resin.  
Furthermore, we have significantly improved the purity of our crude samples for quantification, 
characterization and waste minimization.   2D NMR data did not reveal upper interchain ROEs. 
The synthetic route to SPPS precursor 127 was established by attachment and extension of the 
lower peptide chain. 
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7.0  EXPERIMENTAL 
7.1 GENERAL 
Dry solvents were obtained prior to use by distilling the solvents from the appropriate drying agent 
under nitrogen atmosphere.  DCM was distilled from CaH2, toluene was distilled from CaCl2, 
DMF was vacuum distilled from 4 Å molecular sieves, and diethyl ether and THF were distilled 
from sodium metal and benzophenone.  Dry CCl4 and DMSO were purchased from Aldrich and 
used as supplied.  “Removal of volatile components under reduced pressure” refers to rotary 
evaporation of the sample at 21-65 °C at a pressure of 18-25 mm Hg followed by treatment under 
high vacuum (0.1 mm Hg) at room temperature.  All other reagents and solvents were purchased 
from Aldrich, Baker, EMD, or Fisher and used without further purification.  NovaPEG Rink 
Amide resin, Wang resin, HCTU and Fmoc-protected α-amino acids were purchased from 
Novabiochem. HOBt was purchased from Anaspec Inc. Microcleavages were taken for SPPS 
intermediates.  
Bruker Avance 300, 400, 500, 600 and 700 MHz spectrometers were used to find proton 
and carbon nuclear magnetic resonance spectra (1H and 13C NMR).  TMS (1H) or residual solvent 
(1H; 13C) peak were set as the reference value to report chemical shifts in parts per million (PPM; 
δ).  1D and 2D NMR experiments were performed at room temperature (21 – 27 ˚C) unless 
indicated otherwise.  NMR Data are reported using the following list of abbreviations: s = singlet; 
d = doublet; t = triplet; q = quartet; dd = doublet of doublets; m = multiplet; quin = quintet; ABq 
= AB quartet; quartet of doublets = qd; doublet of quintets = dquin. NMR samples were prepared 
by dissolving peptide in 750–850 μL of degassed 50 mM phosphate, 9:1 H2O:D2O, pH 6.3 
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(uncorrected for the presence of D2O) to a final concentration of 0.8–3 mM. 3-(Trimethylsilyl)-1-
propanesulfonic acid sodium salt (DSS, 50 mM in water) was added to a final concentration of 0.2 
mM.  The NMR tube headspace was purged with a stream of nitrogen prior to capping.  
Thin layer chromatography (TLC) was performed on E. Merck 60F 254 (0.25 mm) 
analytical glass plates.  A Thomas Hoover capillary melting point apparatus was used to obtain 
melting points and are uncorrected. A Nicolet Avatar 360 FT-IR was utilized to determine infrared 
(IR) spectraHigh resolution mass spectra were recorded on a VG 7070 spectrometer.  Percent 
yields are for material of >95% purity as indicated by 1H NMR spectra and/or HPLC data. 
7.1.1 General information for SPPS protocols 
Two SPPS protocols were applied in our synthesis. For all syntheses, after the final deprotection 
reaction, the resin was washed three times with 3 mL of dichloromethane followed by three 3 mL 
washes of methanol. After drying in a vacuum desiccator, the resin was cleaved.   
Compounds were synthesized using microwave-assisted Fmoc solid-phase synthesis 
techniques on a MARS microwave reactor (CEM) using NovaPEG Rink Amide resin.  Couplings 
were carried out in NMP at 70 °C for 4 min using 4 equiv. of Fmoc-protected amino acid, 4 equiv. 
of HCTU, and 6 equiv. DIEA. PyAOP was used in place of HCTU for the coupling of N-
methylated residues and residues immediately following them. Deprotections were performed 
using an excess of 20% 4-methylpiperidine in DMF at 80 °C for 2 min. After each coupling or 
deprotection cycle, the resin was washed three times with DMF. Double couplings were performed 
at sequence positions following proline or N-methylated residues. Prior to cleavage, the resin was 
washed three times each with DMF, dichloromethane, and methanol, and then dried.  Intermediates 
were cleaved from resin by suspension in a solution of 95% trifluoroacetic acid (TFA), 2.5% 
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triisopropylsilane (TIS), and 2.5% water or 95% trifluoroacetic acid (TFA), 5% triisopropylsilane 
(TIS).  This solution was then subjected to purification protocol outlined below.   
7.1.1.1 Purification and Characterization  
Compounds generated by SPPS were purified by preparative C18 reverse-phase HPLC using 
gradients between 0.1% TFA in water and 0.1% TFA in acetonitrile. The identity of each was 
confirmed by MS analysis on a Voyager DE Pro MALDI-TOF instrument or VG 7070 
spectrometer. Following HPLC purification, each was subjected to extraction with H2O and ACN.  
Final samples were ≥ 95% pure by analytical reverse-phase HPLC.  
 
7.1.2 Monte Carlo Simulations and Dynamics 
Monte Carlo simulations were completed by Craig S. Wilcox.   
Line shape analysis was performed using iNMR.  Bond rotational barriers were calculated 
using the Eyring equation.   
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7.2 EXPERIMENTAL PROCEDURES 
Representative Procedures:  A solution of the requisite carboxylic acid and DIEA in DMF or DCM 
was added to a stirred solution of requisite bromide and KI in DMF.  The reaction mixture was 
stirred at room temperature for 16 hours.  For SPPS: The solid-phase was filtered and washed with 
DMF x 3. For SPS: The reaction was concentrated and subjected to purification by flash 
chromatography. Derivatives were synthesized using microwave-assisted Fmoc solid-phase 
synthesis techniques oMARS microwave reactor (CEM) using NovaPEG Rink Amide resin. 
Couplings were carried out in NMP at 70 °C for 4 min using 4 equiv. of Fmoc-protected amino 
acid, 4 equiv. of HCTU, and 6 equiv. DIEA. PyAOP was used in place of HCTU for the coupling 
of N-methylated residues and residues immediately following them. Deprotections were 
performed using an excess of 20% 4-methylpiperidine in DMF at 80 °C for 2 min. After each 
coupling or deprotection cycle, the resin was washed three times with DMF. Prior to cleavage, the 
resin was washed three times each with DMF, dichloromethane, and methanol, and then dried. The 
filtrate was saved and extracted.    
 
 
Dibenzyl 2, 2’-((3’-(2-acetamido-N-methylacetamido)-3,5-dibromo-4-(methoxycarbonyl)-2’-
methyl-[1, 1’-biphenyl]-2,6-diyl)bis(oxy))diacetate (39).  To 0.01 g (0.01 mmol) of 63 in a 
round-bottom flask was added 0.045 mL of a 20% piperidine/DMF solution, and the reaction 
mixture was stirred at room temperature for 20 min.  Then 0.24 mL (mmol) of acetic anhydride 
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and 0.71 mL (mmol) of pyridine were added, and the solution was stirred at room temperature for 
30 min. The volatile components were removed from the filtrate under reduced pressure to give a 
yellow oil. The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate/methanol 
elution gradient 1:1:0/2:3:0/0:1:0/0:9:1) to give 0.007 g (76%) of 39 as a white foam: Rf 0.34 
(100% ethyl acetate); IR (thin film, cm-1) 3338, 2932, 1751, 1723, 1655, 1580, 1423, 1393, 1369, 
1329, 1235, 1193, 1135, 1029, 996, 844, 806, 733; 1H NMR (700 MHz, CDCl3)  7.34-7.27 (m, 
8H), 7.22-7.19 (m, 4H), 7.14-7.13 (m, 1H), 6.26 (broad s, 1H), 5.07 (s, 2H), 5.02 (s, 2H), four 
protons of conformers: [4.25, 3.96 (qAB, J = 15 Hz), 4.20, 4.15 (qAB, J = 15 Hz)], 4.02 (s, 3H), 
two protons of conformers: [3.65 (qd, J = 4.9 Hz), 3.35 (s)], 3.15 (s, 3H), 2.01 (s, 3H), 1.95 (s, 
3H); 13C NMR (500 MHz, CDCl3)  170.0, 169.0, 167.2, 167.1, 166.1, 153.5, 141.6, 139.6, 136.4, 
135.6, 135.3, 133.9, 131.4, 131.3, 127.8, 111.7, 111.3, 69.5, 67.4, 67.1, 53.7, 42.2, 36.3, 23.4, 15.3; 
HRMS (ESI-TOF) m/z: [MCHO2]- calcd for C39H37O12N2Br2 885.0700, found 885.0709. 
 
Methyl 3’-(2-acetamido-N-methylacetamido)-3,5-dibromo-2’-methyl-2,6-bis(2-
(methylamino) -2-oxoethoxy)-[1,1’-biphenyl]-4-carboxylate (43). To a round-bottom flask 
equipped with a condenser and nitrogen gas inlet were added 0.015 g (0.023 mmol) of diacid 45, 
0.006 g (0.068 mmol) of methylamine hydrochloride, 0.013 g (0.17 mmol) of EDCI, 0.010 g (0.068 
mmol) of HOBT, 0.015 mL (0.084 mmol) of DIEA, and 0.46 mL of DCM.  The reaction mixture 
was stirred at room temperature for 16 h and diluted with EtOAc (10 mL) and washed with 1.0 M 
NaOH (5 mL), water (10 mL), and then brine (10 mL).  The organic layers were combined, dried 
over MgSO4 and filtered, and the volatile components were removed from the filtrate under 
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reduced pressure to give a crude brown oil.  The oil was purified twice by flash chromatography 
(SiO2, (first column: hexanes/EtOAc/MeOH elution gradient 1:1:0/2:3:0/0:1:0/0:9:1); (second 
column: DCM/MeOH elution gradient 1:0/49:1/19:1)) to give 0.009 g (63%) of 43 as a white foam: 
Rf  0.15 (100% EtOAc); 
1H NMR (700 MHz, CD2Cl2)  One proton of conformers: [7.43 (t, J = 
15.4 Hz), 7.39 (t, J = 15.4 Hz)], one proton of conformers: [7.30 (d, J = 7.7 Hz), 7.17 (d, J = 7.7 
Hz)], one proton of conformers: [7.30 (d, J = 7.7 Hz), 7.26 (d, J = 7.7 Hz)], one proton of 
conformers: [6.80 (broad s), 6.03 (broad s)], one proton of conformers: [6.36 (broad s), 6.46 (broad 
s)], one proton of conformers: [6.19 (broad s), 6.26 (broad s)], two protons of conformers: [4.30, 
4.27 (qd, J = 18.2, 6.3 Hz), 3.72, 3.36 (ABq, J = 6.3 Hz)], two protons of conformers: [4.18-4.00 
(ABq, J = 6.3 Hz), 4.56-3.79 (ABq, J = 14.7 Hz)], two protons of conformers: [4.10, 4.00 (ABq, 
J = 10.5 Hz), 4.20, 4.00 (ABq, J = 10.5 Hz)], 4.00 (s, 3H), three protons of conformers: [3.36 (s), 
3.21 (s)], 2.65 (d, J = 4.9 Hz, 3H), three protons of conformers: [2.59 (d, J = 4.9 Hz), 2.47 (d, J = 
4.9 Hz)], three protons of conformers: [2.02 (s), 1.98 (s)], three protons of conformers: [2.00 (s), 
1.88 (s)];  13C NMR (700 MHz, CD2Cl2)  168.7, 167.4, 165.9, 153.5, 153.2, 143.4, 142.0, 140.0, 
135.8, 135.3, 134.4, 133.6, 132.1, 132.0, 131.0, 129.3, 128.2, 127.8, 111.4, 111.1,72.2, 72.0, 42.0, 
41.8, 36.5, 30.0, 26.2, 25.8, 23.2, 15.7, 15.2; HRMS (ESI-TOF) m/z: [MH]+ calcd for 
C26H31N4O8Br2 687.0488, found 687.0477. 
 
Methyl 3’-(2-acetamido-N-methylacetamido)-2’-methyl-2,6-bis(2-(methylamino)-2-
oxoethoxy)-[1,1’-biphenyl]-4-carboxylate (44).  To a solution of 0.015 g (0.028 mmol) of 73 in 
DCM (0.045 mL) at room temperature was added 0.009 ml (0.111 mmol) of TFA and the reaction 
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mixture was stirred for 2 h.  The volatile components were removed under reduced pressure to 
give a brown crude oil.  To this crude oil, in a vial equipped with a condenser and nitrogen gas 
inlet were added 0.007 g (0.108 mmol) of methylamine hydrochloride, 0.021 g (0.108 mmol) of 
EDCI, 0.016 g (0.108 mmol) of HOBT, 0.023 mL (0.132 mmol) of DIEA, and 0.72 mL of DCM.  
The reaction mixture was stirred at room temperature for 80 h, and the volatile components were 
removed under reduced pressure to give a crude brown oil.  The oil was purified by flash 
chromatography (SiO2, (first column: hexanes/EtOAc/MeOH elution gradient 
1:1:0/2:3:0/0:1:0/0:9:1); (second column: DCM/MeOH elution gradient 1:0/49:1/19:1)) to give 
0.004 g (24%) of 44 as a white foam: Rf  0.1 (100% EtOAc); 
1H NMR (700 MHz, CD2Cl2)  one 
proton of conformers: [7.44 (t, J = 7.7 Hz), 7.43 (t, J = 7.7 Hz)], 7.39 (d, J = 0.7 1H), 7.38 (d, J = 
0.7 Hz, 1H), one proton of conformers: [7.29 (d, J =7.7 Hz), 7.22 (d, J = 7.7 Hz)], one proton of 
conformers: [7.27 (d, J = 7.7 Hz), 7.17 (d, J = 7.7 Hz)], 6.38 (broad s, 1H), one proton of 
conformers: [6.08 (broad s), 6.23 (broad s)], one proton of conformers: [5.89 (broad s), 5.72 (broad 
s)], two protons of conformers: [4.54, 4.34 (ABq, J = 14.0 Hz), 4.45, 4.44 (qAB, J = 4.9, 3.5 Hz)], 
two protons of conformers: [4.46, 4.42 (ABq, J = 14.7 Hz), 4.39, 4.37 (ABq, J = 7.0 Hz)], two 
protons of conformers: [4.25, 4.23 (qd, J = 18.2, 4.2 Hz), 3.66, 3.54 (ABq, J =17.5, 4.2 Hz)], 3.93 
(s, 3H), three protons of conformers [3.37 (s), 3.24 (s)],  three protons of conformers: [2.71 (d, J = 
4.9 Hz), 2.66 (d, J = 4.9 Hz)], 2.63 (d, J = 4.9 Hz, 3H), three protons of conformers: [2.1 (s), 1.96 
(s)], three protons of conformers: [1.95 (s), 1.88 (s)]; 13C NMR (700 MHz, CD2Cl2) 168.7, 168.0, 
166.2, 155.9, 155.5, 141.7, 136.1, 135.9, 132.5, 131.1, 128.2, 127.7, 123.7, 108.7, 108.2, 69.0, 
68.5, 42.0, 36.5, 30.1, 25.8, 23.1, 14.7; HRMS (ESI-TOF) m/z: [MH]+ calcd for C26H33N4O8 
529.2298, found 529.2289. 
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2,2’-((3’-(2-Acetamido-N-methylacetamido)-3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-
[1,1’-biphenyl]-2,6-diyl)bis(oxy))diacetic acid (45).  To a nitrogen charged flask, 0.01 g (0.01 
mmol) of 39 and 0.01 g (0.01 mmol) of PtO2 were added and dried under reduced pressure for 5 
minutes and backfilled with nitrogen twice.  Under hydrogen atmosphere, ethyl acetate (0.2 mL) 
was added and stirred for 13 hours.  The reaction mixture was passed through a Celite plug and 
washed with ethyl acetate (2 ml).  Volatile components were removed from the filtrate under 
reduced pressure to obtain 0.01 g (91%) of 45 as a glass-like foam.  Rf  0.18 (9:1 ethyl 
acetate:MeOH); 1H NMR (400 MHz, CDCl3)  7.31 (t, J = 8 Hz, 1H) 7.22 (d, J = 8 Hz, 1H), 7.11 
(d, J = 8 Hz, 1H), 6.89 (broad s, 2H), 4.33, 4.03 (ABq, J = 16, 15 Hz, 2H), 4.17-3.97 (m, 2H), 
3.68, 3.58 (ABq, J = 18, 4 Hz, 2H), 3.74 (s, 3H), 3.16 (s, 3H), 2.00 (s, 3H), 1.99 (s, 3H); 13C NMR 
(400 MHz, CDCl3)  172.2, 169.8, 169.4, 168.7, 168.0, 166.0, 154.3, 153.4, 141.0, 139.7 135.9, 
134.2, 132.3, 131.8, 129.2, 128.3, 112.1, 111.4,  70.5, 69.3, 53.8, 47.9, 43.1, 43.0, 36.6, 32.3, 30.0, 
29.7, 26.7, 25.8, 24.7, 23.2, 23.0, 21.5, 15.1; HRMS (ESI-TOF) m/z: [M+H]+ calcd for 
C24H23Br2N2O10  656.9714, found 656.9732. 
 
Methyl 4-bromo-3,5-dihydroxybenzoate (46). To 1.0 g (4.4 mmol) of carboxylic acid 45 in 6.8 
mL of methanol was added .41 mL (7.6 mmol) of H2SO4 dropwise, and the reaction mixture was 
refluxed for 16 h.  The reaction was quenched by addition of NaHCO3 (1.2 g, 14.8 mmol) and the 
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volatile components were removed under reduced pressure.  The residue was diluted with ethyl 
acetate (25 mL) and water (25 mL); the organic layer was extracted, and the aqueous layer was 
washed with additional ethyl acetate (3 x 25 mL).  The organic layers were dried over MgSO4 and 
filtered, and the volatile components were removed from the filtrate under reduced pressure to give 
1.05 g (99%) of 46 as a white solid: Rf  0.34 (hexanes/ethyl acetate 3:2); mp 225-227 C; IR (thin 
film, cm-1) 3416, 3329, 1701, 1594, 1421, 1353, 1270, 1233, 1118, 1033, 990, 907, 857, 760, 705; 
1H NMR (300 MHz, MeOD)  7.03 (s, 2H), 4.85 (broad s, 2H), 3.85 (s, 3H); 13C NMR (600 MHz, 
MeOD)  168.1, 156.7, 131.0, 108.6, 105.1, 52.7; HRMS (EI) m/z calcd for C8H7O4Br 245.9528, 
found 245.9519. 
 
Methyl 4-bromo-3-(-2-t-butoxy-2-oxoethoxy)-5-hydroxybenzoate (47).  In a round-bottom 
flask, 1.0 g (4.2 mmol) of benzoate 46, 0.62 mL (4.2 mmol) of t-butyl bromoacetate, 1.2 g (8.8 
mmol) of K2CO3, and 0.05 g (0.2 mmol) of 18-crown-6 were dissolved in acetone (21.0 mL), and 
the reaction mixture was refluxed for 24 h.  The volatile components were removed under reduced 
pressure, and the residue was diluted with ethyl acetate (50 mL) and water (50 mL); the organic 
layer was extracted, and the aqueous layer was washed with additional ethyl acetate (2 x 50 mL).  
The organic layers were dried over MgSO4 and filtered, and the volatile components were removed 
from the filtrate under reduced pressure to give a crude yellow oil.  The oil was purified by flash 
chromatography (SiO2, hexanes/ethyl acetate, elution gradient 5:1/3:2/0:1) to give 0.49 g (32.4%) 
of 47 as a white solid: Rf  0.44 (hexanes/ethyl acetate 3:2); mp 117-118 C; IR (thin film, cm-1) 
3393, 2923, 2852, 1724, 1590, 1497, 1438, 1354, 1247, 1158, 1117, 1011, 904, 870, 843, 767; 1H 
NMR (400 MHz, CDCl3)  7.24 (s, 1H), 6.92 (s, 1H), 6.41 (s, 1H), 4.57 (s, 2H), 3.81 (s, 3H), 1.18 
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(s, 9H); 13C NMR (500 MHz, CDCl3)  166.9, 166.0, 154.9, 153.7, 130.6, 110.4, 105.8, 105.2, 
82.9, 66.4, 52.5, 28.0; HRMS (EI) m/z calculated for C14H17BrO6 360.0209, found 360.0205.  
 
Methyl 3-(2-(benzyloxy)-2-oxoethoxy)-4-bromo-5-(2-t-butoxy-2-oxoethoxy) benzoate (48).  
In a round bottom flask, 0.49 g (1.36 mmol) of benzoate 47, 0.26 mL (1.63 mmol) of benzyl 
bromoacetate, 0.22 g (1.63 mmol) of K2CO3, and 0.08 g (0.33 mmol) of 18-crown-6 were dissolved 
in acetone (35.4 mL), and the reaction mixture was refluxed for 24 h.  The volatile components 
were removed under reduced pressure, and the residue was diluted with DCM (25 mL) and water 
(25 mL); the organic layer was extracted, and the aqueous layer was washed with additional DCM 
(3 x 25 mL).  The combined organic layers were dried over MgSO4 and filtered, and the volatile 
components were removed from the filtrate under reduced pressure to give a crude yellow oil.  The 
oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 
7:1/6:1/3:1) to yield 0.55 g (80.2%) of 48 as a white solid: Rf  0.48 (hexanes/ethyl acetate 3:2); mp 
68-70 C; IR (thin film, cm-1) 2978, 1753, 1724, 1587, 1423, 1369, 1337, 1241, 1194, 1133, 1029, 
1000, 844, 763;  1H NMR (400 MHz, CDCl3)  7.24 (s, 5H), 7.04 (d, J = 4 Hz, 2H),  5.14 (s, 2H), 
4.70 (s, 2H), 4.56 (s, 2H), 3.77 (s, 3H), 1.40 (s, 9H); 13C NMR (500 MHz, CDCl3)  167.8, 166.9, 
165.9, 155.8, 155.7, 149.9, 149.1, 143.4, 141.7, 140.0, 135.0, 130.5, 130.0, 128.7, 128.6, 128.6, 
128.5, 128.5, 108.2, 107.4, 107.2, 82.9, 67.3, 67.2, 66.6, 66.3, 60.7, 52.5, 28.0; HRMS (ESI-TOF) 
m/z: [MNa]+ calcd for C23H25O8NaBr 531.0630, found 531.0663. 
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4, 4, 5, 5-tetramethyl-2-(2-methyl-3-nitrophenyl)-1,3,2-dioxaborolane (50).  To a third flame-
dried 200 ml round-bottom flask, 3.00 g (13.9 mmol) of 49, 5.29 g (20.8 mmol) of (Bpin)2, 4.09 g 
(41.7 mmol) of KOAc, and 0.45 g of [1,1’ 
bis(diphenylphosphino)ferrocene]dichloropalladium(II), complex with DCM (Pd(dppf)Cl2DCM; 
0.56  mmol) were added.  The reaction flask was then placed on vacuum line for 5 minutes and 
backfilled with nitrogen and repeated.   DMSO (83.2 mL) was then added and the solution 
degassed using the freeze-pump-thaw method three times under a nitrogen atmosphere.   The flask 
was sealed; the reaction mixture was stirred at 90 C for 20 hours and then cooled to room 
temperature.  The reaction mixture was then diluted with DCM (100 mL) and H2O (100 mL).  The 
organic layer was extracted and washed with H2O (3 x 100 mL).  The aqueous layer was washed 
with additional DCM (2 x 100 mL).  Organic extracts were combined, and the volatile components 
were removed from the filtrate under reduced pressure to give a brown crude oil.  The oil was 
purified twice by flash column chromatography (SiO2, hexanes/ethyl acetate, elution gradient (2 
columns) 10:1/6:1; then 30:1) to give 2.7 g (76%) of 50 as a pale yellow solid: Rf   0.89 
(hexanes/ethyl acetate, 4:1); mp 52-53 C; IR (thin film, cm-1) 3055, 2982, 2933, 1603, 1569, 1527, 
1474, 1439, 1344, 1267, 1214, 1144, 1109, 1026,1078, 963, 786, 739, 669, 579. 463; 1H NMR 
(300 MHz, CDCl3)  7.94 (d, J = 7 Hz, 1H), 7.77 (d, J = 8 Hz, 1H), 7.27 (t, J = 8 Hz, 1H), 2.67 (s, 
3H), 1.36 (s, 12H); 13C NMR (300 MHz, CDCl3)  151.3, 139.9, 138.2, 126.3, 126.0, 84.4, 25.0, 
18.0; HRMS (ESI-TOF) m/z: [M+H]+ calcd for C13H19BNO4 264.1407, found 264.1405. 
 134 
 
Methyl 2,6-dimethoxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (51).  In a round-
bottom flask, 0.17 g (0.34 mmol) of benzoate 48, 0.14 g (0.55 mmol) of boronic ester 50, 0.013 g 
(0.014 mmol) of Pd2(dba)3, 0.022 g (0.055 mmol) of 2-dicyclohexylphosphino-2’,6’-
dimethoxybiphenyl (SPhos), and 0.24 g (1.03 mmol) of KPO4H2O (ground) were added and dried 
under reduced pressure for 5 minutes and backfilled with nitrogen two times.  Toluene (3 ml) was 
added, and the solution was degassed using the freeze-pump-thaw method three times under a 
nitrogen atmosphere.  The flask was sealed; the reaction mixture was stirred at 90 C for 18 h, and 
cooled to room temperature.  The mixture was diluted with DCM (30 mL) and H2O (30 mL); the 
organic layer was extracted, and the aqueous layer was washed with additional DCM (3 x 30 mL).  
The combined organic layers were dried over MgSO4 and filtered, and volatile components were 
removed from the filtrate under reduced pressure to give a brown crude oil.  The oil was purified 
by flash chromatography (SiO2, hexanes/ethyl acetate, 5:1) to afford 0.13 g (67.6%) of 51 as a 
white foam: Rf   0.36 (hexanes/ethyl acetate, 4:1); IR (thin film, cm
-1) 3442, 2979, 1751, 1725, 
1581, 1528, 1437, 1422, 1354, 1330, 1236, 1194, 1136; 1082, 1029, 999, 867, 844, 810, 771, 741, 
698; 1H NMR (400 MHz, CDCl3)  7.83 (d, J = 8 Hz, 1H), 7.42 (d, J = 7 Hz, 1H), 7.33 (broad s, 
4H), 7.27 (broad s, 2H), 7.19 (s, 2H), 5.16 (s, 2H), 4.67 (s, 2H), 4.49 (s, 2H), 3.91 (s, 3H), 2.27 (s, 
3H), 1.44 (s, 9H); 13C NMR (400 MHz, CDCl3)  168.2, 167.4, 166.2, 156.2, 155.9, 150.8, 136.2, 
135.3, 135.1, 132.8, 131.5, 128.8,128.6, 126.0, 123.9, 122.5, 106.5, 106.0, 82.9, 67.3, 66.0, 65.4, 
52.6, 28.2, 16.5; HRMS (ESI-TOF) m/z: [MNa]+ calcd for C30H31NO10Na 588.1840, found 
588.1854.  
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Methyl 4-bromo-3,5-dimethoxybenzoate (53). To a stirred solution of 2.50 g (10.7 mmol) of 
carboxylic acid 45 and 6.2 g (45.1 mmol) of K2CO3 in acetone (67.0 mL), 3.46 mL (36.5 mmol) 
of dimethyl sulfate was added.  The mixture was stirred at reflux for 4.5 h and cooled to room 
temperature.  Volatile components were removed under reduced pressure.  The residue was then 
diluted with ethyl acetate (75 mL) and H2O (75 mL); the organic layer was extracted, and the 
aqueous layer was washed with additional ethyl acetate (2 x 75 mL).  The combined organic layers 
were washed with brine (200 mL), dried over MgSO4 and filtered, and the volatile components 
were removed under reduced pressure to yield a white solid.  The solid was purified by 
recrystallization to give 2.9 g (100%) of benzoate 53 as white crystals: Rf  0.45  (hexanes/ethyl 
acetate, 4:1); mp 121-122˚C ; 1H NMR (300 MHz, CDCl3) δ 7.23 (s, 2H), 3.95  (s, 6H), 3.93 (s, 
3H); 13C NMR (300 MHz, CDCl3) 166.7, 157.3, 130.4, 106.9, 105.8, 56.9, 52.7; HRMS (ESI-
TOF) m/z calc for C10H11BrO4 273.9827, found 273.9829.  
 
Methyl 2,6-dimethoxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (54).  In a round-
bottom flask, 1.45 g (5.29 mmol) of benzoate 53, 2.08 g (7.94 mmol) of boronic ester 50, 0.19 g 
(0.21 mmol) of Pd2(dba)3, 0.35 g (0.85 mmol) of SPhos, and 3.66 g (15.87 mmol) of K3PO4H2O 
(ground) were added and dried under reduced pressure for 5 minutes and backfilled with nitrogen 
two times.  Toluene (30 ml) was added, and the solution was degassed using the freeze-pump-thaw 
method three times under a nitrogen atmosphere.  The flask was sealed; the reaction mixture was 
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stirred at 90 C for 18 h and cooled to room temperature.  The mixture was diluted with DCM (150 
mL) and H2O (150 mL); the organic layer was extracted, and the aqueous layer was washed with 
additional DCM (3 x 150 mL).  The combined organic layers were washed with brine (200 mL), 
dried over MgSO4 and filtered.  Volatile components were removed from the filtrate under reduced 
pressure to give a reddish brown crude oil.  The oil was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, elution gradient, 8:1/6:1) to give 1.19 g (74%) of 54 as a pale yellow solid: 
Rf  0.28 (hexanes/ethyl acetate, 4:1); mp 119-120 C; IR (thin film, cm-1) 3436, 2919, 2881, 1721, 
1580, 1527, 1456, 1434, 1409, 1351, 1326, 1242, 1126, 997, 770; 1H NMR (400 MHz, CDCl3)  
7.84 (dd, J = 6, 3 Hz, 1H), 7.36-7.34 (m; 4H), 3.97 (s ,3H), 3.78 (s, 6H), 2.20 (s, 3H); 13C NMR 
(400 MHz, CDCl3)  167.0, 157.7, 150.9, 137.0, 135.4, 132.6, 131.8, 126.1, 123.8, 121.8, 105.4, 
56.3, 52.7, 16.4; HRMS (ESI-TOF) m/z: [MH]+ calcd for C17H18NO6 332.1134, found 332.1124. 
 
Methyl 2,6-dihydroxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (55). In a third-flame 
dried round-bottom flask, 5.35 g (21.36 mmol) of a 1.0 M solution of BBr3 in DCM was added 
dropwise over 30 minutes to a stirred solution of 1.18 g (3.56 mmol) of 54 in DCM (8 mL) at 0 
C.  The reaction mixture was stirred at 0 C for 3 hours and gradually warmed to room temperature 
and stirred for an additional 21 h.  The volatile components were removed under reduced pressure.  
The residue was charged with nitrogen and slowly diluted with MeOH (7 mL).  0.33 mL (6.14 
mmol) of H2SO4 was added dropwise at 0 C.  The reaction mixture was then heated to reflux for 
20 h.  After cooling to room temperature, the reaction was quenched by addition of NaHCO3 (1.03 
g, 12.3 mmol) and the volatile components were removed under reduced pressure. The residue was 
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diluted with ethyl acetate (75 mL) and H2O (75 mL); the organic layer was extracted, and the 
aqueous layer was washed with additional ethyl acetate (2 x 75 mL).  The combined organic layers 
were washed with brine (200 mL), dried over MgSO4 and filtered.  Volatile components were 
removed from the filtrate under reduced pressure to yield a brown oil.  The oil was purified by 
flash column chromatography (SiO2, hexanes/ethyl acetate, elution gradient, 2:1) to give 0.84 g 
(78%) of 55 as a white solid: Rf  0.22 (hexanes/ethyl acetate, 2:1); mp 160-161 C; IR (thin film, 
cm-1) 3310, 2524, 2219, 2043, 1653, 1451, 1113, 1034; 1H NMR (300 MHz, CDCl3)  7.92 (d, J 
= 6 Hz, 1H), 7.49-7.47 (m, 2H), 7.31 (s, 2H), 5.71 (broad s, 2H), 3.92 (s, 3H), 2.31 (s, 3H); 13C 
NMR (400 MHz, CDCl3)  154.4, 151.7, 135.53, 134.6, 133.7, 131.9, 127.5, 125.2, 118.6, 109.5, 
53.0, 16.4; HRMS (ESI-TOF) m/z: [MH]+ calcd for C15H14NO6 304.0821, found 304.0837.      
 
Methyl 3,5-dibromo-2,6-dihydroxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (56).    
In an oven-dried round-bottom flask, 0.26 ml (4.12 mmol) of Br2 in CCl4 (2.9 mL) was added 
dropwise over 30 min to a stirred solution of 0.52 g (1.72 mmol) of 55 in CCl4 (7 mL) in the dark.  
The reaction mixture was stirred for 1 h.  Saturated NaHSO3 was then added until red color 
dissipated.  Mixture was diluted with ether (30 mL) and organic layer was extracted.  The aqueous 
layer was washed with additional ether (2 x 30 mL).  The combined organic layers were washed 
with brine (75 mL), dried over MgSO4 and filtered, and the volatile components were removed 
from the filtrate under reduced pressure to yield a brown oil.  The oil was purified by flash column 
chromatography to give 0.60 g (76%) of 56 as an off-white foam: Rf    0.36 (hexanes/ethyl acetate, 
4:1); mp 158-159 C; IR (thin film, cm-1) 3431, 2101, 1642, 1264, 790; 1H NMR (400 MHz, 
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CDCl3)  7.90 (dd, J = 7, 2 Hz, 1H), 7.44-7.39 (m, 2H), 5.91 (broad s, 2H), 4.02 (s, 3H), 2.28 (s, 
3H); 13C NMR (600 MHz, CDCl3)  166.0, 151.1, 150.5, 137.0, 135.0, 134.6, 132.9, 126.8, 124.9, 
115.7, 99.3, 53.7, 16.4; HRMS (ESI-TOF) m/z: calcd for C15H11NO6Br2 461.8900, found 
461.8882. 
 
Dibenzyl 2,2’-((3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-3’-nitro-[1,1’-biphenyl]-2,6-
diyl)bis(oxy))diacetate (57).  In an oven-dried round bottom flask, 0.46 g (1.0 mmol) of 56, 0.38 
mL (2.4 mmol) of benzyl bromoacetate, 0.42 g (3.0 mmol) of K2CO3, and 0.10 g (0.40 mmol) of 
18-crown-6 were dissolved in acetone (11.1 mL), and the reaction mixture was refluxed for 24 h.  
The volatile components were removed from the filtrate under reduced pressure, and the residue 
was diluted with DCM (30 mL) and water (30 mL); the organic layer was extracted, and the 
aqueous layer was washed with additional DCM (3 x 30 mL).  The combined organic layers were 
washed with brine (90 mL), dried over MgSO4 and filtered, and the volatile components were 
removed from the filtrate under reduced pressure to give a crude yellow oil.  The oil was purified 
by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 6:1) to yield 0.60 g (80%) 
of 57 as a light yellow foam: Rf  0.48 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, CD2Cl2)  
7.82 (d, J = 8 Hz, 1H), 7.43 (d, J = 8 Hz, 1H), 7.36-7.34 (m, 6H), 7.30 – 7.24 (m, 5H), 5.02 (q, J 
= 4 Hz, 4H), 4.22, 4.10 (ABq, JAB = 15 Hz, 4H), 2.30 (s, 3H); 
13C NMR (400 MHz, CD2Cl2)  
167.2, 166.1, 154.0, 151.3, 140.4, 135.8, 135.5, 134.5, 133.1, 131.0, 129.1, 129.0, 128.9, 127.1, 
125.5, 111.7, 70.0, 67.4, 17.2; HRMS (ESI-TOF) m/z: [MH]+ calcd for C33H28NO10Br2 
758.01052, found 758.0080. 
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Dibenzyl 2,2’-((3’-amino-3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-[1, 1’-biphenyl]-2,6-
diyl)bis(oxy))diacetate (58). 0.5 g (0.67 mmol) of 57 were dissolved in ethyl acetate (11 ml) and 
concentrated HCl (0.33 ml).  The solution was cooled to 0 C and Zn powder (.21 g, 3.3 mmol) 
was added in portions over 20 min with stirring.  The mixture was gradually warmed to room 
temperature and stirred for 15 h.  The reaction mixture was passed through a Celite plug and 
washed with ethyl acetate (5 ml).  The filtrate was washed with saturated NaHCO3 solution (1 x 5 
ml), water (1 x 5 ml), and brine (1 x 10 ml).  The organic layer was dried over anhydrous MgSO4, 
filtered, and volatile components were removed from the filtrate under reduced pressure to give a 
crude yellow oil.  The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 
elution gradient 3:1/2:1) to yield 0.41 g (82%) of 58 as a light yellow foam: Rf  0.21 (hexanes/ethyl 
acetate 2:1); mp 58-59 C;  1H NMR (400 MHz, CDCl3)  7.34-7.30 (m, 5H), 7.28-7.25 (m, 5H), 
6.99 (t, J = 8 Hz, 1H), 6.64 (d, J = 8 Hz, 1H), 6.58 (d, J = 7 Hz, 1H), 5.05 (s, 4H), 4.17, 4.00 (ABq, 
JAB = 15 Hz, 4H), 4.01 (s, 3H), 3.61 (broad s, 2H), 1.90 (s, 3H);  
13C NMR (400 MHz, CDCl3)  
167.6, 166.4, 153.6, 145.6, 138.7, 135.4, 132.1, 131.6, 128.9, 128.8, 128.7, 126.9, 121.9, 120.9, 
115.9, 111.0, 69.4, 67.0, 53.6, 30.0, 14.8; HRMS (ESI-TOF) m/z: [MH]+  calcd for C33H30NO8Br2 
728.02395, found 728.02593.  
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Dibenzyl 2,2’-((3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-3’-(methylamino)-[1,1’-
biphenyl]-2,6-diyl)bis(oxy))diacetate (60).  To biaryl-methylaamide (0.1 g, 0.14 mmol) of 58  
0.025 g (0.17 mmol) of 59 in THF (0.1 mL) were sonicated for 5 minutes to give a homogenous 
solution.  The mixture was then diluted with EtOH (0.16 mL) and stirred at room temperature for 
12 h.   Volatile components were removed under reduced pressure, and reaction vial was cooled 
to 0 C for 10 minutes.  The residue was rinsed with chilled, dry DCM followed by hexanes to 
produce an off-white solid.  The precipitate was isolated and taken up into DCM, dried over 
K2CO3, filtered, and volatile components were removed under reduced pressure to give an off-
white solid. The dry intermediate was dissolved in THF (0.3 mL), and 0.01 g (0.18 mmol) of 
NaBH4 were added and stirred for 14 h.  The reaction mixture was concentrated under reduced 
pressure and the residue was diluted with ice, cold H2O, and DCM; the organic layer was extracted 
and aqueous layer washed with additional DCM (2 x 4 mL).  The combined organic layers were 
washed with additional H2O (5 mL) and then brine (5 mL); the organic layer was dried over 
MgSO4, filtered, and volatile components were removed from the filtrate under reduced pressure 
to give a yellow foam.  The foam was purified by flash chromatography (SiO2, hexanes/ethyl 
acetate, elution gradient 7:1/6:1) to yield 0.040 g (41%) of  60 as a white foam: Rf  0.38 
(hexanes/ethyl acetate 2:1; IR (thin film, cm-1) 3432, 3059, 2978, 2303, 2053, 1648, 1420, 1375, 
1241, 1122, 892, 743; 1H NMR (400 MHz, CDCl3)  7.33 (broad s, 5H), 7.26 (broad s, 5H), 7.12 
(t, J = 8 Hz, 1H), 6.59 (d, J = 8 Hz, 1H), 6.53 (d, J = 8 Hz, 1H), 5.04 (s, 4H), 4.12, 4.00 (ABq, J = 
15 Hz, 4H) 4.01 (s, 3H), 3.66 (broad s, 2H), 2.87 (s, 3H), 1.86 (s, 3H); 13C NMR (500 MHz, 
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CDCl3)  167.7, 166.4, 153.7, 147.9, 138.7, 135.5, 132.3, 131.1, 128.9, 128.8, 128.6, 127.2, 121.4, 
119.2, 111.0, 109.9, 69.4, 67.0, 53.6, 31.2, 30.1, 28.7, 14.6, 14.5; HRMS (ESI-TOF) m/z: [MH]+ 
calcd for C34H32Br2NO8 742.0495, found 742.0496. 
 
(9H-Fluoren-9-yl)methyl (2-chloro-2-oxoethyl)carbamate (62). To a solution of 0.030 g (0.1 
mmol) of commercially available Fmoc-gly (61) in DCM (0.5 mL) was added 0.07 ml (1.0 mmol) 
of thionyl chloride (SOCl2) and the reaction mixture was refluxed for 30-45 min.  The solution 
was cooled to room temperature and the volatile components were removed under reduced 
pressure.  The residue was dissolved in minimal DCM followed by hexanes to produce an off-
white precipitate.  The solid was filtered and dried in vacuo to afford 0.025 g (81%) of 62 as an 
off-white solid.  Only an IR spectra was obtained to confirm this highly reactive intermediate: (thin 
film, cm-1) 3315, 3066, 2967, 2947, 1811, 1702, 1540, 1477, 1448, 1395, 1349, 1271, 1182, 1104, 
1087, 1051, 991, 955, 919, 780, 758, 742. 
 
Dibenzyl 2, 2’-((3’-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-N-methylacetamido)-
3,5-dibromo-4-(methoxycarbonyl)-2;-methyl-[1,1’-biphenyl]-2,6-diyl)bis(oxy))diacetate 
(63).  To 0.05 g (0.07 mmol) of 60 in 0.62 mL of CHCl3 was added 0.03 g (0.09 mmol) of Fmoc-
gly acid chloride 61 (generated according to above procedure and used immediately thereafter) in 
0.37 mL of CHCl3 followed by 0.62 mL of saturated NaHCO3 solution, and the reaction mixture 
was stirred at room temperature for 20 min.  The solution was diluted with DCM (10 mL) and 
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saturated NaHCO3 solution (10 mL), the organic layer was extracted, and the aqueous layer was 
washed with DCM (3  10 mL). The organics were dried over MgSO4, filtered and the volatile 
components were removed from the filtrate under reduced pressure to give a light brown crude oil. 
The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 
5:1/3:1/2:1) to give 0.046 g (67%) of 63 as a white foam: Rf 0.31 (hexanes/ethyl acetate, 1:1); IR 
(thin film, cm-1) 3392, 2926, 2855, 1751, 1722, 1660, 1581, 1421, 1369, 1329, 1299, 1234, 1193, 
1134, 1028, 998, 864, 845, 806, 735; 1H NMR (400 MHz, CDCl3)  7.66 (d, J = 7 Hz, 2H), 7.48 
(d, J = 7 Hz, 2H), 7.32-7.25 (m, 5H), 7.22-7.18 (m, 5H), 7.14-7.06 (m, 7H), 5.49 (broad s, 1H), 
4.94 (s, 4H), 4.23-4.14 (m, 4H), 4.10-4.01 (m, 4H), 3.94 (s, 3H), 3.88 (d, J = 15 Hz, 2H), 3.65, 
3.32 (qd, J = 4, 17 Hz, 2H), 3.08 (s, 3H), 1.95 (s, 3H); 13C NMR (400 MHz, CDCl3)  168.6, 166.8, 
165.8, 156.1, 153.1, 144.0, 143.9, 141.3, 141.3, 139.3, 136.2, 135.1, 135.0, 133.6, 131.0, 128.7, 
128.6, 128.5, 128.4, 128.3, 127.7, 127.4, 127.1, 125.2, 120.0, 111.3, 111.0, 69.2, 69.1, 67.0, 66.8, 
53.4, 47.1, 43.2, 36.3, 15.3; HRMS (ESI-TOF) m/z: [MH]+ calcd for C51H45N2O11Br2 1019.1384, 
found 1019.1366.  
 
Methyl 3'-amino-3,5-dibromo-2,6-diisopropoxy-2'-methyl-[1,1'-biphenyl]-4-carboxylate 
(71). Diisopropyl biaryl 72 (0.10 g, 0.18 mmol) were dissolved in ethyl acetate (4 ml) and 
concentrated HCl (0.08 ml).  The solution was cooled to 0 C and Zn powder (.08 g, 3.3 mmol) 
was added in portions over 20 min with stirring.  The mixture was gradually warmed to room 
temperature and stirred for 15 h.  The reaction mixture was passed through a Celite plug and 
washed with ethyl acetate (5 ml).  The filtrate was washed with saturated NaHCO3 solution (1 x 
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2.5 ml), water (1 x 5 ml), and brine (1 x 10 ml).  The organic layer was dried over anhydrous 
MgSO4 and filtered, and volatile components were removed from the filtrate under reduced 
pressure to give a crude yellow oil.  The oil was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, elution gradient 3:1) to yield 0.077 g (83%) of 71 as a light yellow solid: Rf  
0.37 (hexanes/ethyl acetate 2:1); mp 141-3 C;  1H NMR (400 MHz, CD2Cl2)  6.99 (t, J = 4 Hz, 
1H), 6.73 (d, J = 8 Hz, 1H), 6.59 (d, J = 8 Hz, 1H), 4.45 (broad s, 2H), 3.90 (s, 3H), 3.73 (sext, J 
= 6 Hz,  2H), 1.88 (s, 3H), 0.87 (d, J = 6 Hz, 12 H);  13C NMR (400 MHz, CD2Cl2) 167.6, 154.1, 
145.9, 138.5, 134.4, 133.9, 126.6, 122.6, 122.1, 115.8, 110.9, 77.2, 49.6, 49.4, 49.2, 49.0, 48.8, 
48.5, 48.3, 22.39, 14.73; HRMS (ESI-TOF) m/z: [MH]+  calcd for C21H26NO4Br2 514.0223, found 
514.0204. 
 
Methyl 3,5-dibromo-2,6-diisopropoxy-2'-methyl-3'-nitro-[1,1'-biphenyl]-4-carboxylate (72). 
Dihydroxy biaryl 56 (0.30 g, 0.78 mmol) was dissolved in 4 mL of DMF, followed by addition of 
potassium carbonate (0.2 g, 1.7 mmol), and then the solution was heated to 60 °C.  After 
approximately fifteen minutes, 2-iodopropane (1.6 mL, 1.7 mmol) was added dropwise to the 
mixture and the solution stirred at 60 °C for three hours under an argon atmosphere.  After cooling 
to room temperature, the reaction mixture was partitioned between ethyl acetate and water.   The 
aqueous layer was extracted with ethyl acetate (3 x 10 mL) and the combined organic layers were 
dried over MgSO4 and filtered, and volatile components removed under reduced pressure to give 
a crude product. The crude was purified by flash chromatography (SiO2, hexanes/ethyl acetate, 
20:1) to afford 0.23 g (54%) of 72 as a pale yellow solid: Rf   0.34 (hexanes/ethyl acetate, 5:1); mp 
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109 °C ; 1H NMR (400 MHz, CDCl3) δ 7.82 (d, J = 8 Hz, 1H), 7.43 (d, J = 8 Hz, 1H ), 7.32 (t, J 
= 8 Hz,  1H), 3.95 (s, 3H), 3.79 (sext, J = 6 Hz, 2H), 2.25 (s, 3H), 0.86 (d, J = 9.2 Hz, 12H); 13C 
NMR (400 MHz, CDCl3) δ 166.6, 153.5, 151.1, 139.6, 136.8, 136.3, 132.8, 131.6, 126.1, 124.3, 
111.0, 53.5, 22.4, 22.4, 17.0; HRMS (ESI-TOF) m/z calcd for [M+H]+ C21H24Br2NO6 543.9970, 
found 543.9923. 
 
Di-t-butyl 2,2’-((3’-(2-acetamido-N-methylacetamido)-4-methyoxycarbonyl)-2’-methyl-
[1,1’-biphenyl]-2,6-dilyl)bis(oxy))diacetate (73).  To 0.02 g (0.03 mmol) of carboxylate 74 in a 
vial was added a 0.11 mL of a 20% piperidine/DMF solution, and the reaction mixture was stirred 
at room temperature for 30 min. Then 0.35 mL (4.06 mmol) of acetic anhydride and 1.16 mL (15.4 
mmol) of pyridine were added, and the solution was stirred at room temperature for 30 min. The 
volatile components were removed from the filtrate under reduced pressure to give a crude brown 
oil.   The oil was purified by flash chromatography (SiO2, hexanes/ethyl acetate/methanol elution 
gradient 1:5/1:20) to give 0.02 g (90%) of 73 as a white foam: Rf  0.22 (100% ethyl acetate); 
1H 
NMR (400 MHz, CDCl3)  7.31-7.27 (m, 2H), 7.19-7.12 (m, 3H), 6.47 (broad s, 1H), four protons 
of conformers [4.64, 4.53 (ABq, JAB = 16 Hz), 4.55, 4.50 (ABq JAB = 15 Hz)], 3.91 (s, 3H)], 3.70 
(qd, J = 18, 4 Hz, 2H), 3.29 (s, 3H), 2.03, (s, 3H), 1.98 (s, 3H), 1.45 (s, 18H); 13C NMR (500 MHz, 
CDCl3)  169.7, 168.9, 167.7. 166.3, 155.9, 155.7, 140.1, 135.8, 135.7, 131.3, 130.7, 127.0, 126.8, 
123.1, 106.1, 105.98, 82.5, 82.2 65.9. 65.6, 52.3, 42.2, 36.3, 28.0, 23.1, 14.6; HRMS (ESI-TOF) 
m/z: [MNa]+ calcd for C32H42N2O10Na 637.2737, found 637.2761. 
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Bromo Wang resin (80b).  A suspension of PPh3Br (0.03 g, 0.08 mmol) in DCM (0.33 mL) was 
slowly added to a stirred suspension of Wang resin 80a (0.09 g, 0.03 mmol) in DCM (0.67 mL) at 
room temperature.  After stirring for 3 hours, the reaction mixture was filtered and the resin was 
washed with DCM (4 x 0.7 mL) and used immediately for SPPS. 
 
Methyl 2,6-dihydroxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylate (100).  In a third-
flame dried round-bottom flask, 98.1 mL (98.1 mmol) of a 1.0 M solution of BBr3 in DCM was 
added dropwise over 45 minutes to a stirred solution of 5.01 g (15.1 mmol) of 56 in DCM (50.3 
mL) at 0 ˚C.  The reaction mixture was stirred at 0 ˚C for 3 hours and gradually warmed to room 
temperature and stirred for an additional 13 h.  After cooling to 0 ˚C, the reaction mixture was 
slowly poured over chilled H2O (40 mL) and diluted with Et2O (30 mL); the organic layer was 
extracted, and the aqueous layer was washed with additional ether (3 x 30 mL).  The combined 
organic layers were washed with 0.5 N NaHCO3; the basic layer was extracted and acidified to pH 
= 1.  The acidified aqueous layer was diluted with Et2O; the organic layer was extracted, and the 
aqueous layer was washed with additional ether (2 x 30 mL).  The combined organic layers were 
washed with brine, dried over MgSO4 and filtered, and the volatile components were removed 
under reduced pressure to yield a brown oil.  The oil was purified by flash column chromatography 
(SiO2, hexanes/ethyl acetate, elution gradient, 1:3) to give 3.73 g (86%) of 100 as a pale yellow 
solid: Rf  0.34 (hexanes/ethyl acetate, 1:6); mp 160-161 C; IR (thin film, cm-1) 3310, 2524, 2219, 
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2043, 1653, 1451, 1113, 1034; 1H NMR (300 MHz, CD3OD)  7.81 (d, J = 7 Hz, 1H), 7.44-7.7.37 
(m, 2H), 7.14 (s, 2H), 4.93 (broad s, 2H), 2.25 (s, 3H); 13C NMR (400 MHz, CDCl3)  154.4, 
151.7, 135.53, 134.6, 133.7, 131.9, 127.5, 125.2, 118.6, 109.5, 53.0, 16.4; HRMS (ESI-TOF) m/z: 
[M-H]- calcd for C14H10NO6 288.0502 found 288.0519.      
 
2,2'-((3,5-Dibromo-4-carboxy-2'-methyl-3'-nitro-[1,1'-biphenyl]-2,6-diyl)bis(oxy))diacetic 
acid (102). Biaryl (0.02 g, 0.03 mmol) as a suspension in 3 ml of THF:H2O (2:1), was stirred at 
reflux with 0.3 ml of LiOH/H2O (5 M) overnight.   The reaction mixture was cooled in an ice bath 
and acidified with HCl until pH = 1.  The mixture was diluted with EtOAc (10  mL) and H2O (10 
mL); the organic layer was extracted, and the aqueous layer was washed with additional EtOAc (3 
x 10 mL).  The combined organic layers were dried over MgSO4 and filtered. Volatile components 
were removed under reduced pressure, and the crude solid was purified by flash chromatography 
(SiO2, ethyl acetate, methanol 80:1) to afford 0.87 g (90.8%) of 102 as a white crystal: Rf   0.16 
(ethyl acetate/methanol, 20:1); mp 69 ˚C; 1H NMR (400 MHz, CD3OD) δ 7.94 (d, J = 8 Hz, 1H), 
7.59 (d, J = 7 Hz, 1H), 7.47 (t, J = 8 Hz, 1H), 4.86 (broad s, 2H) 4.26, 4.12 (ABq, JAB = 16 Hz, 
4H), 2.31 (s, 3H); 13C NMR ( MHz, CDCl3) δ 170.7, 154.8, 152.4, 136.4 135.8, 133.6, 132.6, 
131.6, 127.7, 125.9, 111.4, 70.2, 61.6, 30.92, 17.1, 14.6; HRMS (ESI-TOF) m/z calcd for [M-H]-  
C18H12Br2NO8 561.8910, found 561.8918. 
 
2,2'-((4,6-Dibromo-5-carboxy-1,3-phenylene)bis(oxy))diacetic acid (102).  Pd(PPh3)4 (0.01 g, 
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0.05 mmol) in 1.2 mL DCM was transferred to a stirred solution of 111 (0.01 g, 0.02 mmol) and 
PhSiH3 (0.10 mL, 0.03 mmol) in DCM (0.66 mL) under argon atmosphere.  The reaction mixture 
was stirred at room temperature for 30 min and filtered.  The reaction mixture was filtered through 
a Celite plug and rinsed with DCM.  Volatile components were removed by a stream of nitrogen 
and product dried in vacuo to give 0.39 g (89%) of product as a white solid with identical 
spectroscopic properties to those described above. MS (MALDI-TOF) m/z calc for [M+Na]+ 
C14H11Br3O8Na 426.8459, found 426.8479. 
 
2,6-Bis(2-(allyloxy)-2-oxoethoxy)-3,5-dibromo-2'-methyl-3'-nitro-[1,1'-biphenyl]-4-
carboxylic acid (103).  Biaryl 102 (0.15 g, 0.33 mmol) and TEA (0.14 mL, 0.65 mmol) in DCM 
(3 mL) were added to a stirred solution of allyl-2-bromoacetate 110 (0.08 mL, 0.98 mmol) in 0.5 
mL DCM and stirred for 13 h at room temperature.  The mixture was diluted with Et2O (10  mL) 
and H2O (10 mL); the organic layer was extracted, and the aqueous layer was washed with 
additional Et2O (3 x 10 mL).  The combined organic layers were dried over MgSO4 and filtered.  
The volatile components were removed under reduced pressure, and the crude oil was purified by 
flash chromatography (SiO2, hexanes/ethyl acetate elution gradient 3:1) to afford 0.87 g () of 103 
as a white crystal: Rf   0.29 (hexanes/ethyl acetate, 1:1);  
1H NMR (300 MHz, CDCl3) δ 7.16 (s, 
2H), 3.89 (s, 3H), 1.05 (s, 18H), 0.26 (s, 12H); 13C NMR (400 MHz, CDCl3) δ 166.7, 157.3, 130.4, 
106.9, 105.8, 56.9, 53.2, 29.3, 17.1, 4.3; HRMS (ESI-TOF) m/z calc for [M-H]- C24H20Br2NO10 
639.9448, found 639.9446.   
Diallyl 2,2'-((4-((2-(allyloxy)-2-oxoethoxy)carbonyl)-3,5-dibromo-2'-methyl-3'-nitro-[1,1'-
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biphenyl]-2,6-diyl)bis(oxy))diacetate. 1H NMR (400 MHz, CDCl3) δ 7.93,7.91 (dd, J = 8, 2 Hz, 
2H), 7.91-7.41 (m, 2H), 6.01-5.90 (m, 1H), 5.82-5.75 (m, 2H), 5.41,5.37 (dd, J = 15,2 Hz, 1H), 
5.32,5.29 (dd, J = 9,1 Hz, 1H), 5.24-5.23 (m, 2H), 5.21-5.20 (m, 2H),  4.96 (s, 2H), 4.76-4.74 (m, 
2H), 4.51-4.48 (m, 4H), 4.18, 4.06 (qAB, J = 15 Hz, 4H), 2.35 (s, 3H); 13C NMR (500 MHz, 
CDCl3) δ 166.6, 166.5, 164.5, 153.6, 150. 9, 138.8, 135.1, 134.1, 132.8, 131.4, 131.3, 131.2, 126.7, 
125.2, 119.6, 119.5, 111.9, 69.6, 66.4, 66.1, 62.3, 17.1; HRMS (ESI-TOF) m/z calc for [M+H]+ 
C29H28Br2NO12 739.9972, found 739.9966.  
  
 
Methyl 4-bromo-3,5-bis(2-t-butoxy-2-oxoethoxy)benzoate (104). In a round-bottom flask, 0.25 
g (1.0 mmol) of benzoate 122, 0.45 mL (3.0 mmol) of t-butyl bromoacetate, 0.41 g (3.0 mmol) of 
K2CO3, and 0.26 g (1.0 mmol) of 18-crown-6 were dissolved in acetone (25.0 mL), and the reaction 
mixture was refluxed for 16 h. The volatile components were removed under reduced pressure, 
and the residue was diluted with DCM (50 mL) and water (50 mL); the organic layer was extracted, 
and the aqueous layer was washed with additional DCM (3 x 50 mL). The organic layers were 
dried over MgSO4 and filtered, and the volatile components were removed under reduced pressure 
to give a crude yellow oil. The oil was purified by flash chromatography (SiO2, hexanes/ethyl 
acetate elution gradient 3:1) to give 0.39 g (89%) of 104 as a white solid: Rf 0.47 (hexanes/ethyl 
acetate, 7:3); mp 103-105 °C; IR (thin film, cm-1) 3090, 2980, 1753, 1725, 1588, 1423, 1394, 1369, 
1339, 1304, 1239, 1161, 1132, 1030, 1000, 951, 900, 844, 763; 1H NMR (400 MHz, CDCl3) δ 
7.16 (s, 2H), 4.67 (s, 4H), 3.92 (s, 3H), 1.51 (s, 18H); 13C NMR (400 MHz, CDCl3) δ 167.0, 166.0, 
155.8, 129.9, 108.0, 107.1, 82.8, 66.6, 52.5, 28.0; HRMS (Q-TOF) m/z calcd for [M+Na]+ 
C20H27O8BrNa 497.0787, found 497.0819. 
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2,2'-((2,4,6-Tribromo-5-carboxy-1,3-phenylene)bis(oxy))diacetic acid (105). 
Method A:   Benzoic acid 104 (0.11 g, 0.21 mmol), as a suspension in 5 ml of THF:H2O (2:1), was 
stirred at reflux with 0.5 ml of LiOH/H2O (5 M) overnight.  The reaction mixture was cooled in 
an ice bath and acidified with HCl until pH = 1.  The precipitate was filtered and washed with 
chilled water.  The solid was taken up into ethyl acetate and diluted with H2O; the organic layer 
was extracted, and the aqueous layer was washed with additional EtOAc (10 mL).  The combined 
organic layers were dried with brine (15 mL) and filtered over MgSO4.  Volatile components were 
removed under reduced pressure, and the crude solid was subjected to bromination conditions 
without further purification.  To a stirred solution of 0.07 g (0.30 mmol) of 105 in CCl4 (2.2 mL) 
in the dark, 0.04 ml (0.6 mmol) Br2 in CCl4 (0.6  mL) was added dropwise over 15 min.  The 
reaction mixture was stirred for 5 h.  The reaction mixture was then cooled in an ice bath and 30% 
NaHSO3 was added until red color dissipated.  The precipitate was isolated and washed with ice 
water.  The crude solid was purified by flash column chromatography (SiO2, ethyl acetate/hexanes, 
50:1) to afford 0.06 g (54%) of 105 as a white solid: Rf   0.21 (ethyl acetate/methanol, 20:1); mp 
70 ˚C ; 1H NMR (300 MHz, CDCl3) δ 6.83 (broad s, 3H), 3.89 (qAB, J = , 4H); 13C NMR (400 
MHz, CDCl3); HRMS (ESI-TOF) m/z calcd for [M+Na]
+ C11H6O8Br3 502.7607, found 502.7616.  
Method  B: Bromo Wang resin (g, mmol) was suspended in (ml) and left to swell for 15 minutes.  
A solution of benzoic acid 111 (0.09 g, 0.12 mmol), PyAOP (0.06 g, 0.12 mmol), HOBt (0.02 g, 
0.12 mmol) and DIEA (0.02 g, 0.18 mmol) in NMP was vortexed and left to activate for 2 minutes.  
DMF was filtered and the activated acid solution added to swelled resin.  The stirred solution was 
heated at 70 °C for 4 min using microwave irradiation. The solution was then stirred at room 
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temperature for 5 min, filtered and resin washed with additional DMF (3 x 3 mL).  The following 
protocol was repeated twice for allyl deprotection.  The resin was suspended in DMF (0.73 ml), 
treated with DIEA (0.45 mL) and Ac2O (0.22 mL) and stirred at room temperature for 20 min.  
After filtration and washing with DMF (3 x 3 mL) and DCM (2 x 3 mL), the resin was suspended 
in DCM (0.76 mL) under Argon atmosphere and PhSiH3 (28 ul, 0.23 mmol) added.  Pd(PPh3)4 (2.6 
mg, 15 umol) in 1.37 mL of DCM was transferred to the stirred solution.  The reaction mixture 
was stirred at room temperature for 30 min and filtered.  The resin was rinsed and filtered with 
THF (3 x 3 mL), DMF (3 x 3 mL), DCM (3 x 3 mL), 5% DIEA in DCM (3 x 3 mL), and 0.02 M 
sodium diethyldithiocarbamate (NaDDTC) (3 x 3 mL).   
 
3,5-Bis(2-(allyloxy)-2-oxoethoxy)-2,4,6-tribromobenzoic acid (107).  In a round-bottom flask, 
0.8 ml (12.8 mmol) of Br2 in CCl4 (5  mL) was added dropwise over 30 min to a stirred solution of 
1.0 g (4.29 mmol) of 45 in CCl4 (10 mL) in the dark.  The reaction mixture was stirred for 4.5 h.  
The reaction mixture was cooled in an ice bath, and 30% NaHSO3 was added until red color 
dissipated.  The precipitate was isolated and washed with ice water.  The crude solid was purified 
by flash column chromatography (SiO2, hexanes/ethyl acetate, 1:5) to give 0.92 g (56%) of 107 as 
a yellow solid: Rf  0.19 (hexanes/ethyl acetate, 1:10); 
1H NMR (300 MHz, CD3OD) δ 4.92 (s, 3H); 
13C NMR (400 MHz, CD3OD) δ 169.19, 152.95, 139.70, 102.40, 98.3; HRMS (ESI-TOF) m/z 
calcd [M-H]- for C7H2Br3O4 388.7651, found 388.7687.  
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2,4,6-Tribromo-3,5-bis((t-butyldimethylsilyl)oxy)benzoic acid (108). To a stirred solution of 
0.08 g (0.5 mmol) of t-butylchlorodimethylsilane in 0.75 mL of DCM, 0.10 g (0.26 mmol) of 107 
and 0.1 mL (0.76 mmol) TEA in DCM (1.50 mL) was added and stirred for 15 h at room 
temperature.  The mixture was diluted with DCM (5 mL) and H2O (5 mL); the organic layer was 
extracted, and the aqueous layer was washed with additional Et2O (3 x 10 mL).  The combined 
organic layers were dried over MgSO4 and filtered, and volatile components removed under 
reduced pressure to give a crude white solid.  The powder was purified by flash chromatography 
(SiO2, ethyl acetate/hexanes, 1:50) to afford 0.08 g (90.8%) of 108 as a white crystal: Rf   0.34 
(hexanes/ethyl acetate, 2:1); 1H NMR (500 MHz, CDCl3) δ 4.44 (s, 1H), 1.04 (s, 18H), 0.34 (s, 
12H); 13C NMR (600 MHz, CDCl3) δ 167.4, 152.0, 138.7, 112.5, 105.5, 27.0, 19.9, 0.98;  HRMS 
(ESI-TOF) m/z calcd for C19H31Br3O4Si2 617.93, found 617.932.  
2,4,6-Tribromo-3-((t-butyldimethylsilyl)oxy)-5-hydroxybenzoic acid (109). 1H NMR (400 
MHz, CDCl3) δ 6.04 (broad s, 1H), 1.05 (s, 9H), 0.36 (s, 6H); 13C NMR (400 MHz, CDCl3) δ 
166.9, 151.7, 150.8, 138.3, 106.1, 104.2, 99.5, 29.9, 26.9, 19.7; HRMS (ESI-TOF) m/z calcd for 
C13H17Br3O4Si 503.84, found 503.8457.  
 
Allyl-2-bromoacetate (110).  To 5.0 g of bromoacetic acid (35.98 mmol) and 2.45 ml of allyl 
alcohol (35.98 mmol) in cyclohexane (36 mL) was added 0.01 g pTsOH and the resulting reaction 
mixture was heated at reflux for 3 hours with azeotropic removal of the formed water employing 
a Dean and Stark apparatus.  The reaction mixture was neutralized by washing with dil. Na2CO3. 
After washing with brine and drying (MgSO4) the volatile components were removed under 
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reduced pressure to give  4.33 g (68%) of 110 as a colorless very irritating liquid (bp = 73 ºC/15 
mmHg). Rf 0.47 (hexanes/ethyl acetate, 7:3); mp 103-105 °C; 
1H NMR (400 MHz, CDCl3) δ 5.93 
(dquin, J = 17, 6 Hz, 1H), 5.39,5.35 (dd, J = 17,1 Hz, 2H), 4.67 (d, J = 6 Hz, 2H), 3.87 (s, 2H); 
13C NMR (300 MHz, CDCl3) δ 170.9, 132.1, 117.6, 65.6, 48.3.  
 
3,5-Bis(2-(allyloxy)-2-oxoethoxy)-2,4,6-tribromobenzoic acid (111).  Benzoic acid 107 (0.16 g, 
0.41 mmol) and TEA (0.17 mL, 1.24 mmol) in DCM (3 mL) were added to a stirred solution of 
allyl-2-bromoacetate x (0.10 mL, 0.98 mmol) in 0.6 mL DCM and stirred for 13 h at room 
temperature.  The mixture was diluted with Et2O (10  mL) and H2O (10 mL); the organic layer 
was extracted, and the aqueous layer was washed with additional Et2O (3 x 10 mL).  The combined 
organic layers were dried over MgSO4 and filtered.  The volatile components were removed under 
reduced pressure, and the crude oil was purified by flash chromatography (SiO2, hexanes/ethyl 
acetate, elution gradient 2:1) to afford 0.11 g (48%) of 111 as a white crystal: Rf   0.29 
(hexanes/ethyl acetate, 1:2); 1H NMR (300 MHz, CDCl3) δ 5.95 (dquin, J = 17,6 Hz, 2H), 
5.40,5.32 (dABq, J = 10,1 Hz, 2H), (dABq, JAB = 10,1 Hz, 2H), 4.76,4.74 (dt, J = 6,1 Hz, 4H), 
4.63 (s, 4H); 13C NMR (400 MHz, CDCl3) δ 167.1, 153.4, 131.6, 119.6, 111.8, 69.3, 66.4; HRMS 
(ESI-TOF) m/z calcd for C17H15Br3O8 581.7524, found 581.7545. 
 
3,5-Dibromo-2,6-dihydroxy-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-carboxylic acid (113).  In a 
third-flame dried round-bottom flask, 1.0 mL of a 1.0 M solution of BBr3 in DCM was added 
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dropwise over 30 minutes to a stirred solution of 0.35 g (0.76 mmol) of 15 in DCM (4 mL) at 0 
˚C.  The reaction mixture was stirred at 0 ˚ C for 3 hours and gradually warmed to room temperature 
and stirred for an additional 13 h.  After cooling to 0 ˚C, the reaction mixture was quenched by the 
slow addition of chilled H2O (15 mL) and diluted with Et2O (30 mL); the organic layer was 
extracted, and the aqueous layer was washed with additional ether (3 x 30 mL).  The combined 
organic layers were washed with 1 N NaOH (50 mL); the basic layer was extracted and acidified 
to pH = 1.  The acidified aqueous layer was diluted with Et2O; the organic layer was extracted, 
and the aqueous layer was washed with additional ether (3 x 30 mL).  The combined organic layers 
were washed with brine, dried over MgSO4 and filtered, and the volatile components were 
removed under reduced pressure to yield a brown oil.  The oil was purified by flash column 
chromatography (SiO2, hexanes/ethyl acetate, elution gradient, 1:2) to give 0.27 g (76%) of 72 as 
a pale yellow solid: Rf  0.22 (hexanes/ethyl acetate, 1:4); 
1H NMR (300 MHz, CD3OD) δ 7.88,7.85 
(dd, J = 8, 2 Hz, 1H), 7.47-7.39 (m, 2H), 5.03 (broad s, 2H), 2.24 (s, 3H); 13C NMR (400 MHz, 
CD3OD) δ 210.7, 169.5, 152.7, 152.1, 140.6, 137.2, 136.3, 133.3, 127.6, 124.8, 118.7, 98.9, 30.7, 
24.0, 16.1; HRMS (ESI-TOF) m/z calc for [M-H]- C14H8Br2NO6 443.8716, found 443.8712.   
 
Diallyl 2,2'-((3'-(2-((((9H-fluoren-9-yl)methoxy)carbonyl)amino)-N-methylacetamido)-3,5-
dibromo-4-((2-(t-butoxy)-2-oxoethoxy)carbonyl)-2'-methyl-[1,1'-biphenyl]-2,6-
diyl)bis(oxy))diacetate (127).  To 0.06 g (0.08 mmol) of 155 in 0.75 mL of CHCl3 was added 
0.03 g (0.11 mmol) of Fmoc-gly acid chloride 62 (generated according to above procedure and 
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used immediately thereafter) in 0.5 mL of CHCl3 followed by 0.75 mL of saturated NaHCO3 
solution, and the reaction mixture was stirred at room temperature for 20 min.  The solution was 
diluted with DCM (10 mL) and saturated NaHCO3 solution (10 mL), the organic layer was 
extracted, and the aqueous layer was washed with DCM (3  10 mL). The organics were dried 
over MgSO4, filtered and the volatile components were removed from the filtrate under reduced 
pressure to give a light brown crude oil. The oil was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, elution gradient 4:1/3:1) to give 0.05 g (67%) of 127 as a white foam: Rf  
0.39 (hexanes/ethyl acetate, 1:1);  1H NMR (400 MHz, CDCl3)  7.75 (d, J = 7 Hz, 2H), 7.58 (d, 
J = 7 Hz, 2H), 7.38 (t, J = 7 Hz, 2H), 7.36-7.24 (m, 4H), 7.22-7.18 (dquin, J = 7 Hz, 2H), 5.61 
(broad s, 1H), 5.24,5.21 (dABq, J = 4,1 Hz, 2H), 5.18,5.12 (qAB, J = 23,10 Hz, 2H), 4.82 (s, 2H), 
4.31 (d, J = 6 Hz, 2H), 4.19,4.13 (ABq, J = 7 Hz, 4H), 3.77,3.46 (qd, J = 4 Hz, 2H), 3.27 (s, 3H), 
2.09 (s, 3H), 1.53 (s, 9H);  13C NMR (600 MHz, CDCl3)  168.8, 166.7, 165.8, 164.6, 153.3, 153.3, 
144.1, 144.0, 141.5, 141.4, 138.5, 136.3, 133.7, 131.6, 131.5, 131.3, 131.2, 128.9, 127.8, 127.5, 
127.1, 125.3, 120.0, 119.1, 119.0, 111.8, 111.6, 83.1, 69.3, 69.2, 67.2, 66.0, 65.7, 62.8, 47.2, 43.2, 
36.2, 28.2, 15.2; HRMS (ESI-TOF) m/z calcd for [M+H]+ C44H40Br2N2O13 962.5919, found 
962.5928. 
 
Dibenzyl 2,2’-((3,5-dibromo-4-(methoxycarbonyl)-2’-methyl-3’-(methylamino)-[1,1’-
biphenyl]-2,6-diyl)bis(oxy))diacetate (128).  Biaryl 126 (0.12 g, 0.17 mmol) and 0.027 g (0.18 
mmol) of 69 in THF (0.12 mL) were sonicated for 5 minutes to give a homogenous solution.  The 
mixture was then diluted with EtOH (0.16 mL) and stirred at room temperature for 12 h.   Volatile 
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components were removed under reduced pressure and reaction vial was cooled to 0 ˚C for 10 
minutes.  The residue was rinsed with chilled dry DCM followed by hexanes to produce an off-
white solid.  The precipitate was isolated and taken up into DCM, dried over K2CO3, filtered, and 
volatile components were removed under reduced pressure to give an off-white solid. The dry 
intermediate was dissolved in THF (1.18 mL), and 0.013 g (0.33 mmol) of NaBH4 were added and 
stirred for 6 h.  The reaction mixture was concentrated under reduced pressure and the residue was 
diluted with ice, cold H2O, and DCM; the organic layer was extracted and aqueous layer washed 
with additional DCM (2 x 5 mL).  The combined organic layers were washed with additional H2O 
(5 mL) and then brine (5 mL); the organic layer was dried over MgSO4, filtered, and volatile 
components were removed under reduced pressure to give a yellow foam.  The foam was purified 
by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 6:1) to yield 0.08 g (65%) 
of 128 as a white foam: Rf  0.32 (hexanes/ethyl acetate 3:1; 
1H NMR (400 MHz, CDCl3) δ 7.19 (t, 
J = 8 Hz, 1H), 6.62 (d, J = 8 Hz, 1H), 6.56 (d, J = 8 Hz, 1H), 5.83,5.78 (dquin, J = 20, 8 Hz, 2H), 
5.23 (dd, J = 12 Hz, 2H), 5.20 (dd, J = 6 Hz, 4H), 4.81 (s, 2H), 4.50 (d, 2H), 4.12,3.99 (ABq, J = 
15 Hz,  4H), 2.91 (s, 3H), 1.92 (s, 3H), 1.53 (9H);13C NMR (500 MHz, CDCl3) δ 167.7, 166.4, 
153.7, 147.9, 138.7, 135.5, 132.3, 131.1, 128.9, 128.8, 128.6, 127.2, 121.4, 119.2, 111.0, 109.9, 
69.4, 67.0, 53.6, 31.2, 30.1, 28.7, 14.6, 14.5; HRMS (Q-TOF) m/z calcd for [M+H]+ 
C31H36Br2NO10 740.0700, found 740.0669. 
 
Diallyl 2,2’-((3,5-dibromo-4-((2-(t-butoxy)-2-oxoethoxy)carbonyl)-2’-methyl-3’nitro-[1,1’-
biphenyl]-2,6-diyl)bis(oxy))diacetate (129).  In a round bottom flask, 0.18 g (0.33 mmol) of 89, 
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0.09 mL (0.72 mmol) of allyl bromoacetate, 0.09 g (0.65 mmol) of K2CO3, and 0.01 g (0.01 mmol) 
of 18-crown-6 were dissolved in acetone (3.3 mL), and the reaction mixture was refluxed for 14 
h.  The volatile components were removed under reduced pressure, and the residue was diluted 
with DCM (10 mL) and water (10 mL); the organic layer was extracted, and the aqueous layer was 
washed with additional DCM (3 x 10 mL).  The combined organic layers were washed with brine, 
dried over MgSO4 and filtered, and the volatile components were removed under reduced pressure 
to give a crude brown foam.  The foam was purified by flash chromatography (SiO2, hexanes/ethyl 
acetate, elution gradient 2:1) to yield 0.18 g (74%) of 129 as a pale yellow foam: Rf  0. 
(hexanes/ethyl acetate 2:1); 1H NMR (400 MHz, CDCl3) δ 7.92 (d, J = 6, 1H), 7.47-7.39 (m, 2H), 
5.79 (dquin, J = 22, 6 Hz  2H), 5.25 (dABq, JAB = 3, 2 Hz, 2H) 5.20 (dABq, JAB = 9,8 Hz, 2H), 
4.82 (s, 2H), 4.49 (dt, J = 6,1 Hz,  4H) 4.20,4.09 (ABq, JAB =  35, 15 Hz, 4H), 2.35 (s, 3H) 1.54 
(s, 9H); 13C NMR (600 MHz, CDCl3) δ 166.6, 165.8, 164.5, 153.6, 150.9, 139.1, 135.1, 134.1, 
132.8, 131.3, 131.1, 126.6, 125.2, 119.4, 111.9, 83.2, 69.5, 66.1, 62.9, 28.3, 17.0; HRMS (ESI-
TOF) m/z calcd for [M+Na]+ C30H31Br2NO12Na  778.0105, found  778.0108. 
 
2-(T-butoxy)-2-oxoethyl 3,5-dibromo-2,6-dihydroxy-2’methyl-3’-nitro-[1,1’-biphenyl]-4-
carboxylate (130).  In an oven-dried round bottom flask, 0.25 g (0.56 mmol) of 113, 0.091 mL 
(0.62 mmol) of t-butyl bromoacetate, 0.06 g (0.56 mmol) of KHCO3, and 0.01 g (0.02 mmol) of 
18-crown-6 were dissolved in acetone (5.5 mL), and the reaction mixture was refluxed for 4 h.  
The volatile components were removed under reduced pressure, and the residue was diluted with 
DCM (20 mL) and water (20 mL); the organic layer was extracted, and the aqueous layer was 
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washed with additional DCM (3 x 20 mL).  The combined organic layers were washed with brine 
(50 mL), dried over MgSO4 and filtered, and the volatile components were removed under reduced 
pressure to give a crude light brown foam.  The foam was purified by flash chromatography (SiO2, 
hexanes/ethyl acetate, elution gradient 6:1/5:1) to yield 0.24 g (78%) of 130 as a pale yellow foam: 
Rf  0.36 (hexanes/ethyl acetate 4:1); 
1H NMR (300 MHz, CDCl3) δ 7.93 (d, J = 8 Hz, 1H), 7.46-
7.38 (m, 2H), 5.73 (broad s, 2H), 4.81 (s, 2H), 2.29 (s, 3H), 1.54 (s, 9H); 13C NMR (400 MHz, 
CD3OD) δ 169.5, 152.7, 152.1, 140.6, 137.2, 136.3, 133.3, 127.6, 124.8, 118.7, 98.9, 30.7, 16.1; 
HRMS (ESI-TOF) m/z calcd for [M-H]- C20H18Br2NO8 557.9393, found 557.9404. 
 
2-((2,6-Bis(2-(allyloxy)-2-oxoethoxy)-3,5-dibromo-2’-methyl-3’-nitro-[1,1’-biphenyl]-4-
carbonyl)oxy)acetic acid (140).  To a solution of 0.17 g (0.23 mmol) of 129 in DCM (1.5 mL) at 
room temperature was added 0.5 mL (6.8 mmol) of TFA and the reaction mixture was stirred for 
2 h.  The reaction mixture was diluted with DCM (10 mL) and water (10 mL); the organic layer 
was extracted, and the aqueous layer was washed with additional DCM (2 x 10 mL).  The 
combined organic layers were washed with brine (30 mL), dried over MgSO4 and filtered, and the 
volatile components were removed under reduced pressure to yield 0.15 g (99%) of 140 as a white 
foam: Rf  0.32 (hexanes/ethyl acetate 1:1); 
1H NMR (400 MHz, CDCl3) δ 7.84 (d, J = 8 Hz, 1H), 
7.40-32 (m, 2H), 6.69 (broad s, 1H), 5.71  (dquin, J = 12, 6 Hz, 2H),  5.18 (dABq, J = 9,1 Hz, 2H), 
5.16 (app dd, J = 9,1 Hz, 2H), 4.92 (s, 2H),  4.44 (dt, J = 6,1 Hz, 4H), 4.13,4.02 (ABq, JAB = 15 
Hz, 4H), 2.28 (s, 3H); 13C NMR (400 MHz, CDCN) δ 168.3, 167.6, 165.5, 154.6, 151.7, 139.3, 
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135.9, 135.0, 133.0, 132.8, 132.0, 127.6, 125.8, 118.8, 118.3, 111.9, 70.35, 66.21, 62.95, 17.00; 
HRMS (ESI-TOF) m/z calcd for [M-H]- C26H22Br2NO12 697.95033, found 697.95150.  
Dially2,2'-((5-((2-(allyloxy)-2-oxoethoxy)carbonyl)-2,4,6-tribromo-1,3-
phenylene)bis(oxy))diacetate. 1H NMR (400 MHz, CDCl3) δ 4.76 (s, 2H), 4.74 (s, 4H), 1.52 (s, 
18H), 1.51 (s, 9H), 2.29 (s, 3H), 1.54 (s, 9H); 13C NMR (500 MHz, CDCl3) δ 166.2, 165.7, 164.3, 
153.6, 137.7, 116.2, 111.6, 83.0, 82.7, 70.8, 69.6, 68.5, 63.9, 62.8, 61.6, 29.7, 28.7, 27.7, 26.7; 
HRMS (ESI-TOF) m/z calcd for [M+H]+ C21H26Br3O10 674.9872, found 674.9865. 
2-(T-butoxy)-2-oxoethyl 2,4,6-tribromo-3-(2-(t-butoxy)-2-oxoethoxy)-5-hydroxybenzoate. 1H 
NMR (400 MHz, CDCl3) δ 6.50 (broad s, 1H), 4.77 (s, 2H), 4.48 (s, 2H), 1.52 (s, 9H), 1.52 (s, 
9H); 13C NMR (500 MHz, CDCl3) δ 166.4, 165.8, 164.5, 153.0, 150.7, 136.8, 108.0, 105.8, 103.5, 
83.1, 82.8, 69.7, 62.8, 28.2; HRMS (ESI-TOF) m/z calcd for [M-H]-  C19H22Br3O8 614.8859, found 
614.8881. 
2,4,6-Tribromo-3,5-bis(2-(t-butoxy)-2-oxoethoxy)benzoic acid. 1H NMR (400 MHz, CDCl3) δ 
6.24 (broad s, 1H), 4.76 (s, 2H), 4.48 (s, 2H), 1.52 (d, 18H); 13C NMR (500 MHz, CDCl3) δ 166.4, 
165.8, 164.6, 153.1, 150.6, 136.9, 107.9, 106.0, 103.4, 83.1, 82.8, 69.7, 62.8, 28.3; HRMS (ESI-
TOF) m/z calcd for [M-H]- C19H22Br3O8 614.8859, found 614.8860.  
 
Dibenzyl 2,2'-((2,2'-((4-((2-amino-2-oxoethoxy)carbonyl)-3,5-dibromo-2'-methyl-3'-nitro-
[1,1'-biphenyl]-2,6-diyl)bis(oxy))bis(acetyl))bis(azanediyl))(2R,2'R)-dipropionate (141). 
NovaPEG rink amide resin (0.07 g, approx. 0.03 mmol) was suspended in DMF (2.5 ml) and left 
to swell for 10 minutes.  A solution of 140 (0.09 g, 0.12 mmol), PyAOP (0.06 g, 0.12 mmol), 
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HOBt (0.02 g, 0.12 mmol) and DIEA (0.02 g, 0.18 mmol) in NMP was vortexed and left to activate 
for 2 minutes.  DMF was filtered and the activated acid solution added to swelled resin.  The stirred 
solution was heated at 70 °C   for 4 min using microwave irradiation. The solution was then stirred 
at room temperature for 5 min, filtered and resin washed with additional DMF (3 x 3 mL).  The 
following protocol was repeated twice for allyl deprotection.  The resin was suspended in DMF 
(0.73 ml), treated with DIEA (0.45 mL) and Ac2O (0.22 mL) and stirred at room temperature for 
20 min.  After filtration and washing with DMF (3 x 3 mL) and DCM (2 x 3 mL), the resin was 
suspended in DCM (0.76 mL) under Argon atmosphere and PhSiH3 (28 ul, 0.23 mmol) added.  
Pd(PPh3)4 (2.6 mg, 15 umol) in 1.37 mL of DCM was transferred to the stirred solution.  The 
reaction mixture was stirred at room temperature for 30 min and filtered.  The resin was rinsed and 
filtered with THF (3 x 3 mL), DMF (3 x 3 mL), DCM (3 x 3 mL), 5% DIEA in DCM (3 x 3 mL), 
and 0.02 M sodium diethyldithiocarbamate (NaDDTC) (3 x 3 mL).  The resin was washed with 
DMF (2 x 3 mL) and suspended in NMP (2.1 mL). To the suspension, PyAOP (0.24 mmol, 0.13 
g), HOBt (0.04 g, 0.24 mmol), and DIEA (0.06 mL, 0.36 mmol) were added and stirred for 3 min.  
Alanine benzyl ester  (0.05 g, 0.24 mmol) was added to the activated acid and heated at 70 °C  for 
4 min using microwave irradiation. The solution was then stirred at room temperature for 5 min 
and filtered.  After filtration with DMF (3 x 3 mL), DCM (3 x 3 mL) and MeOH (3 x 3 mL), the 
resin was dried in a vacuum dessicator for 30 min. TFA (2.19 mL, 28.64 mmol) and TIS (0.12 mL, 
0.57 mmol) were added to the reaction and the vessel shaken for 3 hours. The reaction mixture 
was filtered and resin treated with additional TFA (2.0 mL, 27 mmol) and filtered.  TFA was 
removed from the filtrate by a stream of nitrogen and product dried in vacuo.  The crude product 
was purified using the preparative RP-HPLC standard protocol in Chapter 9.1 and freeze-dried to 
give 141 in >95% purity. 1H NMR (700 MHz, CD3CN) δ 7.90 (d, J = 8 Hz, 1H), 7.57 (d, J = 8 Hz, 
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1H), 7.43 (t, J = 8 Hz, 1H), 7.36 (m, 10H), (q, J = Hz, 2H), 6.49 (broad s, 1H), 6.15 (broad s, 1H), 
5.13-5.08 (m, 4H),  4.80 (s, 2H), four protons of conformers [4.33,4.32 (ABq, JAB = 4 Hz), 
4.18,3.91 (ABq, JAB = 14 Hz), 4.03 (s)], 2.39 (s, 3H), 1.28,1.25 (dd, J = 20,8 Hz, 6H);  
13C NMR 
(400 MHz, CDCl3) δ 167.2, 166.1, 154.0, 151.3, 140.4, 135.8, 135.5, 134.5, 133.1, 131.0, 129.1, 
129.0, 128.9, 127.1, 125.5, 111.7, 70.0, 67.4, 54.6, 54.3, 54.1, 53.9, 53.8, 17.2; HRMS (ESI-TOF) 
m/z calcd for [M+H]+ C40H39Br2N4O13 941.08749, found 941.0873.   
 
Diallyl 2,2'-((4-((2-amino-2-oxoethoxy)carbonyl)-3,5-dibromo-2'-methyl-3'-nitro-[1,1'-
biphenyl]-2,6-diyl)bis(oxy))diacetate (142). NovaPEG rink amide resin (0.02 g, 0.01 mmol) was 
suspended in DMF (2.5 ml) and left to swell for 10 minutes.  A solution of biaryl 124 (0.03 g, 0.04 
mmol), PyAOP (0.02 g, 0.04 mmol), HOBt (0.01 g, 0.04 mmol) and DIEA (0.01 g, 0.06 mmol) in 
NMP (mL) was vortexed and left to activate for 2 minutes.  DMF was filtered, and the activated 
acid solution was added to swelled resin 142.  The stirred solution was heated for 4 minutes at 70 
˚C by microwave irradiation. The solution was then stirred at room temperature for 5 minutes, 
filtered, and resin washed with additional DMF (3 x 3 mL).  The resin was suspended in DMF 
(0.73 ml), treated with DIEA (mL, mmol) and Ac2O (mL, mmol) and stirred at room temperature 
for 15 minutes.  After filtration and washing with DMF (3 x 3 mL), DCM (3 x 3 mL)  and MeOH 
(3 x 3 mL), the resin was dried in vacuo for 20 minutes.  TFA (1.0 mL) was added to resin and 
reaction vessel shaken for 2.5 hours. The reaction mixture was filtered and resin treated with 
additional 0.6 ml TFA, shaken for 1 hour, and filtered.  TFA was removed from the filtrate by a 
stream of nitrogen and product dried in vacuo. The resin was treated with additional cleavage 
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cocktail of TFA (95 µL), H2O (25 µL  and TIS (25 µL), shaken for 30 min, filtered and repeated.  
The crude product was purified using the preparative RP-HPLC standard protocol (see Chapter 
9.1) and freeze-dried to give 0.84 g (78%).   1H NMR (500 MHz, CD3CN) δ 7.92 (d, J = 8 Hz, 
1H), 7.53 (d, J = 8 Hz, 1H), 7.45 (t, J = 8 Hz, 1H), 6.49 (broad s, 1H), 6.13 (broad s, 1H), 5.80  
(dquin, J = 12, 6 Hz, 2H),  5.21, (dABq, J = 9,1 Hz, 2H), 5.18 (dABq, J = 9,1 Hz, 2H), 4.79 (s, 
2H),  4.43 (qt, J = 9,5  Hz, 4H), 4.26,4.13 (ABq, JAB = 16 Hz, 4H), 2.28 (s, 3H); 
13C NMR (400 
MHz, CDCl3) δ 167.2, 166.1, 154.0, 151.3, 140.4, 135.8, 135.5, 134.5, 133.1, 131.0, 129.1, 129.0, 
128.9, 127.1, 125.5, 111.7, 70.0, 67.4, 54.6, 54.3, 54.1, 53.9, 53.8, 17.2; HRMS (ESI-TOF) m/z: 
[MH]+ calcd for C26H24Br2N2O11 699.96598, found 699.96778. 
 2-(4-(2,4-Dimethoxybenzyl)phenoxy)acetic acid (153).  Product 154 was isolated as a side 
product of the above process when TIS was used in the cleavage step.  1H NMR (300 MHz, 
CD3CN)  7.12 (d, J = 5 Hz, 2H), 7.00 (d, J = 8, 1H), 6.84 (d, J = 5, 2H), 6.50 (d, J = 2, 1H), 6.44 
(d, J = 9, 1H), 4.99 (broad s, 1H), 4.38 (s, 2H), 3.79 (s, 2H), 3.77 (s, 3H), 3.75 (s, 3H); 13C NMR 
(400 MHz, CDCl3)  154.4, 151.7, 135.53, 134.6, 133.7, 131.9, 127.5, 125.2, 118.6, 109.5, 53.0, 
16.4;   HRMS (ESI-TOF) m/z: [MH]+ calcd for C17H19O5 303.12270, found 303.12345.         
 
2,2'-((4-((2-Amino-2-oxoethoxy)carbonyl)-3,5-dibromo-2'-methyl-3'-nitro-[1,1'-biphenyl]-
2,6-diyl)bis(oxy))diacetic acid (143). NovaPEG rink amide resin (0.07 g, 0.03 mmol) was 
suspended in DMF (2.5 ml) and left to swell for 10 minutes.  A solution of biaryl 143-i (0.09 g, 
0.12 mmol), HCTU (0.06 g, 0.12 mmol) and DIEA (0.02 g, 0.18 mmol) in NMP was vortexed and 
left to activate for 2 minutes.  DMF was filtered and the activated acid solution added to 143-i.  
 162 
The stirred solution was heated at 70 °C   for 4 min using microwave irradiation. The solution was 
then stirred at room temperature for 15 min, filtered and resin washed with additional DMF (3 x 3 
mL).  The resin was suspended in DMF (0.73 ml), treated with DIEA (0.45 mL) and Ac2O (0.22 
mL) and stirred at room temperature for 20 min.  After filtration and washing with DMF (3 x 3 
mL) and DCM (2 x 3 mL), the resin was suspended in DCM (0.76 mL) under Argon atmosphere. 
The following step was repeated twice for allyl deprotection.  To the solution, PhSiH3 (28 ul, 0.23 
mmol) was added, followed by addition of Pd(PPh3)4 (2.6 mg, 15 umol) in DCM (1.37 mL). The 
reaction mixture was stirred at room temperature for 30 min and filtered.  The resin was rinsed 
with THF (3 x 3 mL), DMF (3 x 3 mL), DCM (3 x 3 mL), 5% DIEA in DCM (3 x 3 mL), 0.02 M 
sodium diethyldithiocarbamate (NaDDTC) (3 x 3 mL) and DMF (2 x 3 mL).  Solid supported 
material was separated (6 mg) and exposed to  TFA (2.19 mL, 28.64 mmol) and TIS (0.12 mL, 
0.57 mmol) were added to the reaction and the vessel shaken for 3 hours. The reaction mixture 
was filtered and resin treated with additional TFA (2.0 mL, 27 mmol) and filtered.  TFA was 
removed from the filtrate by a stream of nitrogen and 143 dried in vacuo.  MS (MALDI-TOF) m/z: 
[MH]+ calcd for C20H17Br2N2O11 618.9156, found 618.9162.       
 
Diallyl 2,2’-((3’-amino-3,5-dibromo-4-((2-(t-butoxy)-2-oxoethoxy)carbonyl)-2’-methyl-[1,1’-
biphenyl]-2,6-diyl)bis(oxy))diacetate (154). In a round bottom flask,  0.25 g (1.33 mmol) of 
SnCl2 were dissolved in DCM (2.2 ml) and MeOH (2.2 ml) and the solution was cooled to 0 ˚C 
and added dropwise to 0.20 g (0.26 mmol) of 130.  The mixture was gradually warmed to room 
temperature and stirred for 16 h.  The reaction mixture was passed through a Celite plug and 
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washed with DCM (10 ml).  The filtrate was washed with saturated NaHCO3 solution (5 ml) and 
H2O (5 ml) and brine (2 x 10 ml).  The organic layer was dried over anhydrous MgSO4, filtered 
and volatile components removed under reduced pressure to give a crude yellow oil.  The oil was 
purified by flash chromatography (SiO2, hexanes/ethyl acetate, elution gradient 3:1) to yield 0.17 
g (91%) of 154 as a light yellow foam: Rf  0.31 (hexanes/ethyl acetate 2:1); 
1H NMR (400 MHz, 
CDCl3) δ 6.98 (t, J = 8 Hz, 1H), 6.64 (d, J = 8 Hz, 1H), 6.54 (d, J = 8 Hz, 1H), (dquin, J = 23, 6 
Hz, 2H),  5.18 (dABq, J = 15 Hz, 2H), 5.16 (app dd, J = 8, 1 Hz, 2H), 4.74 (s, 2H), 4.49 (d, J = 6 
Hz, 4H), 3.95,3.92 (ABq, JAB = 15,2 Hz, 4H), 1.89 (s, 3H), 1.46 (s, 9H);  
13C NMR (400 MHz, 
CDCl3) δ 167.4, 166.1, 165.1, 153.7, 145.5, 137.7, 132.6, 131.7, 131.6, 126.9, 121.9, 120.9, 119.2, 
115.8, 111.4, 83.2, 69.3, 65.9, 62.9, 28.4, 14.8; HRMS (Q-TOF) m/z calcd for [M+H]+ 
C30H34Br2NO10 726.0544, found 726.0517. 
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Figure SI-45.  ROESY/EXSY data of 141 in CD3CN (1.0 mM) at 298 K. 
 166 
 
Figure SI-46.  ROESY/EXSY data of 44 (left) and (right) 43 in CD2Cl2 (0.1 mM) at 298 K. (a) 
Amide proton 1H NMR assignments of the major and minor conformers.  (b) Amide protons and 
their correlation to glycine and N-methyl neighbors. 
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Figure SI-47.   ESI-MS data for test allyl deprotection.  Debromination product was observed in 
both cases.  A decrease in Pd(PPh3)4 from 3.2 to 0.5 equivalents provided improved conditions to 
afford acid 105.  
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